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The elongation factor 1 alpha (eEF1A) exists in mammals as two highly conserved 
isoforms: eEF1A1 and eEF1A2 which share 98% amino acid sequence similarity. When 
bound with GTP, both forms recruit aminoacylated-tRNA for delivery to the ribosome 
during translation elongation. eEF1A1 is expressed ubiquitously during development and 
is downregulated in mature neurones, cardiomyocytes and myocytes. Downregulation is 
observed concurrently with eEF1A2 expression increasing in the terminally differentiated 
cells. This shift in expression may be resultant of non-canonical roles that can differ 
between isoforms, and although eEF1A1 is well characterised, less is known about 
eEF1A2. Given the tissue-specific nature of this shift, it suggests that eEF1A2 may be 
involved in the development of neurodegeneration. eEF1A2 in humans has been 
implicated in severe neurodevelopmental disorders, in which sufferers can display 
symptoms of repeated seizures, intellectual disability and autism. However, patients carry 
differing mutations in eEF1A2 and each case can present varied severity of symptoms. To 
explore the effects that mutations in eEF1A2 have, two mouse lines were generated using 
CRISPR/Cas9; a mutation that was found in humans, D252H and a deletion that arose in 
the founders, Del.22.ex3. Homozygous (-/-) mice displayed a severe neurodegenerative 
phenotype. In Del.22.ex3, eEF1A2 is absent in homozygotes, whereas in D252H, mice 
express eEF1A2 but the protein is impaired or non-functional. An analysis of the founder 
mice identified mosaic alleles, some had incorporated the target mutation but a range of 
insertions and deletions were also present. The expression of eEF1A2 was observed to be 
reduced across the mosaic mice. The extent of neuronal damage that loss of functioning 
eEF1A2 may cause was investigated by immunohistochemistry. Identification of 
biomarkers for prognostic purposes for potential therapies of motor neuron degeneration 
was conducted by a bottom up proteomic approach. Label-free quantitative mass 
spectrometry was used to define the proteome of spinal cords from homozygotes and wild 
types for comparative study and identified potential biomarkers. In complement, an 
analysis on microarray data from wasted mice spinal cords identified differentially 
expressed genes. Some of these supported proteins of interest as being significantly 
differentially regulated, whilst not being confounded by varying protein turnover rates or 
stability. Proteins and genes that were significantly differentially expressed underwent 
gene ontology enrichment analysis exploring which pathways and functions were over-
represented to better understand pathogenesis, some of which demonstrated affiliation 
with neuronal disorders and cell metabolism. Understanding the loss of eEF1A2 and its 
neuronal degeneration phenotype, the affected protein and genetic expression patterns 
across the spinal cord has elucidated proteins enriched for particular pathways, and 
provided possible prognostic benchmarks for future therapeutic development. However 
these finding are only preliminary and more penetrating study is required into the 
differences of expression profiles between healthy and diseased mice with more replicates, 
as well as establishing whether the changes observed are within the translationally 







Mutations in a gene named eEF1A2 have been found in humans that suffer from epilepsy, 
autism and intellectual disabilities. When mice were genetically engineered to have 
mutations in eEF1A2, they developed severe neurological disorders. This thesis aims to 
identify how such mutations affect mice. It has been recognised that mutations in this gene 
result in neuronal degeneration in mice. To examine the extent of this damage I visualised 
a molecule (glial fibrillary acidic protein) whose presence or lack of is reflective of the 
degree of damage in neurons, across different thin slices of the spinal cord to learn if the 
damage is widespread or progressive. In the development of therapies for neuronal 
degeneration there is a need for biological markers that can be indicative of the disease 
progress. To achieve this, I analysed the abundances of different proteins found in spinal 
cords of diseased and healthy mice by a technique called mass spectrometry. This 
technique can identify distinct proteins in a system by comparing certain physical 
characteristics of parts of the protein, whilst informing on the quantity present. As well as 
this I compared the level of gene expression to investigate how active different genes 
were, and if this correlated with the changes in protein quantity. This comparative study 
between healthy mice and those with mutated eEF1A2 genes has illustrated the degree of 
neuronal damage in their spinal cords as well as how the mutations affected the expression 
of their genes. This has uncovered potential biological markers that can be used in monitor 
disease progression. However these findings are only preliminary and further 
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Chapter 1: Introduction 
 
1.1 Translation and Eukaryotic Elongation factor Alpha (eEF1A). 
 
The path to gene expression involves complex synthetic activity in the cell, a series of 
highly regulated stages that ensure translational fidelity. This may be broken down into 
three distinct activities: initiation, elongation and termination. Initiation, through the 
employment of multiple initiation factors, assembles the ribosome to a precise site on the 
mRNA. At the ribosomal P-site, the initiation codon is paired with Met-tRNAMet, allowing 
for advancement into the elongation phase (Jackson et al. 2010).  
Elongation is a series of steps repeated until aminoacylated tRNAs are polymerized into 
a growing polypeptide chain. Translational elongation involves elongation factors which 
vastly improve translational efficiency and accuracy (Alberts, B. et al. 2008). One such 
factor is eEF1, a GTP-dependent pentamer (Marco, et al. 2004). The eEF1A subunit 
protein binds to GTP (Guanosine triphosphate) and aminoacylated tRNA to deliver it the 
acceptor site of the ribosome where they form a ternary complex and position optimally 
for peptide bond formation (Raven et al., 2014). Most incorrectly matched tRNAs 
preferentially dissociate. However once the cognate anti-codon is detected, the ribosome 
triggers hydrolysis of the GTP molecule inducing conformational changes that result in 
eEF1A releasing the aminoacylated tRNA and eEF1A-GDP dissociating from the 
ribosome. In order to restart the cycle, EEF1A requires binding of GTP and eEF1B the 
guanine-nucleotide exchange factor, which consists of three subunits EF1Bα, EF1Bδ and 
EF1Bγ, catalyzes and reactivates it with GTP for further functioning (Fig.1).  
The culmination of the chain occurs when a stop codon signals termination and release 




Fig.1: Translation elongation. Eukaryotic elongation factor 1A (EEF1A), when 
complexed with GTP, delivers the aminoacylated tRNA to the A-site of the ribosome. 
When appropriate codon–anticodon recognition occurs, GTP is hydrolyzed and EEF1A–
GDP is released from the ribosome. EEF1A then interacts with EEF1B, thereby 
promoting the exchange of the bound GDP for GTP to regenerate active EEF1A–GTP. 
The cartoon is schematic and not to scale. Taken from (Abbott and Proud, 2004). 
 
1.2 eEF1A isoforms. 
 
eEF1A is one of the most abundant proteins in cells, making 1-3% of total protein content 
(Abbas et al., 2015), and 3-5% of total protein in brain (Lee et al., 1993). It exists in two 
isoforms; eEF1A1and eEF1A2 and is encoded by separate gene loci in humans, located 
at 6q14 (EEF1A1) and 20q13.3 (EEF1A2) respectively (Lund, et al., 1996). However, the 
encoded proteins share 92% peptide sequence identity and a further 98% sequence 
similarity (Soares et al. 2009). Both isoforms are highly conserved across different 
species, which is expected given their crucial role in translation.  
Alignments of EEF1A2 and EEF1A1 mRNA in vertebrates show high conservation across 
the transcripts, with most species displaying conservation in most base pairs. As 
demonstrated in subsections of EEF1A2 and EEF1A1 sequences (Fig.2, Fig.4). Full 
alignments can be found in Supplementary information. Base pairs in Fig.2 and Fig.4 that 
do not show conservation across all seven compared species, more often than not, are only 
divergent in one or two species, the most deviating in both isoforms being Danio rerio. 
This is also reflected in the phylogenetic trees displaying small evolutionary distances 
between the species with Danio rerio placing as the most evolutionarily distant in the 






Fig.2: Conservation of EEF1A2: Clustal alignments of EEF1A2, mRNA transcripts 
acquired from GenBank of vertebrate species: Mus Musculus (NM_007906.2); Homo 
sapien (NM_001958.3); Danio rerio (NM_00100237); Xenopus tropicalis 
(NM_001011418); Gallus gallus (NM_001032398.3); Oryctolagus cuniculus 
(NM_001082031.1); Bos tarus (NM_001037464).  * denotes site conserved in all species, 
whilst number to the right is the position   of the sequence. 
Fig.3: Phylogenetic tree of EEF1A2: Neighbour-joining tree without distance 
corrections of EEF1A2, mRNA transcripts acquired from GenBank of vertebrate species: 
Mus Musculus (NM_007906.2); Homo sapien (NM_001958.3); Danio rerio 
(NM_00100237); Xenopus tropicalis (NM_001011418); Gallus gallus 
(NM_001032398.3); Oryctolagus cuniculus (NM_001082031.1); Bos tarus 





 Fig.4: Conservation of EEF1A1: Clustal alignments of EEF1A1, mRNA transcripts 
acquired from GenBank of vertebrate species: Mus Musculus (NM_010106.2); Homo 
sapien (NM_001402.5); Danio rerio (AY422992.1); Xenopus tropicalis (BC157768.1); 
Gallus gallus (NM_001321516.1); Oryctolagus cuniculus (NM_001082339.1); Bos tarus 
(NM_174535.2).  * denotes site conserved in all species, whilst number to the right is the 
position   of the sequence. 
Fig.5: Phylogenetic tree of EEF1A1: Neighbour-joining tree without distance 
corrections of EEF1A2, mRNA transcripts acquired from GenBank of vertebrate species: 
Mus Musculus (NM_010106.2); Homo sapien (NM_001402.5); Danio rerio 
(AY422992.1); Xenopus tropicalis (BC157768.1); Gallus gallus (NM_001321516.1); 
Oryctolagus cuniculus (NM_001082339.1); Bos tarus (NM_174535.2). Numbers specify 




The folded 3D structure of eEF1A has three domains (Fig.6). Domain I has been identified 
to bind to GDP, whilst the aminoacetylated-tRNA binds to domain II (Li et al, 2013). The 
variations of amino acids between the eEF1A1 and eEF1A2 are located across all three 
domains (Fig.6), however most appear to congregate in two regions in the tertiary 
structure. One clusters within domain I whilst the other cluster stretches across domain II 
and III. These differences however are not located near the eEF1Bα interface nor domain-
domain junctions, which could be the reason behind the structural integrity being 
conserved between the two isoforms (Soares, et al. 2009). 
 
Fig.6: Human eEF1A1 and eEF1A2 structure: Cartoon schematic representations of 
the 3D-models from two views rotated by 180° along the y-axis. (Above) eEF1A1 
coloured in blue with the domains outlined and the binding regions of GDP, eEF1B and 
aminoacylated-tRNA respectively highlighted. (Below) eEF1A2 coloured in red. The 
location of variant side chains between the two isoforms are coloured in green. Image 
taken from (Soares, et al. 2009), with added binding regions information from (Li, et al. 
2013). 
GDP Binding 







Notably the variants were found to show differing affinities for GTP and GDP; with 
eEF1A1 showing equal affinities for both as the ratio of bound GTP and GDP was 0.82, 
whereas eEF1A2 scored 1.50, demonstrating a great affinity for GDP (Kahns et al., 1998). 
However, this does not seem to have a significant influence on their GTPase activity, as 
release of GDP was not rate limiting (Kahns et al., 1998). 
The lack of drastic 3D structural divergence and restricted variation that does not appear 
to affect binding sites greatly might imply that there little difference in the isoforms 
function in the cell. However this is not the case, as outlined later, and further study into 
the tertiary structures revealed the clusters as enriched for post-translational modifications 
such as phosphorylation and methylation (Soares and Abbott, 2013).  This supports the 
possibility that isoforms are enacted upon differently, allowing them to deviate function 
from one another. 
The EEF1A variants have been observed to be expressed differentially across specific 
tissues and at different stages of development. EEF1A1 is ubiquitously expressed during 
development across a range of species; S.cerevisiae, M.racemosus, A.salina, 
D.melanogaster and X.laevis. Yet it has been shown in mice and rats to decline in 
terminally differentiated neurons, myocytes and cardiomyocytes concomitantly with 
EEF1A2 RNA and protein expression increasing in mature cells (Lee et al., 1993, Khalyfa 
et al., 2001, Pan et al., 2004). However, in transgenic studies the eEF1A1 promoter is still 
active in mature neurons (Stanley et al., 2013). In neurons translation is controlled 
selectively, adjusting the proteome at specific subcellular locations which at the synapse 
maintain synaptic plasticity. Translation is regulated at the axonal growth cone and 
appears enhanced at proximal dendrites and more infrequent in distal dendrites (Wu et al., 
2016).  
Fig.7: Differential expression of eEF1A-1 and eEF1A-2/S1 proteins during 
development of wild-type, heterozygous, and mutant mice. Mouse tissues from Brain 
(A), Heart (B), Skeletal muscle (C), and liver (D) obtained at ages of embryonic day 18 
(E18) and postnatal (P) days 1-, 7-, 14-, 20- and 28 days old were used for 
immunoblotting assays for eEF1A1 and eEF1A2/S1 from wildtype (+/+), heterozygous 




eEF1A2 expression patterning is unique among translation factors as it is tissue-specific, 
being solely expressed in neurons and muscle (Doig et al., 2013). EEF1A2 expression in 
humans has also been observed in the adrenal gland, pancreatic islet cells and at low rates, 
squamous epithelial cells in the oesophagus and oral mucosa, as well as the seminal 
vesicles (Fig.8). In contrast, EEF1A1 was found across a wide range of tissues at far higher 
reads than EEF1A2. RNA expression of EEF1A1 appears lower in tissues that report 
higher RNA expression of EEF1A2 in humans (Fig.9), much like observations made in 
other species. 
Fig.8: RNA expression overview of EEF1A2 in Humans: RNA expression data of 
EEF1A2 in 20 human tissue samples. Expression levels measured in Reads Per Kilobase 
of transcript per Million mapped reads (RPKM). Skeletal muscle present high levels of 
EEF1A2, whereas neuronal cells and heart muscle medium levels of expression and 
glandular, squamous epithelial cells and seminal vesicles are low. Image generated from 




















Fig.9: RNA expression overview of EEF1A1 in Humans: RNA expression data of 
EEF1A1 in 20 human tissue samples. Expression levels measured in Reads Per Kilobase 
of transcript per Million mapped reads (RPKM). Most tissues present high levels of 
expression. Image generated from (NCBI Bioproject data, 2017). 
eEF1A has a demonstrated involvement in a range of functions other than its translational 
role. Despite the conservation between the two isoforms, in some cases they have been 
identified as behaving differently in terms of their non-canonical roles. Although eEF1A1 
is well characterised, less is known about eEF1A2. The variations between isoforms may 
be credited to the differential non-canonical roles, their respective interactions with other 
non-translational molecules. 
eEF1A has been shown to be involved with the cell’s response to stress. When cells 
undergo stress that leads to proteotoxic environments such as extreme heat or oxidative 
stress, proteins are prone to misfolding and aggregating. In response to this, a highly 
conserved mechanism to maintain proteostasis in cells is enacted: the synthesis of heat 
shock proteins (HSPs) (Akerfelt et al.2010). These function as molecular chaperones that 
work to restore proteostasis. eEF1A plays a role in activating the transcription of heat 
shock factor-1 (HSF1) when cells experience thermal stress. It forms a complex with heat 
shock RNA-1 (HSR1) which facilitates the trimerization of HSF1 or stability of it 
(Shamovsky et al., 2006), which in turn promotes the transcription of HSP by binding to 
HSP mRNA stabilizing it for nuclear export to the ribosomes (Vera et al. 2014). However, 
eEF1A1 also acts as a repressor of transcription when the stress response is inactive by 
binding to the promoter region of HSPs. When cells experience stress, a direct effect is a 
reduction in translation rates, which releases eEF1A for functioning in the heat shock 



























































































































































inducing the heat shock response (HSR) showed an increase in HSF1/eEF1A complexes 
(Shen et al., 2009). Knock down of ~70% of eEF1A1 was sufficient to generate a 
deficiency in several HSPs in mouse and human cells. However when eEF1A2 was 
knocked down and levels of HSP70 were monitored, there was no such decrease, implying 
that eEF1A2 alone cannot support the heat shock response (Vera et al. 2014), therefore as 
eEF1A2 replaces eEF1A1, the cells response to stress is impaired. As motor neurons 
cannot express eEF1A1 they cannot mount the heat shock response and as a result are 
more vulnerable to stress and disease (Shamovsky et al., 2006). 
eEF1A in plants and trout has also been implicated in the cold shock response (Ejiri, 
2002). During the cold response in plants eEF1A transcripts are detected at higher levels 
(Filipowicz and Hohn, 1996) and in trout cold acclimatisation appears to improve 
translational functions. However these are predominantly correlation studies but support 
the associations of cell stress response with eEF1A expression. 
A common outcome of cells too damaged or impaired is programmed cell death; 
apoptosis. Therefore if a cell struggles to maintain homeostasis, particular pathways are 
initiated resulting in elimination of that cell. eEF1A became understood as an element 
coordinating apoptosis when initial studies identified increased levels of eEF1A to be 
associated with more expeditious cell death (Duttaroy et al., 1998) and that this increase 
is facilitated posttranscriptionally (Chen et al., 2000). Yet as further research was 
conducted into the separate isoforms, eEF1A1 was revealed to be proapoptotic whereas 
eEF1A2 behaved protectively and was suggested to be anti-apoptotic (Ruest et al., 2002). 
eEF1A2 became implicated in the regulation of Caspase 3 and this is potentially the 
mechanism behind its involvement in cell survival. Ruest et al.. 2007, speculated that the 
isoforms promote or protect against apoptosis respectively by differential translation 
efficiency; eEF1A1 may display affinity for translation of proapoptotic genes mRNA 
and/or repress those that are prosurvival, whilst eEF1A2 conducts itself contrariwise. 
Additionally in vivo and in vitro eEF1A2 is observed to interact with Peroxiredoxin-1 
(Prdx-1), which when cotransfected into cells displayed higher apoptotic resistance than 
when either were transfected alone. The increase in eEF1A2/Prdx-1 also correlated with 
an increase in the apoptosis suppressive element Akt as well as seeing a decrease in 
Caspase 3 and 8, proteins that act proapoptotically (Chang and Wang, 2007). However, 
no recent studies have further researched this and eEF1A2’s role in apoptosis as outlined 
should be treated with caution. 
EEF1A mRNA levels are escalated in proliferating cells, more so than other elongation 
factors (Condeelis, 1995). In vitro both isoforms bind F-actin when dimerised which 
results in actin bundling, conversely monomers are unable to bundle F-actin. 
Monomerization of either eEF1A1 or eEF1A2 is dependent upon Ca2+/calmodulin (CaM) 
binding, upon this F-actin filaments loosen (Bunei et al., 2006). Interestingly, eEF1A2 has 
presented a reduced ability to bind with calmodulin (Novosylna et al., 2017) which may 




remodelling or be required to constrain it, a concept which also aligns with the fact that it 
is only in terminally differentiated cells that eEF1A2 is upregulated. The involvement of 
eEF1A1 in F-actin detachment may serve as one reason for its aforementioned increased 
expression in apoptotic cells, as apoptosis can be induced by microtubule severing factors 
(Ruest et al., 2002). 
In addition to the roles mentioned above, eEF1A has been implicated in other non-
canonical roles. Preliminary findings suggest a model in which it may regulate protein 
degradation (Mateyak and Kinzy, 2010), as well as nuclear export, as it has been found in 
the nucleus and shown to be associated with the export of tRNA species in yeast (Mateyak 
and Kinzy, 2010, Khacho et al., 2008).  
Although having a crucial canonical roles to play in the cell, eEF1A demonstrates many 
differing capabilities in other pathways that too, that are vital to the cell and decisive of 
its fate. The study of isoforms separately has been growing as it is no longer hindered by 
antibody limitations, previously unable to discern between each variant in specific tissues 
(Newbury et al. 2007). However, observing the expression of variants postnatally in 
neuronal cells is still complicated as glial cells express high levels of eEF1A1, making a 
whole tissue analysis impossible. Furthermore, studies that probe for the roles of eEF1A1 
and eEF1A2 separately are identifying differing, and in some cases, opposing functions. 
Therefore the developmental switch from eEF1A1 to eEF1A2 in long-lived, terminally 
differentiated neurons, myocytes and cardiomyocytes can be postulated as driven by these 
differing non-canonical roles as these cells require less actin remodelling and protection 
against apoptosis.  
As mentioned before, EEF1A1 and EEF1A2 are highly conserved isoforms and 
differences in sequence do not drastically change tertiary structure or function in theory. 
However given their contrasting expression patterns and ‘moonlighting’ functions and the 
small localised variations that are enriched for post-translational modification, EEF1A1 
and EEF1A2 are non-redundant and vital in their differing properties. 
 
1.3 Translation factors and EEF1A in disease. 
 
The essentialness of translation factors for protein synthesis and survival means that 
mutations that lead to dysregulated or dysfunctional proteins can have wide reaching 
consequences across the cell as a fundamental cell mechanism is impeded. A range of 
diseases are known to develop because of inherited or de novo mutations that impair 
translational machinery (Scheper et al.,2007, Nakajima et al., 2015, Ejiri 2002, Bottley 
and Kondrashov, 2013). Many studies have identified abnormal expression of eEF1A in 
disease but have not entirely outlined the involvement of eEF1A as of yet. Given the 




function and the high degree of conservation across species, EEF1A isoforms are strongly 
implicated in the development of disease. 
EEF1A mRNA expression was observed as upregulated in skeletal muscle tissue in 
humans and rodent models with Type 2 and Type 1 diabetes respectively, whilst subunits 
EF1Bδ and EF1Bγ remained unchanged. Insulin treatment was then able to reverse this 
(Reynet and Kahn, 2001), intriguingly insulin is known to regulate the elongation by 
altering phosphorylation of eEF1A isoforms. In addition, defective HSP function is 
associated with diabetes (Atalay et al., 2009). This may allude to a symptom of diabetes - 
uncontrolled oxidative stress in cells, resulting in dysregulation of eEF1A1 and in turn 
impaired stress response. However the location of measured EEF1A implies that it is the 
EEF1A2 isoform being enhanced. Also, notably, genome-wide linkage analysis has 
identified a diabetes susceptibility locus at 20q13.3 (EEF1A2s’ gene locus) (Rotimi et al., 
2004).  
 
1.4 eEF1A isoforms in Neurological disease. 
 
eEF1A isoforms are involved in a range of neurological disorders, either directly or via 
observed changes in expression levels. The tissue-specific nature of eEF1A2 suggests that 
it may be involved in the development of neurodegeneration. Its inability to take part in 
the heat shock response suggests that in the cells expressing solely eEF1A2, the reaction 
to cell stress and proteotoxicity might be impaired. Included in these stressors is oxidative 
stress, a condition induced by an imbalance between reactive oxygen species and 
antioxidant defences leading to damage of DNA structure, cell membrane and protein 
structure and function from oxidation. Not only are neuronal cells vulnerable to oxidative 
damage because of their high demand for oxygen and abundance of peroxidisable 
substrates (known to induce cell death (Whittemore et al.,1995)), the sole expression of 
the eEF1A2 isoform could weaken them further. Notably, particular types of neuronal 
groups can be more susceptible to oxidative stress (Gandhi and Abramov, 2012). 
Oxidative stress is a key factor in neurodegenerative pathophysiology. Alzheimer’s 
disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) pathogenesis has not 
been completely outlined, but it is proposed that the misfolded, dysfunctional proteins 
aggregating to toxic levels because of oxidative damage are in part responsible for disease 
development and progression (Kim et al., 2015, Kumar and Ratan, 2016). Human brain 
tissue from patients diagnosed with these diseases have found decreased eEF1A protein 
levels (Garcia-Esparcia et al., 2015). 
Dysregulation of eEF1A has also been identified in less severe neurological disorders; 
depression and anxiety. Through a proteomic study of Zebrafish experiencing chronic 




of eEF1A in brain was detected. This again was determined to be indicative of 
neuroprotective roles (Chakravarty et al., 2013). This downregulation of eEF1A may be 
due to the fact that long-term potentiation stimulates eEF1A synthesis (Panayiotis et al., 
2005), yet CUS has been shown to impair long-term potentiation and in turn synaptic 
plasticity (Alfarez et al., 2003). 
There has been a growing consensus that many of the previous idiopathic cases of 
neurological disorders such as neurodevelopmental and neurodegenerative actually have 
a genetic basis Macleod and Appleton, 2007, Kaufman et al., 2010), despite many having more 
complex modes of inheritance that are not entirely known; with 70-80% not being 
attributed to acquired conditions (Hidlebrand et al., 2013). However one can conject that 
the elusive nature of the cause may be due to a limit in current diagnostic tests.  
Growing evidence has revealed associations between particular genes and the emergence 
of severe neurodevelopmental disorders and an epilepsy phenotype (Myers and Mefford, 
2015). A meta-analysis of genome wide association studies has identified statistically 
significant loci and implicated genes in forms of epilepsy (International League against 
Epilepsy Consortium on Complex Epilepsies, 2015). Facilitated by exome sequencing and 
advances in technologies, more data is being collated and genetic studies have identified 
that de novo heterozygous missense mutations in EEF1A2 are associated with disease (see 
Table 1) (Lam et al., 2016) and two cases of homozygous missense mutation (Cao et al., 
2017). In humans, manifesting from early childhood, mutations in EEF1A2 have been 
implicated in severe neurodevelopmental disorders, in which sufferers can display 
symptoms of repeated seizures, intellectual disability, and autism. In some severe cases 
no purposeful movement and patients are wheelchair bound and/or have respiratory issues.  
Various different mutations in eEF1A2 were reported in affected children that were not 
present in the parents, except in the case of the P33L mutation (Table 1.). These are 
predicted to have a damaging effect on the protein, especially as eEF1A2 is under 
excessive selective constraint (Samocha et al., 2014), and mutations identified in humans 











Mutation Developmental delay Reference 
A92T  Global developmental delay Lopes et al., 2016 
D252H  Developmental delay Nakajima et al., 2015 
D252H  Global developmental delay DDD 
D91N  Non-Verbal, global 
developmenatal delay 
Lam et al., 2016 
E122K  Non-Verbal, gross motor 
delay 
Lam et al., 2016 
E122K  Non-Verbal, 
developmenatal delay 
Inui et al., 2015 
E122K  Non-Verbal, 
developmenatal delay 
Inui et al., 2015 
E122K  Motor delay Nakajima et al., 2015 
E124K  Significant language delay Lam et al., 2016 
F98L  Global developmental delay Lam et al., 2016 
G70S  Global developmental delay Lam et al., 2016 
G70S  Non-Verbal Veeramah et al.2013 
G70S  Global developmental delay de Ligt et al.,2012. 
G70S  Not reported de Kovel  et al., 2016 
G70S  Global developmental delay Yang et al. 2014 
I71L  Global developmental delay Lam et al., 2016 
P33L Global developmental delay Cao et al., 2017 
P33L Global developmental delay Cao et al., 2017 
R266W Not reported DDD 
R382H Not reported Iossifov et al., 2014 
R423C  Global developmental delay Lam et al., 2016 
T432M  Not reported DDD 
Table 1: Mutations found in eEF1A2. The various amino acid mutations found in human 




The location of some of the different eEF1A2 mutations identified are illustrated in Fig.10. 
These mutations have been reported as located near regions of importance for eEF1A 
functioning. Notably, the least severe phenotype mutation (E124K) is more distally 
located from eEF1A2’s binding sites. 
 
Fig.10: Mutations in eEF1A2. Location of reported missense mutations in humans in 
the protein structure (Red). eEF1β binding site (Blue). GTP binding site (Yellow) and 
variable amino acids between eEF1A isoforms (Green). Model and annotations by 
Soares. 
 
1.5 Motor neuron disease and eEF1A2. 
 
It has been previously seen that mice absent of eEF1A2 expression appear to develop 
aggressive early onset motor neurodegeneration (Chambers et al., 1998) with evidence of 
distinct vacuolation of the motor neurons in the spinal cord, alongside neuromuscular 
junctions deteriorating signal transmission, progressive retraction of motor endplates 
(Newbery et al. 2005). Motor neuron disease (MND) encompasses a range of disorders; 
amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP) and spinal 
muscular atrophy to name a few, differentiated by the selective regions of motor neurons 
affected. The most common form is ALS, in which the both the upper motor neurons 
(motor cortex in the brain) and lower motor neurons (brain stem and spinal cord) are 
affected. Cases predominantly occur sporadically with only ~10% being identified as 
familial with primarily autosomal dominant inheritance (Boylan, 2015). Characterised by 
the premature degeneration and death of motor neurons in the brain and spinal cord, the 




Death of upper motor neurons results in spasticity and hyper-excitability of reflexes, 
whereas death in the lower motor neurons are responsible for muscle atrophy and paralysis 
(Dadon-Nachum et al. 2011). The disease is progressive with rate and pattern varying 
greatly between patients but leading eventually to death, usually due to respiratory 
paralysis. Paralysis manifests itself focally initially then advances in a pattern suggesting 
that the spread of degeneration occurs through contagious pools of motor neurons 
(Pasinelli, and Brown, 2006). Given the heterogeneity of motor neuron disease, the 
pathophysiology is still not entirely understood. The pathology of neuronal damage is well 
outlined, on the other hand, involving axonal swelling, accumulation of phosphorylated 
neurofilaments, deposition of inclusions (spheroids) and ubiquitinated material in these 
axons as well as the activation and proliferation of astrocytes and microglia in reactive 
gliosis. The pathological observations however, give little or no reference to the stage of 
the disease and are limited in describing the mechanistic workings behind the cellular 
distress. The causes are undefined with several theories postulated, nevertheless 
researchers have identified various cellular processes influenced such as protein 
misfolding, excessive excitatory tone, altered axonal transport and activation of proteases 
and nucleases (Pasinelli, and Brown, 2006).  
A mechanism preceding the death of neurons is the dying-back phenomenon, in which 
distal axons degenerate and progresses towards the cell body. This ‘die-back’ of axons 
has been observed in the motor neurons of ALS mouse models (Dadon-Nachum et al. 
2011, Fischer et al. 2004). When considering that the death of motor neurons occurs in a 
disseminated fashion, it could mean that initial stages of the disease may start with the 
dying-back of axons that perhaps eventually initiate cell death. Motor neuron degeneration 
in the spinal cords of mice has been linked to null mutations in eEF1A2, with similarities 
in that the damage is preceded by axonal degeneration and the phenotype is of neurogenic 
origin, as restoration of eEF1A2 expression in muscle failed to rescue any of the 
phenotypic aberrations (Newbury et al., 2005, Doig et al., 2013, Murray et al. 2008).  
This loss of eEF1A2 expression in mice has triggered dying-back neuropathy (Murray et 
al. 2008). eEF1A2’s role in this maybe due to its cytoskeletal remodelling function as 
there have been links made with axonal damage and impaired microtubule assembly 
(Bommel et al., 2002). In the cells in which dying-back occurs, only the eEF1A2 isoform 
is expressed and this has reduced actin bundling capabilities in comparison to the eEF1A1 
isoform.  
As of yet there is no cure for MND, there are only measures for management of the 
disorder and a single drug approved, Riluzole, which delays advancement of disease 
marginally (MND Association, 2017)). The lack of understanding combined with 
homogeneity of initial symptoms with other less severe disorders, has meant that diagnosis 
is limited to the interpretation of physiological symptoms, electro-diagnostic and in some 
cases muscle biopsies upon manifestation of symptoms (NHS, 2017). In many cases this 




uncertain of their wellbeing and fate. Hence, to develop therapies to target progression of 
MND, understanding why selective regions of motor neurons are deteriorating and why 
the advancement is patterned is crucial. Therapies for diseases that are progressive in 
nature, often work best if they are enacted during initial stages of disease development 
and before symptoms worsen. This is why research into non-invasive diagnosis and 
prognosis at a quantifiable biological level is paramount. However, preceding this is the 
ability to confidently diagnose and examine prognosis from acquired tissue in humans and 
in animal models. 
 
1.6 Mouse Models: 
 
An unprecedented spontaneous recessive mutation arose in a HRS/J stock mice from 
Jackson laboratory. This was subsequently found to be a 15.8-kb deletion that 
encompassed the promoter region and first non-coding exon of Eef1a2 and no other gene, 
resulting in mice with complete loss of eEF1A2 expression. These mice were termed 
wasted (wst), their phenotype being characterised by ataxia, weight loss, progressive 
paralysis (Chambers et al., 1998). The loss of eEF1A2 expression appears to result directly 
to the development of the wasted phenotype (Newbery et al. 2007). As mentioned 
previously, the phenotype displays a very aggressive and early onset motor neuron 
degeneration, demonstrating vacuolation of the motor neurons in the spinal cord, as well 
as neuromuscular junctions deteriorating signal transmission, progressive retraction of 
motor endplates (Newbery et al. 2005) and reactive gliosis (Abbott et al., 2009). These 
changes are preceded by axonal and somatic degeneration ((Murray et al. 2008). (Doig et 
al., 2013) identified the phenotype as being of neurogenic origin, as restoration of eEF1A2 
expression in muscle failed to rescue any of the phenotypic aberrations. However it is only 
mice homozygous (wst/wst) for the deletion that develop the phenotype. Heterozygous 
mice, despite having approximately 50% reduced eEF1A2 protein expression, do not 
develop the wasted phenotype, they were instead observed to have normal neuromuscular 
functioning, and are indistinguishable from the wild type mice at both a physical and 
pathological level (Griffiths et al., 2012). The onset of physical deterioration is observed 
at ~21 days where the expression of Eef1a1 is downregulated – whilst independently 
Eef1a2 is reaching peak expression (Khalyfa et al., 2001, Pan et al., 2004). Survival rates 
of wasted mice do not exceed ~28 days (Davis et al., 2017). However onset of the neuronal 
degeneration is detectable by 17 days postnatal on the basis of enhanced GFAP staining 
Table.2 in spinal cords, and the retraction and denervation of motor endplates in thoracic 






Region wst/wst +/wst 
19 Cervical 48 2 
 
Thoracic 27 3 
 
Lumbar 7 4 
24 Cervical 43 7 
 
Thoracic 37 2 
 
Lumbar 22 0 
28 Cervical 37 0 
 
Thoracic 31 0 
 
Lumbar 4 0 
29 Cervical 148 0 
 
Thoracic 52 3 
 
Lumbar 16 0 
Table.2: Mean Number of GFAP-Positive Cells in the Grey Matter of the Spinal Cord at 
Cervical, Thoracic and Lumbar regions in wst/wst and +/wst mice at ages 19,24,28 and 
29. Taken from (Newbery et al. 2005). 
The pathology of motor neuron degeneration appears as a progressive rostrocaudal 
gradient, with more motor neuron deterioration occurring initially at the cervical level. 
There is speculation as to whether these changes work as a cascade and eEF1A1 is 
switched off progressively which would explain why caudal areas do not seem to be as 
affected (Newbury et al. 2005). 
The wasted phenotype shows great similarity with the pathology of MND and has been 
suggested as a potential model for therapeutic study. Previous work in the Abbott group 
has concerned the development of various mouse lines to recapitulate particular EEF1A2 
mutations that have been reported on page 22.  
The most common mutation, G70S, when genetically engineered into the purebred 
C57BL/6 mice was found to result in a non-functional protein, resulting in motor neuron 
degeneration and in some cases sudden unexplained deaths and audiogenic seizures in 




The D252H mutation was also recreated in mice using CRISPR/Cas9. This line of mice 
displayed similar phenotypes to that of wasted in homozygotes with heterozygotes 
remaining unaffected. Onset of physiological symptoms, akin to wasted occurs at ~21 
days where the switch is said to be near complete. Initial study show homozygotes express 
eEF1A2 but that the protein is impaired or non-functional. However this line remains 
largely uncharacterised and the nature of eEF1A2 expression and pathology has yet to be 
fully understood and will be outlined subsequently. 
A 22 base pair deletion within exon 3 of Eef1a2 that arose from CRISPR/Cas9 
mutagenesis resulted in a null mutation, this was bred into a line labelled Del.22.Ex3. The 
mice within this line present a phenotype so severe that mice do not survive much longer 
after the onset of disease (~ 21-23 days) suffering from the aforementioned symptoms 
with the addition of fatal seizures in some cases of homozygous mice. This limits their 
use as potential models for MND as the mice would be at risk of spontaneously dying in 
addition to being unethical. However they remain largely uncharacterized, yet again, this 
phenotype is only present with mice homozygous for the deletion.  
The genetically engineered lines have shown to be robust and reproducible and relatively 
easy to develop with CRISPR/Cas9 techniques making them reliable to study aspects of 
MND and probe for potential biomarkers. Additionally, there is a lack of disparity 
between the females and male, thus reducing further variation (which can be a problem 
with other current models) (Perrin, 2014). Unlike the SOD1 and C9ORF72 mouse models, 
among others, (see supplementary information) (Chew et al., 2014), the phenotype 
manifests very early. This is beneficial for studying biomarkers as changes resultant from 
therapies can be detected earlier and robustly unlike the current models (e.g.SOD1) in 
which to establish if there is any delay in death, it can be over 100 days. Although the 
Eef1a2 mutation has not been observed in human MND cases, the model would be 
validated for its use in cell based experimentations and observations of therapies. 
However, the effects of the various mutations in Eef1a2 have in these mice must first be 
interpreted.   
 
1.7 Biomarkers for Motor neuron degeneration. 
 
Currently there are no clinically used biomarkers for MND and a great deal of research is 
being conducted to identify prospective biomarkers for diagnostic and prognostic 
purposes. Initial symptoms being in common with other disorders complicates diagnosis, 
which often can only be made confidently after significant progression of the disease and 
thus left to human interpretation, creating demand for molecular markers indicative of 
MND. The repeated failures of clinical trials are also an issue; vast sums of resources, 




therapy in models before advancing to clinical trials, as well as improve the efficiency of 
clinical trials. The search for biomarkers is increasingly becoming data-driven, with the 
development of molecular (proteins, genes or metabolic products) neurophysiological 
(changes in upper and lower motor neurons) and neuroimaging markers, achieved by 
proteomic, genomic and metabolomics studies. 
Genetic molecular markers can be complex to identify as cases of disease development 
may be polygenic. Studies in proteins as potential markers have shown greater success 
with some reporting over 90% sensitivity for distinguishing ALS sufferers from healthy 
controls. Levels of the Nf light chain protein (the light chain of neurofilaments – 
cytoskeletal proteins of neurons that are released subsequent to neuronal damage) in blood 
samples were more than 20-fold higher in ALS 49 patients (Gaiottino et al., 2013). 
Proteomic studies have identified a superior marker: Tau. Tau proteins stabilise 
microtubules and are found in abundance in neuronal cells. Dysfunctional tau proteins 
have been associated with neurological disorders such as Alzheimer’s and Parkinson’s 
disease. Hyperphosphorylation of Tau leads to protein aggregation and sequestration of 
other cytoskeletal proteins. Patients experiencing abated disease progression 
demonstrated reduced levels of Tau and phosphorylated neurofilament heavy chain during 
drug trials for ALS (Levine et al., 2010). The associated oxidative damage with motor 
neuron degeneration made biochemical markers of the oxidative stress response a 
promising focus area. However contradicting results have transpired; molecules involved 
in the glutathione pathway and Cu/Zn superoxide dismutase (SOD1) were observed to be 
reduced in the erythrocytes of ALS patients (Babu et al., 2008), but were also found 
increased in the same cells (Tuncel et al., 2006, Cova et al., 2010) and in cerebrospinal 
fluid (CSF) (Boll et al. 2003, Kokic et al. 2005).  
Although there are promising biomarkers being developed, they have yet to be translated 
into a clinical setting. With contradictory results emerging and most research being geared 
towards biomarkers for primary end points, seeking further potential biochemical markers 
that can act as surrogate end points is of great value. In addition to this, investigating 
possible biomarkers for MND can inform our understanding of the disease’s enigmatic 
mechanisms and the identification of pathogenesis. This information in turn may lend 









1.8 Project Aims: 
 
The aims of this research project are to characterise the effects of mutations in Eef1a2 in 
mice at a genetic and protein level, alongside identifying potential markers that are 
indicative of motor neuron degeneration through use of ‘wet’ laboratory work in 
conjunction with computational biology.  
I aimed to understand how the loss of eEF1A2 and its neuronal degeneration phenotype 
affects protein and genetic expression pattern, as well as the pathways and biochemistry 
involved with its loss. I also aimed to provide possible prognostic benchmarks for future 
therapeutic development. 
The research has been carried out predominantly on two lines of mice; the D252H line 
and Del.22.Ex.3. eEF1A2 expression in these mice was identified as well as the extent of 
neurodegeneration experienced by using immunohistochemistry for markers of 
neurodegeneration. To probe for biomarkers, a bottom up proteomics approach was 
applied. A comparative study of the differences in protein expression between eEF1A2 
null and wildtype mice was conducted. In complement to this, previous RNA expression 
data was also analysed. Proteins and genes that were significantly differentially expressed 
were then investigated further for biological significance. 
 
An outline of the steps taken to achieve these aims: 
1. Characterisation of founder mice from D252H line, the mutations resulting 
from CRISPR experiments and their effects on eEF1A2 expression. 
2. Pathology of spinal cords from these mice at the cervical, thoracic and lumbar 
regions probing for glial fibrillary acidic protein (GFAP) to observe any 
gliosis, and whether neurodegeneration occurs as a progressive rostrocaudal 
gradient 
3. Quantitative analysis of eEF1A2 null and wild type spinal cord proteome by 
Label-free Quantitative Mass spectrometry (LFQ-MS). 
4. Microarray data analysis of spinal cord RNA from wasted mice and wild type 
mice.  
5. Gene ontology enrichment analysis of proteins and genes significantly 
differentially expressed and regulated, exploring which pathways and 













Chapter 2: Materials and methods. 
 
2.1: Clustal Alignments and Phylogenetic trees. 
 
For EEF1A2, mRNA transcripts acquired from GenBank. Accession numbers of each 
species: Mus Musculus (NM_007906.2); Homo sapien (NM_001958.3); Danio rerio 
(NM_00100237); Xenopus tropicalis (NM_001011418); Gallus gallus 
(NM_001032398.3); Oryctolagus cuniculus (NM_001082031.1); Bos tarus 
(NM_001037464). Clustal alignments of EEF1A1, mRNA transcripts acquired from 
GenBank of vertebrate species: Mus Musculus (NM_010106.2); Homo sapien 
(NM_001402.5); Danio rerio (AY422992.1); Gallus gallus (NM_001321516.1); 
Oryctolagus cuniculus (NM_001082339.1); Bos tarus (NM_174535.2).  However for 
Xenopus tropicalis (BC157768.1), the sequence was from cDNA clone MGC:184686. 
Alignments and Neighbour-joining tree without distance corrections were used Clustal 
Omega, version 1.2.4. Multiple sequence alignment tool with input parameters: Output 
guide tree: false. Output distance matrix: false. Dealign input sequences: false. mBed-like 
clustering guide tree: true. mBed-like clustering iteration: true. Number of iterations: 0. 
Maximum guide tree iterations: -1. Maximum HMM iterations: -1. Output order: Aligned, 




2.2.1: Genomic DNA extraction. 
For genotyping ear notches acquired at 14 days from the founder mice underwent the 
sodium hydroxide method of DNA extraction. 300μl of 15mM NaOH was added to ear 
notches then heated at 100°C for 10 minutes and vortexed before adding 25μl of Tris 1M 
at pH8 the sample was then stored at -20°C. 
2.2.2: Nested PCR. 
A nested PCR for D252H founder mice to amplify a region of exon 5 of the Eef1a2 gene. 
The 1st round of PCR reaction was performed using 1x Taq PCR buffer, 2mM MgCl2, 
0.2µM dNTPs, 0.4µM of primers, 5% 1,2 propanediol and 1U of Taq polymerase. With 
primer sequences: mD252H 1F (5’- AGGCTACCCCTTAGGCAGGT-3’) and mD252H 
1R (TGAACAAATGGTAGGTGGGAGG). On a program of Denaturation at 95°C for 
3min, 20 cycles of (denaturation) 95°C for 30s, (annealing) 60°C for 30s and (extension) 
72°C for 1min, the final extension at 72°C for 5 minutes then held at 10°C. The PCR 
products were then diluted 1:10 and 1µl was used in the 2nd round of PCR reaction. With 




1R (GTCCCTAGCTTGTGGCTGAG). On a program of Denaturation at 95°C for 3min, 
20 cycles of 95°C for 30s, 67°C for 30s and 72°C for 45S, the final extension at 72°C for 
5 minutes then held at 10°C. Products were then visualized by electrophoresis on a 1.5% 
agarose gel. 
2.2.3: TOPO Cloning. 
TOPO cloning was conducted by mixing 0.5µl of PCR product was with 1µl salt solution, 
3.5µl dH2O and 1µl TOPO® Vector at room temperature for 30min, placed on ice briefly 
before transforming. 2µl of TOPO reaction was mixed into cells and heat shocked for 30s 
at 42°C then transferred to ice. 250µl of SOC was added to the transformed cells which 
was then shaken at 37°C, 200rpm for an hour. This was then spread on L-ampicillin plates 
and left to incubate overnight at 37°C. Colonies with incorporated gene were identified 
by the blue-white test and picked to be sequenced. Clones were sequenced by Sanger 
sequencing using 3130 or 3730 Genetic Analyser (Applied Biosystems).  
 
2.3: Protein expression. 
 
2.3.1: Sample preparation. 
Muscle tissue of founder mice were prepared by adding 10µl of 0.32M sucrose with 
protease inhibitor per 1mg of tissue. Samples were then homogenised mechanically for 1 
minute in bead beating tubes with 1.4mm large ceramic beads. These were then 
centrifuged at 10000g for 15minutes at 4°C, the pellet was then discarded. Protein 
concentrations were quantified using the Thermo Fischer Pierce BCA Protein Assay kit. 
Concentrations were then equalised and equal volumes of Laemmli loading buffer was 
added to each sample. These were then heated at 95°C for 5minutes before adding 1M 
DTT at 10% v/v of sample and stored at -20°C. 
2.3.2: Protein separation. 
A 10% separating gel was used due to the proteins size of 50kDa and was composed of 
1.5M Tris at a pH of 8.8, 30% acrylamide, 20% SDS, TEMED and 25% Ammonium 
Pisulphate. Whilst a 4.3% stacked gel consisted of 0.5M Tris-HCL pH6.8, 30% 
acrylamide, 20% SDS, TEMED and 25% Ammonium Pisulphate. Samples were then 
mixed with Laemmli loading buffer and a total of 15 µl was deposited into the wells, 
alongside 5 µl Full range Rainbow ladder. This was run at 120V for 2 hours.  
2.3.3: Protein transfer, immunoblotting and quantification. 
Hybond-P membranes were transferred by electrophoresis on a stir plate at 100V for 1 
hour in a cold room. The membranes were blocked overnight in Licor Odyssey buffer. 
Followed by incubation with primary AbCAM eEF1A2 1:1000 dilution in blocking 
solution and GAPDH 1:2000 dilution for 1 hour. After a series of washes with 2% PBS-




GAPDH, Licor anti-mouse, both diluted at 1:5000 in blocking solution and incubated for 
1 hour. Membranes were visualized using the Licor Transilluminator.Visualised 
membranes were then analysed using Image J Lite Studio version 5.2. The signal 
intensities of the bands generated at 50kDa and 37kDa to quantify the levels of eEF1A2 
and GFAP respectively were measured. Readings from the eEF1A2 bands were 
normalised to those of the GAPDH bands for each sample. 
 
2.4: Immunohistochemistry.  
 
2.4.1: Sample preparation. 
The spinal cords of mice from the Del.22.Ex.3 and D252H lines were extracted for 
immunohistochemistry. For the Del.22.Ex.3 line three repeats of each homozygote, 
heterozygote and wildtype were prepared, whereas for the D252H only a singular mouse 
was used from each genotype. These were a mixture of females and males. The spinal 
cords were extracted by ejection using a 1.1x50mm needle. Mice were partially skinned 
dorsally and decapitated. A transverse incision was made through the lower lumber spine 
cranial of the iliac crest muscles. The needle attached to PBSx1 filled syringe was inserted 
into the exposed spinal canal, ejected whole and immediately frozen on dry ice. Spinal 
cords where then submerged in formalin for fixation for 24hrs. The formalin was 
exchanged for 10% EDTA pH7.4 changed weekly for three weeks and then submerged in 
formalin for 24hrs. The spinal cords were then processed by the University of Edinburgh 
Pathology Histology service using a Leica tissue processor ASP 300S. Paraffin embedded 
tissue were then sectioned by the Pathology Histology service into 4μm sections and 
mounted on Superfrost plus slides in preparation for immunohistochemistry. 
 
2.4.1: Section staining. 
For staining with GFAP the paraffin embedded spinal cords were first deparaffinised by 
emersion in xylene (2x5 minutes) followed by rehydration in 100% ethanol (2x5 minutes) 
and 70% ethanol (2x5 minutes). To remove any remaining residuals the slides were 
washed in running water for 5 minutes. Antigen retrieval was done by treating slides with 
proteinade K at RTM for 10 minutes and washed for 5 minutes. Slides were submerged in 
3% hydrogen peroxide for 10 minutes and washed in water for 5 minutes before being 
washed with PBS for 5 minutes. The slides were blocked with 100µl of 1:5 diluted goat 
blocking serum in PBS for 10 minutes. The primary antibody Dako GFAP rabbit 1:500 
diluted in PBS was applied overnight at 4°C. After washes in PBS, slides were incubated 
with the secondary antibody (dako goat anti-rabbit diluted 1:500 in PBS) for 30 minutes 
then washed before incubating with 3 drops of Strept ABC for 30 minutes. Slides were 
washed with PBS the treated with DAB (diaminobenzidene, Abcam) for 10 minutes for 
visualisation of staining. The slides were washed in water and counterstained with 
haematoxylin for 5 minutes, washed in water, then differentiated in Blue in lithium 




submerged for 5 minutes in 70% ethanol, 100% ethanol and xylene then finally mounted 
using DPX. 
 
2.5: Proteomics.  
 
2.5.1: Sample extraction and preparation. 
The spinal cords of mice from the Del.22.Ex.3 line were extracted for mass spectrometry. 
Six mice: three homozygotes and three wildtypes from the same litter were extracted at 
21 days. Null.1, Null.2, Null.3, Wt.2 and Wt.3 were all males whilst Wt.1 was female. 
The spinal cords were extracted by ejection using a 1.1x50mm needle. Mice were partially 
skinned dorsally and decapitated. A transverse incision was made through the lower 
lumber spine cranial of the iliac crest muscles. The needle attached to PBSx1 filled syringe 
was inserted into the exposed spinal canal, ejected whole and immediately frozen on dry 
ice. Spinal cords were washed twice in pre-cooled 1xPBS and 500μl of cold lysis buffer 
(RIPA buffer (50mM Tris pH 7.5, 150mM NaCl, 0.5% (w/v) Sodium Deoxycholate, 1% 
(v/v) NP-40 (Igepal), 0.1% SDS (v/v) with protease inhibitor) was added per 10mg of 
tissue. This was homogenised mechanically for 2 minutes before sonication using Covaris 
E220 Sonicator (PIP 90W, Duty factor 20%, Cycles per burst 200) for 180s, at 6°C. Lysate 
was cleared by centrifugation at 12000rpm for 20 minutes at 4°C. These were then 
submitted for mass spectrometry. 
  
2.5.2: Mass spectrometry.  
LFQ-MS/MS was conducted by using Filter Aided Sample Preparation (FASP) combining 
each prepared samples with 200µl UA (8M urea, 100mM tris) in a Vivaon 500 30,000 (R) 
(Sartorius VN01H22).  All centrifugation steps were performed at 14,000x g. The filter 
was then washed twice with 200µl UA.  100µl 50mM iodoacetamide in UA was applied 
to the samples and incubated in the dark for 30 minutes to alkylate.  Post spinning, this 
was followed by two washes with UA and another two washes with 50mM ammonium 
bicarbonate.  100µg trypsin (Life Technologies 90058) in 2ml 50mM ammonium 
bicarbonate was prepared on ice and 40µl added to each filter.  After overnight incubation 
in a wet 37°C chamber, samples were acidified by addition of 5µl 10% trifluoroacetic 
acid, pH check by spotting onto pH paper, and peptide concentration estimated using a 
NanoDrop. 10µg of the resulting peptide solution was loaded onto an activated (20µl 
methanol), equilibrated (100µl 0.1% TFA) C18 StAGE tip, and washed with 100µl 0.1% 
TFA.  The bound peptides were eluted into a Protein LoBind 1.5ml tube with 20ul 80% 
ACN 0.1% TFA and concentrated to less than 4ul in a vacuum concentrator.  The final 
volume was adjusted to 6µl with 0.1% TFA. 
Online LC was performed using a Dionex RSLC Nano.  Following the C18 clean-up, 5µg 
peptides were injected onto a C18 packed emitter and eluted over a gradient of 2%-80% 




before data-dependent analysis on a Thermo Q-Exactive Plus.   MS1 was acquired with 
mz range 300-1650 and resolution 70,000, and top 12 ions were selected for fragmentation 
with normalised collision energy of 26, and an exclusion window of 30 seconds.  MS2 
were collected with resolution 17,500.  The AGC targets for MS1 and MS2 were 3e6 and 
5e4 respectively, and all spectra were acquired with 1 microscan and without lockmass. 
2.5.3: Statistical tests. 
The data was analysed using MaxQuant in conjunction with uniprot fasta database, with 
match between runs (MS/MS not required). LFQ with 1 peptide required, and statistical 
analyses performed in R. Contaminants were removed from database along with proteins 
with <1 unique peptide. Proteins with a median of zero across LFQ Intensities were 
removed from the dataset. Any remaining missing values were imputed by MNAR is left-
censoring. P-values were calculated by pooled variance, two-tailed t-test in R and fold 
changes based on means of the three samples from each group. 
 
2.6: Microarray.  
 
The microarray data was conducted by Andy Sims and exact protocol is unknown. 
2.6.1: Sample extraction and preparation. 
The spinal cords of wasted mice were extracted at 21 days old from six homozygotes and 
six wildtype. 
2.6.2: Statistical tests. 
The p-values for volcano plot were calculated by two-tailed student’s t-test in R and fold 
changes based on means of the three samples from each group. The Significance Analysis 
of Microarrays (SAM) was conducted in R. 
 
2.7: Gene Ontology analysis.  
 
Differentially expressed proteins as identified as significantly downregulated and 
upregulated by pooled variance, two-tailed t-test in R. As well as genes:  identified as 
significantly downregulated and upregulated by SAM. These lists were separately 
subjected to PANTHER classification system; version 12.0 released 2017-07-10 
(http://www.pantherdb.org/). GO terms enriched for molecular functions and pathways 





Chapter 3: Characterisation of the D252H mutation in 
eEF1A2 in mice. 
 
3.1 Development of mouse lines. 
 
Transgenic founder mice were generated by others by injecting CRISPR/Cas9 into 
fertilised mouse oocytes of the C57BL/6 inbred line. The microbial clustered regularly 
interspaced short palindromic repeats (CRISPR) and its associated RNA-guided Cas9 
nuclease is an immune response of prokaryotes against viruses which has been harnessed 
to mediate genomic engineering (Marraffini, 2015). Non-coding RNA otherwise referred 
to as guide RNA (gRNA) directs Cas9 nuclease to induce double stranded breaks at 
specific sites which include protospacer adjacent motifs (PAM), a sequence located 5’ of 
the target DNA. The damaged DNA then undergoes one of two repair mechanisms, the 
non-homologous end joining DNA repair pathway (NHEJ) or the homology directed 
repair (HDR) pathway. NHEJ repair is error prone and often results in insertions and/or 
deletions of varying lengths, whereas HDR is more precise in introducing mutations and 
insertions from the donor templates (Ran et al., 2013). However an issue when the HDR 
and NHEJ pathways are enacted and Cas9 nuclease may continue to operate and cleave at 
intact PAM sites. In order to avoid this and because the PAM site was located in a coding 
region, a silent mutation was incorporated into the PAM site of the donor template, thus 
protecting it against Cas9. The donor template would also include the targeted mutation. 
Located in exon 5 of the Eef1a2 gene Exon 5, it would convert 252 Aspartic acid into a 
Histidine, which was shown to be damaging as human cases suffer from intellectual 
disability and autism, it was also predicted to be damaging (using the PolyPhen-2 tool) 
and affect protein functioning, as the site overlaps with Eef1β binding site; this may 
impede Eef1a2’s regenerative ability to its active GTP-bound state. 
The CRISPR D252H line was developed from breeding on from two founders 
heterozygous for the D252H mutation. The CRISPR D252H line has been shown to be 
robust and reproducible and relatively easy to develop with CRISPR/Cas9 techniques 
making it a practical model. This mutation was also presented in human cases, as outlined 
in the introductions. I characterised the remaining mice from the experiment to evaluate 
how successful the CRISPR experiment was and analysing the resultant mutations. 
Despite the progression in transgenesis and widespread practice of CRISPR gene editing 
technology, there still remain limitations and complications in the resulting genome. 
Issues arose with the founder mice displaying mosaicism and range of insertions and 
deletions whilst not always incorporating the intended PAM site and targeted mutation. 
This may have been because the DNA repair pathway selected for by the cell was the 




upon CRISPR/Cas9 injection the cell continued to divide whilst the system remained 
active, or repair pathways were not activated until DNA replication causing different cells 
to carry varying mutations and/or insertions and deletions. 
Following the CRISPR/Cas9 experiment characterisation of the founder mice was 
required. Therefore I genotyped the mice by TOPO cloning and sequencing as previous 
sequencing results had overlaying peaks that needed to be separated in order to recover 
specific alleles. Alongside examining their respective expression of eEF1A2 through 




As initial sequencing identified the founder mice as mosaic with overlapping sub-peaks, 
an allele sensitive method was required to delimit the varying point mutations, insertions 
or deletions incorporated into each mouse. I carried out nested PCR with a 678 bp final 
product region surrounding the D252H mutation and encompassing PAM sites located 
from exon 5 of the Eef1a2 gene, followed by TOPO cloning and Sanger sequencing. This 
allowed me to analyse the products of each allele found in each mouse to allow clear reads 
of each allele. 
Three out of the twelve mice genotyped appeared mosaic having more than two alleles 
(table 3), mice #14, #16 and #18. Mouse #14 had three alleles none with CRISPR induced 
mutations to include the target by HDR: a wildtype allele, an 11bp deletion and an 
insertion of 34bp, both of which caused the reading frame to shift. Mouse #16 was also 
mosaic with a wildtype allele, a 1bp insertion in another as well as the D252H mutation 
and PAM site mutations G→C and C→T respectively in the third allele. The other mosaic 
mouse #18 had incorporated a missense mutation, changing the proline into a leucine, in 
the second nucleotide of the PAM site. In this same allele downstream of the target sites 
a large 113bp insertion was found. Another two alleles had a 6bp deletion, one of which 
demonstrated a T→C mutation downstream of the D252 site. The phenotype of #18 
phenotype was not comprehensively reported but it had normal weight gain, which 
suggests there was no deterioration phenotype, this may have been either because the 
mutations experienced were non-harmful, or that the presence of the wildtype allele was 
sufficient to resist the development of the phenotype, as seen in non-mosaic heterozygotes. 
Mouse #10 was recorded as having a phenotype of tremor, absence seizures, periods of 
ataxia/gait changes/low movement interspersed with periods of more normal movement 
and a lack of tremor. On one allele a 16bp insertion was found and on the other allele a 
5bp deletion that encompassed a PAM site. Evidently these indels were enough to cause 
a phenotype so severe that for ethical reasons, led to an early culling. Although these 




eEF1A2 protein being either non-functional, ablated or another allele that was 
predominant in the brain. Mouse #11 appeared to have successfully incorporated a C→T 
mutation in the PAM site and the D252H mutation. It also had a 1bp deletion just prior to 
D252H resulting in a frameshift. Its other allele was wildtype. This mouse had developed 
a slight tremor and moved slower than its littermates but gained weight normally. Mouse 
#12 too had one wild type allele but on the other I saw a 26bp insertion. Mouse #15 had 
wild-type sequence except for the target D252H site (G→C) and at one of the PAM sites 
(G→C), along with a wild type allele. Although the #15.2 clone (see supplementary 
information) there is an S in the position of the D252 site, this denotes a strong possibility 
that the nucleotide is either a Guanine or a Cytosine, and since this clone did not have any 
other mutations, it is most likely also a wild type allele. Mouse #17 had a wildtype allele 
and another with the largest deletion at 37bp between the PAM sites which appears to 
have deleted the D252 site. The one allele identified in mouse #21 did not incorporate any 
of the desired mutations but had a 16bp insertion, which was a repeat of the base pairs 
surrounding the original D252 location (6bp upstream and 2bp downstream), causing a 
frameshift. Using the Provean software, a tool developed to predict whether protein 
sequence variation would affect the resultant proteins function, the effect of this insertion 
was revealed to be deleterious, scoring -9.31. The threshold value for whether a variant is 
deleterious is ≤ -2.5, any higher and the variant would be predicted to have a neutral effect 
(Choi et al., 2012). 
Mouse #23 was wildtype and unaffected by CRISPR in the region sequenced. The alleles 
in mouse #24 had a 19bp deletion and 18bp insertion respectively. The insertion has 
changed the reading frame of the resulting protein which would strongly suggest that the 
eEF1A2 protein is non-functional. Across the topo clones from #24 some point mutations 
were observed in what had been thought to be a wildtype allele. The possible causes were 
that Cas9 had cut here incidentally, that the Taq error rate had introduced these changes 
into the PCR products before cloning, These reasons may have also been behind the T→C 
mutation in one of #18s alleles, which would have reduced its apparent level of mosaicism. 
Mouse #25 had not incorporated any of the targeted mutations, but had an insertion of 
16bp just preceding the D252 location causing a frameshift, whereas the other allele has 










Some mice experienced a disruption in the reading frame, these frameshifts usually result 
in abnormal protein products that can be truncated or misfolded. 
 
Table 3. Resultant alleles and mutations from CRISPR/Cas9 experiment: Mutations 
seen in the targeted for regions and whether a frameshift was observed, as well as the 









10 2 - Deleted - Severe 
11 2 G→C C→T Frameshift Normal 
12 2 - - - Normal 
14 3 - - Frameshift Normal 
15 2 G→C G→C - Moderately 
slowed 
movement  
16 3 G→C C→T Frameshift Normal 
17 2 Delete
d 
- - Normal 
18 4 - C→T - Normal 
21 1 - - Frameshift Normal 
23 1 - - - Normal 
24 2 - - Frameshift Normal 






Fig.11. D252H CRISPR experiment mice alleles: Graphical representation of average 
of 120bp length of sequence excerpt of the alleles found in D252H founder mice showing 
the relative sizes of deletions (Red) and insertions (Green), PAM sites (Blue), D252 



































3.3 Protein Expression.  
 
To investigate the degree of effect the differing mutations in Eef1a2 had on its protein 
expression, western blot analysis on the muscle tissue of the D252H founder mice was 
conducted. The mice were 60 days at age of culling therefore should be expressing 
eEF1A2 alone, as myocytes would be terminally differentiated and the switch from 
eEF1A1 to eEF1A2 complete.  
Antibodies selecting for eEF1A2 were used and normalised with the protein levels 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) a housekeeping gene expressed 
ubiquitously that is commonly employed as loading control. Signals were present at the 
correct sizing of 50kDa and 37kDa respectively.  
The founder mice exhibit varying expression levels of eEF1A2, this is most likely due to 
the variation of mutations found observed across them, and the varying degrees of 
mosaicism. Unfortunately tissue from mice #10, #15 and #16 were not collected as #10 
had been euthanised and mice #15 and #16 were not culled and bred on from, therefore 



















Fig 12. Expression of eEF1A2 in D252H founder mice and signal strengths of 
eEF1A2 relative to GAPDH: Western blotting results of eEF1A2 (red band) observed at 
50kDa and relative GAPDH expression (green band) observed at 37kDa of mice #11, 
#12 and #14, alongside a wasted homozygote, heterozygous and wild type mouse. 
Founder mice demonstrate abated expression of eEF1A2 whilst the wildtype and 






































Fig 13. Expression of eEF1A2 in D252H founder mice and signal strengths of 
eEF1A2 relative to GAPDH: Western blotting results of eEF1A2 (red band) observed at 
50kDa and relative GAPDH expression (green band) observed at 37kDa of mice #17, 
#18, #21, #23, #24 and #25 alongside a wasted homozygote, heterozygous and wild type 
mouse. Founder mice demonstrate abated expression of eEF1A2 whilst the wildtype and 
heterozygous significantly more upon statistical analysis. 
Mouse #11 had incorporated the desired D252H mutation. Supporting the suspicion that 
the mutation impairs eEF1A2 expression, there were lowered levels of eEF1A2. However 
the protein was still detected which may have been due to the wildtype allele expressing, 
although it did not demonstrate nearly as much expression as in the control heterozygote. 
Notably, the mice bred on from the D252H #15 and #16 expressed eEF1A2 but it appeared 
non-functional, therefore the reduced expression in #11 may be attributed to the 1bp 
deletion and not the D252H mutation which is the most likely explanation as this too was 
predicted as damaging by Provean analysis. Mouse #12 also had reduced eEF1A2 
expression. This was not surprising considering the large deletion found in one of its 
alleles, but again it had a wildtype allele yet still did not express as much as the control 
heterozygote. The mosaic mouse #14 experienced mutations that caused frameshifts in 
two of its alleles, ensuing from indels, explaining why it had ablated expression as the 
protein may have not been able to fold correctly or be truncated. Mouse #17 had the largest 























reduced eEF1A2 expression. Mouse #18 also had reduced expression, which can be 
attributed to the missense mutation and deletions impairing the stability of the resultant 
protein and preventing it from being detected. However it still retained a wild type allele 
that might be responsible for the expression detected. Mouse #21 was reported as having 
a single allele with an insertion and presented ~60% less eEF1A2 expression than its 
comparative wild type control. Mouse #23 surprisingly despite being noted as wildtype 
showed far lower levels of eEF1A2 expression than controls and many of the other mice 
who had a range of mutations and/or indels. Mice #24 and #25 exhibited similar levels of 
eEF1A2 that were significantly lower than the wildtype expression. Although #24 had a 
wildtype allele whereas #25 consisted of two with indels. However this may be because 
of undetected mosaicism; the tissues used for analysis in the western blot were different 
from the tissue used in the preparation of DNA analysis therefore the cells may have 
sampled from a different population with different eEF1A2 sequence. 
The controls used were acquired from wasted mice; the homozygotes had no or 
insignificant amounts of eEF1A2 in contrast to the wildtype which showed high levels of 
expression. Unpredictably however, the heterozygous control had either equal or 
excessive eEF1A2 levels which is surprising considering wasted homozygotes are 
reported as having the expected ~50% of normal expression. Most founder mice retained 
a wildtype allele, despite this, eEF1A2 expression parallel to the expected heterozygous 
level was not demonstrated. Reasons for this may have been that the ages of the controls 
and founder mice were different, therefore expression of eEF1A2 may have varied in the 
older controls. The sex of the controls were also unknown therefore it may have been an 
effecting factor however this is less likely as previous work done on the mice reveal little 
to no difference in eEF1A2 expression between males and females. Therefore the 
comparisons made and conclusions drawn upon in regards to the control heterozygote are 
questionable. They were from different sexes and various ages which may have affected 
expression of eEF1A2. 
A repeat of the western blot using alternative controls was conducted to ensure 
reproducibility and found some discrepancies between the expression patterns but the 
majority of samples were observed to be expressing at similar levels. Mouse #12 saw an 
increase in expression in the repeat experiment reaching nearly 50% eEF1A2 levels 
compared to the wildtype. This is more in line with the identified genotype as it had 
reserved a wildtype allele and mimics, as mentioned previously, the wasted heterozygous 
expression profile. Mice #21 and #25 also demonstrated enhanced eEF1A2 levels in the 
repeat. These findings suggest for both mice that the indels borne were not damaging to 
the protein. On the other hand, this supports the postulation that the mice have more alleles 
that were not detected. 
The D252H line that was established from these founder mice used only #15 and #16, 
breeding them with wildtypes. Similar to wasted, homozygotes manifest symptoms of 









The D252H mutation in eEF1A2 has been identified in humans with the two cases 
showing symptoms of global developmental delay, one of which has also been reported 
as being non-verbal whilst the other is too young to report fully on (Nakajima et al., 2015). 
To explore the role of eEF1A2 in the development of the aberrant neurological phenotype 
the mutation was recreated in mice. A CRISPR/Cas9 experiment caused a range of 
mutations in the C57BL/6 mouse fertilised oocytes in attempts to generate the D252H 
mutation. The resultant founder mice revealed a range of mutations including large indels 
when genotyping and also revealed that some mice were mosaic. Their respective eEF1A2 
expression was also analysed by western blotting, which had shown that among most of 
the founders, expression was reduced.  
After genotyping it was clear that few mice had incorporated the desired mutation which 
may have been a consequence of the cell employing the NHEJ mechanism as opposed to 
the HDR with constructed repair templates with the mutations. This is a common issue 
with CRISPR/Cas9 experiments as it is dependent on the efficiency of the cell to utilize 
the HDR pathway. The various differing mutations observed in the founders in some cases 
would cause a frameshift in the amino acid sequence. These often have damaging effects 
upon the resultant protein as they alter the stop codon in the sequence either by introducing 
it prematurely causing a truncated protein, or later to cause an abnormally long protein 
which can have an effect on the proteins overall structure. These changes cause non-
functional proteins that can have dominant negative effect or deleterious gain of function 
activity. In cases with premature stop codons the nonsense mediated decay pathway is 
activated. This is a cellular surveillance mechanism that can recognise these premature 
stop codons and essentially mark them for degradation by the nonsense mediated decay 
complexes. However the pathway model suggests that it is only applied when the 
premature stop codon is located 50-55 nucleotides upstream from an exon junction 
complex (EJC), which are assembled predominantly at exon-exon junctions (Hug et al., 
2016). 
As only a specific region was sequenced, it cannot be certain that there were no off target 
effects from the CRISPR/Cas9 experiment in the founders. The induced mutations that 
did not necessarily cause a frameshift can still cause issues with the resultant protein. 
Important regions of the sequence may have been lost or amino acids change that impede 
the proteins functioning. In the case of the mosaic mouse #18, one of the alleles had a 
missense mutation changing the proline amino acid into a leucine. Proline is a cyclic 




ring, it has been repeatedly reported that when mutated into another amino acid protein 
stability is decreased (Ge and Pan, 2009,Suzuki et al., 1987, Gray et al., 1996). Although 
the degree of destabilisation tends to be marginal, it may have had an effect on eEF1A2, 
however this is unlikely. Leucine is a nonpolar aminio acid that can pass the blood-brain 
barrier more rapidly than other amino acids. It serves as a donor of amino acid groups for 
glutamate synthesis (a neurotransmitter), which is usually maintained at low intrasynaptic 
concentrations to minimize excitotoxicity in neurons (Yudkoff et al., 2005). However, this 
may not be the case for mouse #18. 
Nearly all founders retained a wildtype allele, meaning that most were heterozygous for a 
type of mutation in eEF1A2. These mice, apart from #10 and #15, did not demonstrate 
any physical phenotype and as the expression of eEF1A2 in these mice was significantly 
lower, there was no evidence of compensation by this allele. However, it does suggest for 
haplosufficiency; the wildtype allele was able to produce enough functional protein to 
prevent the diseased phenotype. This appeared to be the case in the wasted line 
heterozygotes, which showed 50% reduced eEF1A2 expression but no wasted phenotype 
(Griffiths et al., 2012). The levels of eEF1A2 detected below 50% in the D252H mice 
survived for up to 60 days without a diseased phenotype. This observation can have 
repercussions in the development of therapies for patients with neuronal developmental 
disorders. It suggests that only low levels of eEF1A2 is required to prevent development 
of disease which is a promising factor for possible gene therapy as it would not need as 
much compensation for the therapy to be effective. It also suggests that the missense 
mutation does not entirely result in loss of function.  
A limitation of the genotyping methods used was at the TOPO cloning stages in which the 
detection of alleles is dependent on whether or not they are transfected and grown 
successfully. In all cases an abundance of colonies were grown and a predicted to be 
sufficient number were sequenced, but there is always a possibility of excluding alleles 
unintentionally. Furthermore, an issue with drawing conclusions on the connection 
between the genotypes of #21 and #23 on eEF1A2 expression is that from the multiple 
colonies, the only clear sequencing results were obtained from two clones for #21 and a 
singular clone from #23 TOPO cloning (see supplementary information). The fact that the 
Provean software predicted #21 as having deleterious effects, yet this not being reflected 
in either the eEF1A2 expression or the phenotype of the mouse supports the idea that some 
alleles may have remained undetected. TOPO cloning may have failed to manifest all 
alleles present and some may have been lost through incoherent sequencing, this offers an 
explanation for some inconsistencies in eEF1A2 expression and Eef1a2 alleles, although 
the genotype and protein expression correlates for most of the founder mice. The 
discrepancies between the western results and the genotype may have been because of 
undetected mosaicism. There is no assurance that tissues used for analysis in the western 




the cells may have sampled from different populations with different levels or forms of 
eEF1A2. 
A study into the expression of RNA by qPCR to measure the gene expression levels would 
have been beneficial as it would have identified any differences in transcription or 
translation and possible protein degradation. The greatest issue with results from the 
western blotting were the discrepancies between the eEF1A2 expression levels of the 
wasted heterozygous tissue used and the levels recorded in another study (Griffiths et al., 
2012). The heterozygous eEF1A2 levels I detected were either similar to or higher than 
the wildtype expression levels. Upon further examination of the signals without 
normalising to GAPDH there was still no drastic improvement in the heterozygous 
controls demonstrating the expected 50% eEF1A2 expression, however wasted mice do 
not have the same genetic background as the D252H mice, this may also have some effect 
on the expression of eEF1A2. A repeat using alternative wasted heterozygous samples 
that were age and sex matched may clarify this issue, or studying whether there is a degree 
of variation across wasted heterozygous mice. However, it may be an issue with 
normalisation with GAPDH an alternative method to normalise would be using the total 
protein concentration in the lane. The issue with the heterozygous control confounded 
identifying the degree of eEF1A2 reduction in these mice as it would be inconclusive to 
draw comparisons with eEF1A2 null heterozygous and the various heterozygous 

















Chapter 4: Analysis of eEF1A2 null and Wildtype spinal 
cord quantitative proteome and neuronal damage. 
 
To identify potential biomarkers for MND, a comparative quantitative analysis into the 
proteome of the spinal cords of eEF1A2 null and wildtype mice was conducted using 
Label free Mass spectrometry (LFQ-MS) to identify the proteins present and their relative 
abundances. The results from this experiment were processed and statistically analysed to 
identify proteins that were identified as differentially expressed between the groups. 
Significant findings were probed further for biological significance by gene ontology 
enrichment analysis exploring which pathways and functions were over-represented, in 
order to better understand pathogenesis. In addition to this analysis, the extent of neuronal 
damage in the spinal cords of the eEF1A2 nulls, as well as the D252H homozygous and 
heterozygous mice was analysed by immunohistochemistry (IHC). This would evidence 
the degree of neuronal degeneration experienced with differing levels of eEF1A2 and 
identify how severe the pathology of MND is in eEF1A2 mutant mice. Understanding the 
loss of eEF1A2 and its neuronal degeneration phenotype, the resultant affected protein 
expression within the spinal cord has elucidated proteins enriched for particular pathways 
and provided possible prognostic benchmarks for future therapeutic development. 
 
4.1 Biological specimens. 
 
Spinal cords from three wild type mice and three eEF1A2 null mice from one litter of the 
Del.22.Ex.3 line were subjected to proteome analysis. A comparative study between these 
two groups is likely to yield a difference associated with neuronal degeneration. The 
absence of eEF1A2 expression and severity of symptoms observed in the homozygotes of 
this line suggests that there may be differential expression of a protein or group of proteins 
that are distinctive and would act as biomarkers of neuronal degeneration. Whereas mice 
heterozygous for eEF1A2 null mutations have displayed reduced expression of the 
protein, disease phenotype and pathology has not presented itself in live mice or spinal 
cords, so this genotype was therefore not included in the analysis.  
Spinal cords were extracted from 21 day old mice, a time-point in which the switch 
between eEF1A isoforms is more or less completed, with only trace amounts of eEF1A1 
being expressed (Chambers et al., 1996). As mentioned before, this is concurrent with the 
onset of symptoms of motor neuron degeneration associated with eEF1A2 null genotypes 
(Newbury et al. 2005).  
The spinal cord would be appropriate, as changes in protein expression will be monitored 




observations of changes made in glial cells being more telling as they would not be 
affected directly by the mutation and downregulation of protein synthesis given that glial 
cells only expresses the eEF1A1 isoform (Newbury et al 2007). Whereas motor neurons 
expression only eEF1A2 will display a quantity of changes in expression, predominantly 
resultant of downregulation of protein synthesis. Ergo p21 spinal cords should display 
changes affected by mutated eEF1A2 but before differences in protein expression can be 
heavily influenced by impaired translation; if analysis was conducted upon later time-
points any resulting differences may be confounded by the loss of translation.  
 
4.2 Establishing the extent of neurodegeneration in the new 
homozygous mice. 
 
A study into the pathology of the developing aberrant neurological phenotype of mice 
from the D252H and Del.22.Ex.3 lines was conducted using immunohistochemistry to 
establish the degree of neurodegeneration seen in the new homozygous mutant mice. 
Previous work on the wasted mice revealed that neurons in the spinal cord experienced 
vacuolation, progressive retraction of nerves from motor endplates, as well as evidence of 
gliosis(Newbury et al. 2005, Abbott et al., 2009). This pathology appears as a progressive 
rostrocaudal gradient. With more motor neuron deterioration occurring initially at the 
cervical level, there is speculation as to whether these changes work as a cascade and 
eEF1A1 is switched off progressively, which would explain why caudal areas do not seem 
to be as affected (Newbury et al. 2005). The gliosis reaction of glial cells upon damage in 
neuronal cells is commonly observed in central nervous system (CNS) injury including 
motor neuron diseases (Ince et al.,1998, Burda and Sofroniew, 2014). Reactive gliosis is 
a response that characterised by the accumulation of glial filaments, a constituent of which 
is glial fibrillary acidic protein (GFAP). As a result, GFAP has been commonly employed 
as a biomarker of neuronal damage (O’Callaghan and Sriram, 2005). The spinal cords of 
homozygous and heterozygous Del.22.Ex.3 and D252H at the ages of 21 days were 
stained using this to demonstrate, if any, pathological changes between homozygotes, 
heterozygotes and wildtypes that may be connected to the neurological phenotype. In 
order to visualize the levels of neuronal degeneration and to examine if, as observed in the 
wasted line, degeneration is progressive in the Del.22.Ex.3 and D252H lines, the spinal 
cords of wild type, heterozygous and homozygous mice at cervical, thoracic and lumbar 
sections were stained for GFAP. These experiments were an important part of the 
characterisation of the new lines of mice prior to carrying out proteomic analyses of spinal 
cords.  
Colin Smith (Professor of Neuropathology) analysed H+E staining of homozygote, 
heterozygote and wildtype spinal cords of D252H and Del.22.Ex.3 mice. He identified 




cords whilst heterozygotes appears unaffected when compared to the wildtype. In sections 
from homozygous mice there were clear signs of vacuolation along with various indicators 
of the evolution of neuronal degeneration; abnormal nuclei that have lost their nucleoli 
which then deteriorate further losing cell structure and disintegration of the cell 
membrane, eventually leading to a dead neuron with no definitive cellular structure. The 
cervical regions had greater degrees of vacuolation and neuronal degeneration, with the 
lumbar regions demonstrating less degeneration. Therefore this analysis supports the case, 
as recorded in the wasted mice, that the switch between isoforms works progressively 
rostrocaudally in this eEF1A2 null line, however this was only an observational 
conclusion. The D252H homozygote showed similar neuron degeneration in all regions 
in comparison to the Del.22.Ex.3 homozygote, whilst heterozygotes in both lines showed 
no damage. 
GFAP staining in Del.22.Ex.3 spinal cords (Fig.14) was markedly increased in 
homozygous mice and not prolific in wildtype and heterozygous mice. A high abundance 
of GFAP is observed in the eEF1A2 null sections across all regions. An apparent decrease 
in GFAP can be detected from the cervical through to lumbar region. This is in line with 
the neuronal degeneration witnessed in the H+E stains, again supporting the concept that 
eEF1A1 is switched off in neurons in a rostrocaudal fashion. However GFAP is also 
present in the heterozygous and wildtype spinal cord. The heterozygote displays a 
surprising amount of GFAP whereas the H+E stains revealed no neuronal damage. This 
finding is also in contradiction with the findings in heterozygous wasted mice which were 
recorded to have rare amounts of GFAP (Newbury et al. 2005).  It is anomalous in its 
nature as the mouse also did not manifest any phenotype indicative of the damage. The 
wildtype retained the least amount of GFAP staining although there was still some present.  
The D252H mice exhibited similar results, with the homozygote showing a similar 
rostrocaudal pattern of decreasing GFAP present (Fig.15). There appeared to be less 
GFAP detected in the D252H homozygote in comparison to the Del.22.Ex.3 homozygote. 
This is curious on account of the D252H mice having a more severe phenotype than the 
Del.22.Ex.3 mice (personal communication). The heterozygote unmistakably showed a 
degree of GFAP, which did not correlate with the findings from the H+E staining’s 
reporting no degeneration. Such a degree of neuronal damage was unexpected in the 
heterozygote as they demonstrate no phenotype. The wildtype displayed more GFAP than 





Fig.14. GFAP stained Del.22.Ex.3 spinal cords. Spinal cords of Del.22.Ex.3 stained with GFAP (Brown markings) imaged at x40 
magnification. Homozygous, (-/-) B) Heterozygous (+/-) and C) wildtype (+/+).Spinal cords were compared at the cervical, thoracic and 
lumbar regions. The (-/-) demonstrates high levels of GFAP as a rostrocaudal gradient, with cervical and thoracic regions showing 
vacuolation. The (+/-) exhibits a degree of GFAP staining as well as (+/+) but significantly less than the (-/-). 
A) -/- 
Cervical Thoracic Lumbar 
B) +/- 
Cervical Thoracic Lumbar 
C) +/+ 






Cervical Thoracic Lumbar 
A) -/- 
Cervical Thoracic Lumbar 
B) +/- 
Cervical Thoracic Lumbar 
Fig.15. GFAP stained Del.22.Ex.3 spinal cords. Spinal cords of Del.22.Ex.3 stained with GFAP (Brown markings) imaged at x40 
magnification. Homozygous, (-/-) B) Heterozygous (+/-) and C) wildtype (+/+).Spinal cords were compared at the cervical, thoracic and 
lumbar regions. The (-/-) demonstrates high levels of GFAP as a rostrocaudal gradient, with cervical and thoracic regions showing 




4.3 Mass Spectrometry. 
 
4.3.1 Quantitative Label-free Mass spectrometry. 
To illustrate comprehensively the proteome of two different states for comparative studies, 
a bottom up proteomic approach by label free quantitative mass spectrometry has emerged 
as an adept approach for absolute quantification of proteins. This approach can ascertain 
protein profiles by characterizing peptides in proteolytic digests and quantifying each 
protein (Resing et al. 2005). It is a method that can provide efficient sequence coverage 
in protein identification and is also able to examine post-translational modifications 
(Latosinska et al. 2015, Wang et al. 2012, Bantsheff et al. 2012, Witze et al., 2007). It 
does however require robust analytical configuration of ultra-High performance or High 
performance liquid chromatography for mass spectrometry. LFQ-MS is ideal for 
exploring proteins that are differentially expressed between wild type and eEF1A2 nulls 
as one can retroactively quantify proteins, therefore the initial hypothesis is not limited by 
narrowed choice of select proteins of interest. This study is only a preliminary analysis, 
however if taken further, LFQ-MS can also facilitate large-scale projects. 
Its limitation lies predominantly with its inability to detect low abundance proteins, where 
it lacks sensitivity in comparison to labelled methods (Hamacher, et al. 2011), which can 
be a substantial issue if proteins are significantly downregulated below the level of 
detection. There is also an enhanced possibility of introducing technical variance when 
compared to other quantitative proteomic techniques. Biological samples are kept separate 
during processing and analysis, and can unintentionally experience subtle differences that 
may effect and distort the detected proteome and respective abundances, leading to 
misleading results. This also reduces the reproducibility of the experiment, requiring 
replications for confident results. Another limitation is that it is not suitable for enriched 
samples, however this is not applicable to the biological samples used in this study. 
Nonetheless, facilitated by the advancements in instruments and software it has become 
increasingly employed for Biomarker discovery studies as it is comparatively low cost 
and requires less resources in terms of sample preparation (Wang et al. 2012). Although 
there is not a standard method of analysis, LFQ-MS newfound popularity has allowed for 
range of software and protocol to be developed for use accurate protein profiling. 
The results from Label free Mass spectrometry (LFQ-MS) underwent data processing; to 
interpret the raw data from the mass spectrometry (MS) from each fraction and multiple 
runs of samples into quantifiable protein abundance a series of steps were taken. Peptides 
signals were normalized and matched into proteins utilizing MaxQuant software in 
conjunction with Uniprot fasta database, filtered out for contaminants and imputating 
missing values before udergoing statistical analysis. Of this, any significant findings were 
then probed further for biological significance by functional analysis. LFQ-MS and data 




protein identification and abundance profiling was done by the Mass Spectrometry 
services at the Institute of Genomics and Molecular Medicine. 
 
4.3.2 Peptide identification. 
Proteins from the biological samples are digested into peptides which are broken down 
further into fragment ions by tandem Mass spectrometry. These are then accelerated in the 
mass spectrometer with heavier ions ‘flying’ slower than lighter ones, the system 
measures the mass/charge ration of an ion and using this information reconstructs the 
peptide sequence. Protein identities are then inferred from the peptide sequences when 
they are matched to protein groups by organism specific sequence database searches (these 
databases also include contaminants and reverse sequences).  A limitation of this approach 
is that the same peptide sequence can be present in multiple different protein or different 
isoforms, especially in higher eukaryotes having high degrees of sequence homology. This 
can cause dubiousness in protein identifications.  
Fig.16: A simplified example of how proteins are inferred. Peptides are assigned to all 
corresponding proteins and an Occam’s razor philosophy of deriving the minimal list of prote ins 
that can explain all observed peptides. Shared peptides are marked with and asterisk. Proteins 
that are impossible to differentiate on the basis of identified peptides are collapsed into a single 
entry (As shown by F and G), or presented as a group (H,I and J). Proteins that cannot be 
conclusively identified do not contribute towards total protein count, but are still shown. Image take 




Peptide sequences that are unique to a singular protein in the proteome are termed ‘Unique 
peptides’, these are often used to determine the confidence in the proteins’ identification. 
It is common practice for a ‘two-peptide’ rule to be observed, by only including proteins 
that have a minimum of 2 unique peptides, as this would reduce the rate of false-positives. 
However, this two-peptide bias has not been theoretically proven as superior. A study into 
the performance of this rule against including proteins with singular unique peptide for 
analysis, identified that the larger set of protein identifications are generated from the 
single-peptide approach, than from the two-peptide, that are still reliable (Gupta and 
Pevzner, 2009). 
 
4.3.3 Determination of protein abundances. 
Mass spectrometry is inherently non-quantitative as equal amounts of different peptides 
can generate ions with differing signal intensities due to ionisation efficiency varying and 
competition with other analytes. Therefore the proxy used for generated for abundance is 
crucial to true changes in expression being reflected in the analysis. Advances made in the 
field of proteomics has allowed for experimental data from the signals detected to be 
interpreted proficiently into data that is representative of protein abundance.  
MaxQuant has implemented a novel approach to building accurate abundance profiles for 
each protein across samples, permitting its use for comparisons between the diseased and 
wild type groups. Although there are alternative methods of defining protein abundance 
such as spectral counting, the approach outlined is more accurate, has a higher dynamic 
range and if required is capable of quantification of post-translational modifications. 
Termed “LFQ Intensity”, it is upheld as representative of a quantifiable presence of a 
protein, facilitating the assessment of which proteins may be upregulated or 
downregulated in the eEF1A2 null mice. This approach is based entirely upon the 
experimental dataset acquired with no external standards. It can overcome the complex 
issues of normalizing multiple runs across multiple fractions of samples, whilst also 
allowing for greater amounts of data points to be included by increasing the rate of 
identification, thus maximizing quantification of proteins. Normalizing the intensities of 
the peptide ions across fractions of each samples and runs, alongside selecting for peptide 
signals that should optimally determine the protein signals. The normalization step is 
crucial when having to draw conclusions from multiple runs and fractionated samples; 
eliminating signals that were resultant of inevitable variations from technical 
measurements and random effects from biological samples allows for better deductions to 
be made upon the proteome dynamics between the two groups and determine biologically 
significant differences. It is a stage to reduce technical bias introduced such as carry-over 
and drifts in ionisation and detector efficiencies (America and Cordewener, 2008). 
Fractionation of samples for this experiment complicates normalization due to the 




is usually necessary to normalize,which is split across runs of each fraction. Meaning that 
any normalization coefficients cannot be classified. Hence the concept of “Delayed 
normalization” was developed, in which firstly the intensities are summed up with 
normalization coefficients as free variables, followed by determination of the quantities 
by global optimization procedures that would achieve the least overall proteome variation.  
Approaching the issue by attempting to equalize total signals by adjusting the 
normalization coefficients for each fraction can introduce errors if there was a divergent 
average for a particular run. In response to this, the notion that the majority of the proteins 
change minimally between conditions allows for the use of average behaviour to be a 
standard. 
Peptide ion signals, as aforementioned are summed up across the fractions without 
normalization coefficients (𝑁𝑗). The 𝑁𝑗 factors are then determined in a nonlinear 
optimization model which minimizes overall changes for all peptides across all samples. 
Like this, the total intensity of a peptide ion is defined as: 
𝐼𝑝, 𝑎(𝑁) = ∑ 𝑁𝑟𝑢𝑛(𝑘)𝑋𝐼𝐶𝑘
𝑘
 
Where p is the peptide, a, is the sample and k the runs over all isotope patterns for p. With 
XIC, in this case, the area of cross section at retention time when maximum intensity is 
reached. This quantity is then used as the sum of the squared logarithmic changes in all 
samples for all peptides. 







To achieve the least amount of differential regulation for the most amount of proteins, the 
𝐻(𝑁) value is then minimized with respect to  𝑁𝑗 by Levenberg-Marquardt optimization. 
As such the peptide ion intensities were normalized across the different runs of samples 
and their fractions.  
However to generate the abundance profile, a selection of which peptide ions to contribute 
to this intensity must also be chosen. MaxQuant does this by selecting peptide species 
present between samples and then calculating the ratio using the intensities (Cox et al., 
2014). This initial pair-wise ratio is defined as the median to protect against outliers, is 
followed by determination of the other pair-wise ratios, in this analysis the minimal 
number of 1 peptide ratios for a given protein ratio was considered valid. The resulting 
matrix corresponds to the underlying abundance profile across samples and undergoes a 
least-squares analysis to reconstruct the abundance profile so as to satisfy the individual 








Each profile is rescaled to the cumulative intensity across the samples, thus preserving the 
total summed intensity for a protein over all samples.  
 
4.4 Data Analysis. 
 
An experimental issue arose during mass spectrometry in which tandem digestion was 
reduced to digestion only with trypsin. The preparation for spinal cord extracts 
unfortunately was possibly too gentle and did not break down the proteins enough. It 
would have benefitted from a harsher protocol. Trypsin is a serine protease with high 
proteolytic activity, high cleavage specificity and resulting peptides have optimal size 
(700-1500 Da) and charge for mass spectrometry analysis. However, complete digestion 
does not always occur as tightly folded proteins resist trypsin digestion and trypsin is 
inefficient in cleaving at lysine residues. To address these issues, tandem digestion with 
Lys-C drastically improves the efficiency of digestion as it compensates for trypsin’s 
missed cleavage of lysine residues (Giansanti et al., 2016). This ensures higher sequence 
coverage which can discriminate closely related protein isoforms, as well as aid precise 
protein identification and quantification. In the absence of Lys-C incomplete digestion is 
suspected and MaxQuant analysis of peptide and parent protein identification works on 
the assumption of complete digestion. Despite this limiting factor, data analysis was 
conducted as proteomic studies were initially conducted using trypsin as a singular 
enzyme. 
The contaminants and reverse sequences as identified by MaxQuant using Uniprot fasta 
database in the dataset were removed alongside identified proteins with a unique peptide 
<0 for the reasons mentioned in section 4.3.2. 
Missing values can encumber statistical analysis and in LFQ-MS experiments missing 
values are not uncommon. It has been reported that as many  as 70-90% of proteins or 
peptides harbour at least one missing value (Lazar et al., 2016). Due to LFQ-MS known 
issues with detecting peptides and proteins at abundances that border the level of 
sensitivity of the instrument, missing values are classed as ‘missing not at random’ 
(MNAR), hence why a single-value approach was taken with the assumption that missing 
values are present yet below the level of detection. A mechanism of MNAR is left-
censoring; a condition when the missing values pertain to the lower intensities, and that 
intensity distribution of the dataset is truncated on the left side. Upon imputation, a left 
tailed skew emerges across the distribution of intensity. Proteins with a median of 0 




otherwise the confidence of correct detection lies with a singular value. In each sample 
the lowest value for intensity was assigned to the remaining missing values. 
However, even after using an imputation that promotes left tailed skewness, the dataset 
maintained relatively normal distribution. The Shapiro Wilks test tests for normality by 
examining if the dataset is not normally distributed. The null hypothesis is that the dataset 
follows normal distribution, therefore if the p value is less than 0.05, the data is not 
normally distributed, in addition to the giving a measure of ‘closeness’ to an expected 
normal distribution of a W value. The eEF1A2 null sample means when tested had a W 
value of 0.99, as this nears 1 it is indicative of normal distribution, although the p value 
from this test was observed to be 1.42x10-11; this can be attributed to the large sample size 
which has the ability to detect even small deviations from normality. The wildtype means 
also generated a W value of nearing 1 (0.99), and a p value of 8.9x10-12, therefore both 
protein populations are suggested to be normally distributed as the tests conducted do not 
indicate that they are not. However, because the Shapiro Wilk test is subject to bias in 
rejecting the null hypothesis in the case of large sample sizes, further analysis by other 
means are required to support its finding that the eEF1A2 nulls and wildtype means are 
normally distributed.  
A Q-Q plot can demonstrate how well the data compares to that of normal distribution. It 
is a probability plot that is used to compare two distributions by plotting quantiles or 
estimates of the quantiles of two distributions against each other, the pattern of the plot is 
telling as to how they compare. A Normal Q-Q plot was generated by plotting the quantiles 
of either the eEF1A2 null means or wildtype means with the quantiles of a standard normal 
distribution (Fig.17.). Therefore the distribution of the means can be compared with that 
of normal distribution to observe if they too fit normality. In Fig.17 the majority of the 
points fall within the line of normality and although there are bends towards the end tails, 




pattern. Both the Shapiro Wilks test and the Q-Q plot suggest the data is normally 
distributed. 
Fig.17. Q-Q plots assessing normal distribution. Q-Q plots using the quantiles of normally 
distributed data (x-axis) was plotted against the logarithmic eEF1A2 null means (Left) and the 
logarithmic Wildtype means (Right) quantiles (y-axis). The individual points belong to the eEF1A2 
null and Wildtype means. The red line passes through the first and third quantile, this is a robust 
approach for estimating the parameters of normal distribution. The majority of the datasets points 
are positioned in approximately the same line as that of normal distribution. The tails diverge 
somewhat from normal distribution, however their departure from the line are not indicative of non-
normality. 
 
4.4.1 Expression profiles: 
To identify if the proteome of wildtype and Del.22.Ex.3 mice is distinguished from one 
another a cluster analysis was done by complete linkage method for hierarchal clustering. 
This class of cluster analysis functions by initially assigning each observation a separate 
cluster then examines all the distances between the individual and pairs the closest two 
clusters together. The following observations then join it or not depending on the distance 
between the cluster and observation. The complete linkage method of hierarchal clustering 
uses the maximum distance between object and the objects within a cluster when forming 
clusters. This analysis identified no particular dissimilarity in overall protein abundances 
between the wild type mice group and eEF1A2 null group. Usually minimal or no changes 
in majority of the proteins is expected between healthy and mutated/diseased groups. The 
groupings were neither made based on gender as female and male mice were not clustered 
separately. Given the lack of distinguishing variable between clusters and relatively small 
distances between clusters it can be concluded that eEF1A2 nulls at p21 do not have a 




Fig.18. Cluster dendrogram by complete linkage for hierarchal clustering. Wild type mice 
samples denoted as Wt.1, Wt.2 and Wt.3. whilst mice with eEF1A2 null mutation are denoted as 
Null.1, Null.2 and Null.3. Samples are represented on the X axis and are connected by decreasing 
similarity along the Y axis.  
 
This lack of differences are also seen in Fig.19. showing that the means of each sample 
are very similar. Even the outliers from the normal distribution do not great distinction 
between samples and even less so between the wildtype and nulls. 
Fig.19. Box and whisker of protein profiles of each wildtype and null samples. The log 
transformed protein expression of each sample was plotted with 50% of the data centered around 
the median and the 1st and 2nd quartile being the lower and higher whiskers respectively. 
Observations plotted outside the whiskers are extended beyond the 5% and 95% points of normal 
distribution. Features of box and whisker plot are outlined in (Chambers et al. 1987). Wildtype 







Fig.20. Heatmap of protein expression patterns. Abundance of individual proteins detected by 
mass spectrometry (rows) and samples Wt.1, Wt.2 and Wt.3. (Wild type) and Null.1, Null.2 and 
Null.3 (eEF1A2 null) expression profiles (columns) were organised by complete linkage 
hierarchical clustering Euclidean distance. 
A further visualisation of the protein abundance across all samples to search for 
quantitative patterns is shown in Fig.20. A data-matrix heatmap graphically represents the 
numerical data by pseudo-colouring protein expression and arranging the proteins rows 
and sample columns so that similar profiles are closer and it is easier to interpret patterns 
and trends from the dataset. The resultant heatmap however shows no quantitative pattern 
in either individual protein expression nor the samples, the latter being expected as the 
cluster analysis revealed no conspicuous groupings. It is clear in the absence of distinct 
blocks of colour in the heatmap that the individual proteins share similar expression 
profiles and there is great variability across the samples. 
To examine if proteins were, and the degree at which they were, overexpressed or under-
expressed, relative changes in the protein abundance, the logarithmic fold change for each 
gene was calculated: 
𝐿𝑜𝑔2 |
𝑒𝐸𝐹1𝐴2 LFQ intensity mean






This is one of the simplest approaches to identify differentially expressed proteins is by 
measuring the fold change ratio of the protein between the sample means. The higher the 
fold change ratio the larger the difference in expression between groups. However, in its 
simplicity it is reduced to measuring the difference in expression at the surface value, it is 
limited in assessing the significance of a difference in the presence of biological and 
experimental variation. It has been shown to perform poorly when variability in the data 
is high (Murie et al. 2009). Therefore a simple fold change measure may not account for 
real differences, the resultant proteins deemed as differential based on the fold changes 
may contain a high rate of false positives. For this reason, t tests would also be a beneficial 
measure of significant differential expression. T tests use more robust central tendency 
and dispersion estimates to adjudge significant difference in expression, than relying on 
the use of means alone which can be affected by the degree of deviation. 
T tests can measure the observed pairwise differences in individual proteins between 
replicated samples of wildtype and null and evaluate the confidence of these. The p-values 
for each protein across the groups were calculated using pooled variance, two-tailed t-test. 
This was appropriate for the dataset as it meets all the assumptions made for it; both means 
follow normal distribution and homoscedasticity. The p-values for each protein were 
plotted Fig.21 to illustrate how the test behaved across the data and whether the null 
hypothesis rejected (that there was no significant difference in gene expression between 








Fig.21. Histogram of the frequency of p-values. P-values calculated from two tailed t-test of 
protein expression levels acquired by LFQ-MS in wildtype and eEF1A2 mice.  
Fig.21. depicts no statistically significant changes in protein abundance between the 
wildtype group and eEF1A2 null group. The uniform distribution of p-values indicate that 
the null hypothesis is accepted; the majority of the proteins are not present at different 
abundances between the groups. This was expected given the results emerging from the 
previous cluster analysis, heatmap and plots, there appears to be very little differential 
protein expression between the two groups. However, there may be specific proteins that 
are differentially expressed and these may identified by visualising both the fold changes 











Any meaningful changes in the proteins between the spinal cords of wildtype mice and 
eEF1A2 null mice and the proportion of these in the dataset are represented in Fig.22.  
Fig. 22. Volcano plot comparing gene expression between wildtype and eEF1A2 null mice. 
The Log2 Fold changes against –Log10 p-values of each genes expression between p21 wildtype 
and eEF1A2 null mice. Non-significant values are shown in grey. Proteins with fold changes >1.5 
(Pink), p-values ≤0.05 (Blue). Proteins with fold changes >1.5 and) a p-value ≤0.05 (Green). 
Proteins with fold changes >-1.5 and) a p-value ≤0.05 (Yellow). 
The threshold for a significant p value was set at 0.05 and a fold change of 1.5. The 
majority of the proteins were not significantly different between the two groups. However 
~6% of proteins were significantly differentially expressed, the majority of which were 
upregulated in the Del.22.Ex.3 mice, 60% of the significantly differentially expressed 
proteins (see supplementary information). Six proteins experienced a fold change greater 
than 1.5, five of which were downregulated in eEF1A2 nulls (fibroblast growth factor 12 
(Fgf12), Glutathione S-Transferase Kappa 1, Tubulin Folding Cofactor E Like, biquinol-
Cytochrome C Reductase Hinge  and Ubiquitin Like 4A and upregulated epoxide 
hydrolase 1. Such few changes are in line with the observations made prior to this analysis. 
Out of these proteins only Fgf12 was calculated as statistically significant, and was present 
at a 2.4 fold lower level in the eEF1A2 nulls. Very few proteins were detected as 







4.5 Gene Ontology analysis: 
 
Proteins identified as significantly differentially expressed by the t tests conducted were 
then used in gene ontology enrichments analysis so as to explore if particular pathways 
and functions were over-represented. This would aid in understanding how the loss of 
eEF1A2 affects the proteome in spinal cords and perhaps pathogenesis of the MND 
developed in homozygous Del.22.Ex.3 mice. Gene ontology analysis was conducted on 
separate lists from the data analysis output; proteins that were significantly downregulated 
in eEF1A2 nulls and upregulated in eEF1A2 nulls (see supplementary information). The 
reason why proteins with a fold increase greater 1.5 were not included was because there 
were too few, making enrichment analysis redundant. Gene ontology enrichment was 
done using PANTHER (Protein ANalysis THrough Evolutionary Relationships). This is 
a classification system (Mi et al., 2013) that was designed for proteins and their genes to 
facilitate high-throughput analysis. Proteins are classified according to: 
• Molecular function: the function of the protein by itself or with directly interacting 
proteins at a biochemical level. 
• Pathway: similar to biological process, but a pathway also explicitly specifies the 
relationships between the interacting molecules. 
The molecular function enriched in list of proteins that were significantly downregulated 
in the spinal cords of the Del.22.Ex.3 mice is shown in Fig.23. The majority of proteins 
were enriched for binding when classified by their molecular function. Upon further 
inspection many of these proteins were in fact related to actin remodelling and 
transportation. The second most common enrichment term was catalytic activity, these 
included proteins that were involved in hydrolase, transferase and oxidoreductase activity 




linked to actin remodelling. The transporter activity was compromised of proteins 
involved in transmembrane transportation.  
Fig.23. PANTHER molecular function enrichment analysis pie chart of proteins 
downregulated in eEF1A2 null mice. The molecular functions of proteins identified as 
downregulated in the spinal cords of Del.22.Ex.3 mice were enriched for binding, catalytic activity, 















Fig.24 highlights pathways that were over-represented, many of which have been 
implicated in the development of neuronal degeneration, such as Dync1i2, a subunit of 
the cytoplasmic dynein complex functioning as a transporter for axonal transport, 
described further in Chapter 6. However, for each pathway identified, only one protein is 
included in the list of proteins enriched for these particular pathways. The downregulated 
proteins have been enriched for functions and pathways that have been linked to eEF1A2 
non-canonical roles, as well as neuronal damage.  
Fig.24. PANTHER Pathway enrichment analysis pie chart of proteins downregulated in 
eEF1A2 null mice. The proteins identified as downregulated in the spinal cords of Del.22.Ex.3 













Proteins identified as differentially expressed by statistical analysis that were upregulated 
in spinal cords of Del.22.Ex.3 were used in Fig.25. Many of the molecular functions 
enriched for were shared with those of downregulated proteins. Protein binding made up 
the majority of the binding activity function but these proteins were enriched more so for 
G-proteins and GDP associated proteins. The catalytic activity category had the addition 
of ligase and lyase activity. Proteins enriched for structural molecule activity however 
were involved predominantly structural constituents of the ribosome, whereas the 
transporter activity proteins were also associated with transmembrane transportation. The 
identification of translation regulator activity is negligible as it is the differential 
expression of eEF1A that is responsible for this category being identified. 
Fig.25. PANTHER molecular function enrichment analysis pie chart of proteins upregulated 
in eEF1A2 null mice. The molecular functions of proteins identified as upregulated in the spinal 
cords of Del.22.Ex.3 mice were enriched for binding, catalytic activity, receptor activity, signal 
transducer activity, structural molecule activity, translation regulator activity and transporter 
activity. 
Many more pathways were identified from the proteins that were upregulated in eEF1A2 
null mice, some of which have been identified as possible contributors to the pathogenesis 
of neuronal degeneration and the development of disease. These were Alzheimer’s, 
Huntington’s and Parkinson’s. The proteins enriched for Alzheimer’s and Huntington’s 
disease pathways were predominantly related to actin. As described in Chapter 1.4, the 
eEF1A2 isoform has reduced cytoskeleton remodelling, so the upregulation of these genes 
may lead to abnormal actin bundling, which in neurons may also be linked with synaptic 
function (Cingolani and Goda, 2008). The Parkinson’s pathway had also proteins related 
to actin with addition the protein Cytoplasmic FMR1-interacting protein 2 (Cyfip2), which 
has been connected with apoptosis as it is p53-inducible (Jackson et al., 2007), it has also 




al., 2012). This has similar phenotypes to patients who carry heterozygous missense 
eEF1A2 mutations; intellectual disability and autism. The upregulation of this may in part 
be behind some of the neuronal cell death in the eEF1A2 null mice. Many of the other 
pathways enriched for included this protein as well as ADP-Ribosylation factors, these 
are GTP-binding factors some of which can act as regulators for intracellular traffic. 
Excessive expression of such protein can lead to neuronal damage (Skaper, 2003, Lai et 
al., 2017), whilst inhibition of this has shown to improve axon regeneration (Byrne et al., 
2016). Therefore upregulation of ADP-Ribosylation factors may be responsible for the 
axonal degeneration seen in the wasted mice which too are eEF1A2 nulls. 
Fig.26. PANTHER Pathway enrichment analysis pie chart of proteins upregulated in eEF1A2 
null mice. The proteins identified as upregulated in the spinal cords of Del.22.Ex.3 mice were 
involved in a range of pathways.  
The gene ontology enrichment analysis has highlighted that the proteins both 
downregulated and upregulated are involved in binding, catalytic and transporter activity 
functions in the cell and many of these were actin related proteins, suggesting that 
cytoskeleton remodelling and the transportation may be the cause of pathogenesis of 
neuronal damage. Proteins upregulated in the eEF1A2 nulls are associated with pathways 
that when dysregulated cause neuronal damage. Hence the proteins identified as 
significantly differentially expressed between eEF1A2 null and wildtype mice have been 
demonstrated to be contributors to neuronal damage and speculated to be part of the 
pathogenesis of neuronal disorders in other studies. Similar pathology may be occurring 
the D252H eEF1A2 mutated mice, as the loss of eEF1A2 functioning in homozygotes will 







IHC probing for markers of neuronal degeneration by GFAP and H+E staining on the 
D252H and Del.22.Ex.3 lines established the extent of neurodegeneration whilst the label-
free quantitative mass spectrometry and a range of statistical analysis defined the 
proteome of spinal cords from homozygotes and wild types for comparative study. This 
revealed there was little overall difference between them. However, some proteins were 
differentially expressed and may be potential biomarkers for MND as the gene ontology 
analysis showed that some are involved in neuronal pathways that, when dysregulated, are 
implicated in neuronal degeneration.  
The H+E staining Colin Smith described and IHC evidenced neuronal degeneration by 
GFAP staining and that in both Del.22.Ex.3 and D252H homozygotes there was a greater 
presence of degeneration than the heterozygotes and wildtypes. Notably, degeneration in 
homozygotes appeared as a rostrocaudal gradient which agreed with the observations 
made by (Newbury et al. 2005), identifying a similar progression in wasted mice by 
measuring levels of damage at different ages. They suggested that the switch between 
isoforms works as a cascade; eEF1A1 is switched off progressively initiating at rostral 
regions. The spinal cords analysed were extracted at p21 when the switch between 
isoforms should be nearing completion (Khalyfa et al., 2001). The D252H mice have a 
more severe phenotype than the Del.22.Ex.3 mice, as another student in the Abbott group 
identified D252H struggling to gain weight in comparison, however no seizures were 
recorded in the D252H whereas in some cases Del.22.Ex3 mice did experience them. This 
suggests that the D252H missense mutation causes a gain of function. The D252H mice 
still express eEF1A2 as a seemingly non-functional form impairing translation. Yet there 
is the possibility that the D252H mutation may have residual functioning but be greatly 
impaired. These speculations are based upon the conclusion that the mutation is loss of 
function, however this is contradicted by phenotypic observations on the mice (conducted 
by Laura Kaminioti-Dumont, an honours student in the lab group). The D252H 
homozygous mice showed higher phenotypic scores measuring the sum performance from 
four tests: ledge test, hindlimb clasping, gait and kyphosis, where a higher score represents 
impaired performance. As well as this they displayed a lack of weight gain from 15 days 
in contrast to homozygous Del.22.Ex.3 mice (representing a completely null phenotype) 
which continued to gain weight until 21 days. It is also worth noting that for ethical reasons 
the D252H mice are culled before we are able to observe the extent of their degeneration, 
so they may too, eventually develop seizures. Based upon these findings, the mutation 
would be gain of function, hence in addition to impaired translation, it may have gained 




The degree of neuronal damage as detected by GFAP was unprecedented in D252H 
heterozygotes especially as the H+E stain showed no neuronal damage. It contradicts 
entirely the phenotype witnessed in both lines; the heterozygote showed no signs of 
abnormality. Heterozygous wasted mice show no neurodegeneration in their phenotype 
nor pathology (Newbury et al. 2005), therefore the detection of GFAP in Del.22.Ex.3 
heterozygotes (another eEF1A2 null) is highly unlikely. There was also detection of 
GFAP in the wildtypes. Considering the distribution of GFAP in the both the 
heterozygotes and wildtypes was irregular across all sections, it is more likely that there 
was an abundance of non-specific staining. This confounds the results from GFAP. The 
GFAP expression seen in neuronal tissues can be dependent on the abundance of 
astrocytes present (Garman, 2010), if there was a variation of these between the different 
genotypes, it may explain some of discrepancies. Nonetheless, the H+E stains identify 
unequivocally that mice homozygous for the mutations in eEF1A2 develop a rostrocaudal 
gradient of neurodegeneration. However further study in a larger cohort of mice from each 
genotype would confirm this and perhaps with statistical analysis of the degree of 
neurodegeneration. 
The application of LFQ-MS is apt for quantifying the proteins within the spinal cords of 
Del.22.Ex.3 and wildtype mice. However, due to incomplete digestion the identified 
proteins and their respective abundances may not be representative of their presence and 
the differential expression detected between wildtype and eEF1A2 nulls may not be true 
changes of expression. However these proteins upon further investigation were revealed 
to have biological involvement in neuronal functioning and have been implicated in MND 
or other types of neuronal disorders (outlined in Chapter 6). The gene ontology analysis 
highlighted some of these proteins as enriched for pathways which dysregulation of has 
been implicated in neuronal damage, as well as molecular functions that are associated 
with previously studied non-canonical roles of eEF1A isoforms. This implies that the 
pathology of neuronal damage developed in the homozygous eEF1A2 null mice is in part 
due to dysregulation of actin related proteins and these may act as potential biomarkers 
for MND and neuronal death. 
A major challenge of proteomic studies is the limitation in the number of replicates 
available, acquiring biological samples is dependent on many different factors such as 
availability of diseased samples and controls or accessibility of tissues for analysis. This 
is of particular importance in LFQ-MS as the separate treatment of samples can introduce 
variation, therefore replication is required to identify true changes. For this study a 
limiting factor was the availability of homozygous mice at p21 from the Del.22.Ex.3 line 
within the timeline of the project. However this was not a dominating issue, as the nature 
of the study was explorative, which has demonstrated little in proteome differences 
between the wildtype and eEF1A2 null mice spinal cords. The nature of acquiring the 
biological samples for experimentation also meant that the mice were unavailable for 




study as phenotype is homogeneous among Del.22.Ex.3 homozygotes. However, studying 
a larger cohort of homozygote Del.22.Ex.3 mice will be necessary for identifying truly 
differential expression and ensuring the potential biomarkers are reproducible.  One of the 
greatest limitations to LFQ-MS is its inefficiency in detecting proteins with low 
abundances. The proteome of a sample may not be identified in its entirety and as of yet 
it is most likely that proteomics studies fail to do this. This issue means not all proteins 
that were present in the samples were included in the output of proteins detected, hindering 
in the discovery of biomarkers. However given that for a biomarker to be practical it must 
be reproducible, proteins with low levels may not necessarily be promising. Especially if 
the biomarker is for prognostic use in model organisms as it may not always be possible 
to collect enough tissue for low abundance proteins to be measured. However, there are 
other methods that can support low level protein detection, yet these are more targeted 
and biased to proteins suspected of being differentially expressed. As this study was 
explorative by nature this could not have been done.  
Additionally, LFQ-MS is constrained by the potential to misidentify proteins. This can be 
done at different stages of analysis, including initially from the resultant spectrum from 
the mass spectrometer which can have a great deal of noise and unexplained peaks. These 
can often be attributed to fragmentation events where small molecular groups are 
separated from peptides during the fragmentation stage, or these may be contaminants that 
enter the mass spectrometer (Noble and MacCoss, 2012). The noise detected is often 
reduced by using technical replicates so as to reduce its influence in downstream analysis. 
Other issues that are to be dealt with are the background subtraction, outlier detection and 
signal distribution normalization (Sellers and Miecznikowski, 2010). Assigning the peaks 
generated can also be challenging, the various software available for analysing raw data 
such as Progenesis, Peaks Q and MaxQuant can differ modestly in feature detection. 
Feature detection is the detection and quantification of peaks in the spectral data, a crucial 
stage which can cause perpetuated misidentifications, false positives, false negatives and 
missing values. There has been a range of software and algorithms developed to combat 
the dilemmas and confusion of assigning homogeneous peptides to individual proteins. 
MaxQuant performs admirably among these, yet the variation in protein identifications is 
dependent on which software is implemented. Isoforms also present a challenge to protein 
identification, as isoforms can share sequence homology meaning peptide fragments may 
not be confidently assigned to the correct isoforms, hence the abundance of proteins with 
isoforms must not be assumed to be belonging to the specific isoform necessarily. Hence 
proteins identified must not be assumed to be true nor their respective abundances without 
validation.  
As proteomic studies are relatively new, there is yet no definite standards of practice, or 
unequivocally better methods for data pre-processing and analysis the large datasets 
generated. A stage at which proteomics data processing can vary, generating differing 




so as to deal with missing values making downstream data analysis feasible. The 
imputation method applied; assuming that the proteins are present but below the level of 
detection, hence assigned the lowest detected value of that sample. There have not been 
many comparative studies in the assessment of imputation methods in LFQ datasets but 
those that have been carried out have identified no considerably superior method of 
imputation in this or in other types of mass spectrometry experiments (Webb-Roberston 
et al., 2015, Miecznikowski et al., 2010, Karpievitch et al., 2012, Sandra et al., 2017). 
The single value method chosen does lead to a left hand skew of the data but this did not 
influence the downstream analysis as the overall distribution was normal. However, it may 
introduce more false positives, which is of particular interest in this analysis as the proper 
corrections have not been placed and the proteins identified as differentially expressed 
have not been validated thoroughly. Alternatives that could have been used that do not 
rely heavily on assumptions are the Random Forest imputation, K nearest neighbours and 
local least squares. These would have instead integrated information from across the 
sample to impute the missing values and preserve better the variance and distribution of 
the dataset, in addition to reducing the amount of false positives by not increasing the 
differences between the groups. As this is caused by the imputation method utilized it will 
mean that the difference between the groups, which is already not conspicuous, may have 
even less differentially expressed proteins and that the findings must be taken with 
caution.   
There is an assortment of statistical tests and variations of these alongside arbitrary cut-
off values for judging significance. Hence, the same data can be interpreted multifariously, 
with different conclusions being drawn on which proteins are differentially expressed. Just 
as a p-value of <0.05 is conventional to use despite being an arbitrary value, fold change 
cut-offs appear to be set at 1.5 or 2 for proteomics studies (Ting et al., 2009). The lower 
value of 1.5 is less stringent and allows for more potential proteins to be identified as 
being differentially expressed. A limitation of measuring differential expression by fold 
change is the assumption that all proteins have the same variance, which is not necessarily 
the case. As mass spectrometry can struggle to identify proteins bordering the level of 
detection, low abundance proteins have great variability. The implications of a fold change 
at a protein level can vary depending on its abundance, fold changes in lowly expressed 
protein may not have a great impact upon the proteins function within the cell, whereas 
proteins that are highly abundant may alter the dynamics of the cell even if the fold change 
is observed to be identical to that of the lowly expressed protein. Therefore pursuing the 
biological significance of proteins is required to inform whether the proteins with fold 
changes have consequences that alter the cells normal function, or for the case of 
biomarker discovery, act as an indicator of disease and/or disease progression. 
One of the major concerns with the analysis conducted is the lack of control for false 
positives. Some of the differentially expressed proteins have a chance of failing and being 




p-values to account for the occurrence of false positives as t test analysis assesses the 
significance of each protein independent of one another. There are many corrections that 
can attend to this issue and reduce the amount of false findings such as the Bonferroni or 
Hommel corrections. However these are considered quite stringent for large datasets and 
the false discovery rate (FDR) approach is usually more suitable for the dataset resulting 
from LFQ-MS experiments. This would have functioned by identifying false discoveries 
(here a discovery meaning a statistically significant finding) the level of which deemed 
acceptable set usually at 5%. Therefore any significant finding would have a 5% chance 
of being a false positive. This approach differs from others as it doesn’t start with the 
assumption that no differences exist between the groups. The application of FDR 
correction would have reported proteins that more likely to be truly significant and would 
have been most suitable given the size of the dataset and low number of biological 
replicates, as the rate of false discoveries may have been reduced with more replicates to 
an extent. However, the distribution of the p-value from the resultant t-tests (Fig.21) being 
uniform would most likely have led to larger FDR values. This would have meant that the 
significant findings are in fact false positives. In addition to including more replicates to 
identify false positives, increasing the p-value cutoff would have reduced the stringency 
of the tests as 0.05 is an arbitrary cutoff value that is predominantly established by 
common practise, however this would not necessarily mean that the differences are 
significant and the best method to examine significance would be through validation steps 
and increasing the cohort of mice included in analysis by repeating LFQ-MS with more 
samples.  
As differences between the two groups have failed to manifest with great certainty the 
proteins that have been identified as of interest and potential markers must be taken with 
caution as the rigorous analysis into their differential expression has not been conducted. 
The small sample size also means there is low statistical power for identifying differential 
expression. Although the students t test is the most common approach when assessing 
differences between two groups the develops small sample size error estimation methods 
(Murie e al., 2009). The students t test power is reduced also in its underlying assumption 
that each observation is independent of one another, which decreases the overall 
measurement of variance causing an overestimation of statistical significance as the 
samples are in replicate (Ting et al., 2009). Other significance tests that may have 
performed better is the Empirical Bayes test which outperforms other tests in identifying 
true differences and reduced number of false positives overall (Murie e al., 2009). 
However variations in tests for statistical significance have shown to generate differing 
outcomes (Ting et al., 2009). A form of an Empirical Bayes test with appropriate 
corrections may have led to the discovery of truly significant differences within the dataset 
but even with this change the lack of standardization in data analysis causes each 
proteomic study to generate results based on individual interpretation. Although studies 
are attempting to modulate the approach to analysing significantly differential expression, 




It would be interesting to attempt different methods of analysis to compare how the data 
performs. However this would be better suited to a more complete dataset given the 
experimental issues. The sample preparation appeared to not be harsh enough to break 
down the proteins, a revised protocol would be necessary to ensure such an issue does not 
arise again. 
In the expression analysis the lack of distinction between the groups, despite the eEF1A2 
nulls being translationally impaired may be compounded by the ages of the mice; at p21 
the switch between eEF1A1 and eEF1A2 is only just being completed, meaning there may 
still be functional eEF1A1 proteins maintaining regular translation. However if the study 
was to be conducted at any later time points it would be confounded by the loss of 
translation. The proteins detected and their relative abundances would become dependent 
in part on their stability and turnover rates once translations is reduced drastically. The 
clustering of the samples was not found to be due to other factors such as sex whilst their 
ages are consistent and all wildtypes and Del.22.Ex.3 were from the same litter. To 
confirm this later stage westerns may be conducted with later stage mice where it would 
normalise to other proteins. 
The analysis into the pathology revealed that homozygotes have a great degree of neuronal 
damage in their spinal cords that manifests as a rostrocaudal gradient whereas the wildtype 
and heterozygous does not show such neuronal damage. The effects of the mutations when 
present as homozygotes in mice results in non-functional proteins that cause a severe 
phenotype. Whereas heterozygotes do no not appear to manifest this phenotype as there 
is no haploinsufficiency. However these observations were made on a relatively small 
sample size, therefore it be beneficial to use a larger cohort of mice. 
If there was more time the proteomics experiment would require a repeat because of the 
issues with incomplete digestion, along with including more biological replicates to 
increase statistical confidence and utilize the appropriate statistical tests to reduce false 
discoveries. It will also be important to  validate the most differentially expressed proteins 
that also have extensive literature supporting an association with MND, so as to 











Chapter 5: RNA expression profiles of wasted mice and 
wild type mice. 
 
The transcriptional activity in a biological sample can be assessed by microarray 
experiments that allow for genome-wide expression changes between healthy and 
diseased groups to be measured. This is an unbiased, systematic approach that facilitates 
the discovery of novel functional roles of genes, potential diagnostic or prognostic 
biomarkers and implicate potential pathways and mechanisms that cause disease 
development.  
Microarrays are microscopic slides that consist of a large range of ‘spots’ that contain 
multiple identical strands of DNA from the same gene. Genes from the experimental 
samples are converted into complementary DNA (cDNA) with fluorescent tags, these 
hybridize to their matching sequences on the spots. The strength of the binding will 
depend upon how complementary the cDNA is to gene sequences on each spot. The tags 
inform on the levels of hybridization in comparison to a reference sample. These spots are 
arranged in a particular order to allow for detection of genes that are being expressed 
(Scitable by nature, 2017). 
Having described the translational activity of eEF1A2 null mice and identified proteins 
expressed differentially as potential markers of motor neuron degeneration, it would be 
intriguing to see if these changes are reflected at the genomic level, which would 
strengthen confidence in the conclusions derived from the proteomic study.  
The correlation between RNA and protein expression can be influenced by many 
elements. One of the most obvious, and in this study overtly present, are factors that 
impact translational activity which would cause discrepancies between RNA and protein 
expression detected. Alongside translational efficiency that vary between RNA. Samples 
collected at p21 meant that the effects being seen would not as of yet be affected 
drastically by the lack of translation (as eEF1A1 expression is abated) but that the levels 
of protein observed would have become dependent on their respective turnover rates and 
stability. Microarray data would not be confounded by this as the RNA levels are not 
affected. 
The microarray experiment and subsequent data pre-processing, as well as significance 
analysis of microarray (SAM) generating a list of 500 genes with significant differences 
in expression was conducted by Andy Sims, a previous member of the Abbott lab. Further 
data analysis as described in this chapter was done so as to identify genes of interest and 





5.1 Biological specimens. 
 
Spinal cords from six wild type mice and six homozygous wasted mice underwent 
microarray analysis. Taken at p21, the timepoint in which severe phenotypes develop and 
eEF1A2 expression is enhanced, whilst eEF1A1 is reduced to only trace amounts in 
neurons but expressed in glial cells. Samples were collected at the same time-point (p21) 
























5.2 Expression profiles. 
 
To visualise whether overall gene expression was distinctive for each group, a cluster 
analysis was done by complete linkage method for hierarchal clustering calculating the 
pairwise distances between samples based on the gene expression profiles of each sample 
Fig.27: Cluster dendrogram of wasted and wildtype mice gene expression profiles. 
Complete linkage for hierarchal clustering for Wild type mice samples denoted as Wt.1, 
Wt.4, Wt.5, Wt.7, Wt.X10 and Wt.11), whilst wasted mice with eEF1A2 null mutation are 
denoted as Wst.2, Wst.3, Wst.6, Wst.8, Wst.9 and Wst.12. Generated in R program. 
Samples are represented on the X axis and are connected by decreasing similarity along 
the Y axis. 
Fig.27. Unlike in the proteomic analysis, the wildtype and wasted form distinguishing 
clusters indicating that eEF1A2 loss alters overall gene expression in spinal cords. 
Samples Wt.1 and Wst.12 appear to have a closer gene expression pattern between the 
two groups but are nonetheless distinctly separate. A possible reason for the wildtype and 
eEF1A2 nulls forming separate clusters in the microarray data and not mass spectrometry 
could be resultant of experimental differences and not reflective biological factors at play 




The heatmap in Fig.28 shows the relative expression of a random subset of 6000 genes 
out of >30000 in the microarray. It further clarified that the gene expression between 
wildtype and wasted samples differ greatly and be easily distinguished from one another. 
The wasted mice show a distinctively reduced overall expression when compared to the 
wildtype. There is also no clear set of genes that are conspicuously upregulated or 
downregulated, however this is only a subset chosen at random so patterns in gene 
expression may not have manifested. 
Fig.28. Heatmap of gene expression patterns. Expression of individual genes from 
microarray experiment (rows) and samples Wt.1, Wt.4, Wt.5, Wt.7, Wt.X10 and Wt.11. 
(Wild type) and Wst.2, Wst.3, Wst.6, Wst.8, Wst.9 and Wst.12. (wasted) expression 
profiles (columns) were organised by complete linkage hierarchical clustering Euclidean 
distance.  
The p-values for each gene were calculated by two-tailed t-test and the resulting histogram 
for frequency of p-values distributed between 0-1 was plotted to illustrate how the test 
behaved across the data and whether the null hypothesis rejected (that there was no 
significant difference in gene expression between diseased and healthy groups) or 
accepted (Fig.29). The anti-conservative histogram demonstrated that the alternative 




distribution indicates many of the genes were not differentially expressed between the two 
groups but the protruding left hand peaks are confirmation that some are. 
Fig.29. Histogram of the frequency of p-values. P-values calculated from two tailed t-
test of gene expression levels acquired by microarray in wildtype and wasted mice.  
To examine genes that were, overexpressed or under-expressed relative changes in the 






As mentioned previously in Chapter 4, the fold change only functions well if the variance 
of the data is not high. The variance of the wasted means and wildtype means individually 
have very high variability, however when comparing their variability with one another, 





Fig. 30. Volcano plot comparing gene expression between wildtype and wasted. 
The Log2 Fold changes against –Log10 p-values of each genes expression between p21 
wildtype and wasted mice. Non-significant values are shown in grey. Genes with fold 
changes >1.5 (Pink), p-values ≤0.05 (Blue). Genes with fold changes >1.5 and) a p-value 
≤0.05 (Green). Genes with fold changes >-1.5 and) a p-value ≤0.05 (Yellow). 
The volcano plot visualises any meaningful changes between the gene expressions in the 
spinal cords of wildtype mice with wasted mice and can quickly show the proportion of 
genes identified as either significant and/or experience a fold change. The threshold for a 
significant p value was set at 0.05. What is more argued is the threshold set for what is 
deemed as a consequential fold change. For the purposes of this study it was set at a ratio 
change of 1.5.  
A great number of genes were identified as significantly differentially expressed, 4573, 
however this made up only 10% of the total genes measured. Out of these, three genes 
showed to have a greater fold change of 1.5; three of the points measuring to have fold 
changes are all Eef1a2, Neuronal acetylcholine receptor subunit alpha-4 (Chrna4) and 
ChaC glutathione specific gamma-glutamylcyclotransferase 1 (Chac1). Additionally, 
Transthyretin (Ttr) had a 2.2 fold increased abundance in the wasted mice but was not 
observed to be statistically significant in regards to its p-value. Assessing differentially 
expressed genes based on p-value is acceptable, however another computational tool has 
been developed specifically for microarrays large data output: SAM. SAM identified 
genes whose expression is significantly related to the response variable, diseased and 
healthy. It tackles the multiple testing problem that occurs with t tests and works upon the 
q values as a measure of significance. It functions by computing a statistic for each gene 
measuring the strength of the relationship between the genes expression and the response 




missing values by a K-Nearest Neighbour algorithm normalization. A list of 500 genes 
(See supplementary information) was output from SAM as possessing this significance. 
The genes described as differentially expressed in SAM identified 132 genes that were 
not deemed of significance by p-value analysis alone (Fig.29).  
 
5.3 Gene Ontology analysis. 
 
The genes that were listed as differentially expressed by SAM were underwent gene 
ontology analysis using the PANTHER analysis tool. This highlighted the molecular 
functions and pathways enriched for in the eEF1A2 null mice by either upregulation or 
downregulation of genes in the spinal cords. Exploring the molecular functions and 
pathways by this analysis may also insinuate pathogenesis in the mice. Genes that showed 
a fold change greater than 1.5 were not included as they were too few to search for 




















The molecular function enriched in list of genes that were significantly downregulated in 
the spinal cords of wasted mice is shown in Fig.31. The majority of genes were enriched 
for catalytic activity when classified by their molecular function, which included genes 
that were involved in hydrolase, transferase predominantly as well as enzyme regulation 
and oxidoreductase activity among others. The second most enriched for term was 
binding, which predominantly encompassed genes associated with protein and nucleic 
acid binding. Genes enriched for calcium ion binding were also included these were 
calmodulin binding proteins. Structural activity terms were enriched for and genes 
associated with actin binding were downregulated in the wasted mice. In addition to genes 
that are associated with neuronal receptors as well as signal transduction and transporter 
activity. 
Fig.31. PANTHER molecular function enrichment analysis pie chart of genes 
downregulated in eEF1A2 null mice. The molecular functions of genes identified as 
downregulated in the spinal cords of wasted mice were enriched for catalytic activity, 
binding, structural molecule activity, receptor activity, transporter activity, signal 














The pathways that were over-represented in genes significantly downregulated in wasted 
mice are identified in Fig.32. Of these, the greatest number of genes were enriched for 
Integrin and Wnt signalling. Genes involved in the Integrin signalling pathway were 
associated with structural and G-proteins. There were many other pathways that were 
enriched for and the same genes were involved in multiple pathways, for example the 
structural genes found in the integrin pathway also appeared as Huntington disease. 
Across the pathways many of genes involved were part of the Rho family of GTPases, 
which play a role in cytoskeletal dynamics. 
 
 
Fig.32. PANTHER Pathway enrichment analysis pie chart of genes downregulated 
in eEF1A2 null mice. The genes identified as downregulated in the spinal cords of 

















Genes differentially expressed by SAM that were upregulated in the spinal cords of wasted 
mice were used in Fig.33 to identify the molecular functions that were enriched. Many of 
these were shared with those of downregulated proteins, however more were enriched for 
catalytic activity in upregulated proteins.  
 
Fig.33. PANTHER molecular function enrichment analysis pie chart of proteins 
upregulated in eEF1A2 null mice. The molecular functions of proteins identified as 
upregulated in the spinal cords of wasted mice were enriched for binding, catalytic 
activity, receptor activity, signal transducer activity, structural molecule activity, 






















Fig.34. PANTHER Pathway enrichment analysis pie chart of genes upregulated in 
eEF1A2 null mice. The genes identified as upregulated in the spinal cords of wasted 
mice were involved in a range of pathways.  
 
There were far more pathways enriched for in the upregulated genes of wasted than there 
were in the downregulated genes, suggesting genes upregulated had more diverse 
functions. Although there were genes represented in multiple pathways there was still 
more diversity among the upregulated genes. Similar to the pathways for downregulated 
genes, the Rho family of GTPases was represented in the upregulated genes too. Some of 
these were involved in neuronal diseases such as Alzheimer’s, Huntington’s and 
Parkinson’s. The majority of the genes that were included in these pathways were also 
seen to be upregulated in these diseases upon examination and associated with the stress 
response. One as such was the heat shock protein family A (Hsp70) member 9 (Hspa9) 




(Refseq, 2010). In addition to this the oxidative stress response pathway was also enriched 
for and the genes involved were not the same as those identified in the neuronal disease 
pathways. The FGF signaling pathway was also represented, this has been linked to early-
onset epilepsy (Guella et al., 2016, Al-Mehmadi et al., 2016), a symptom that is also 
present in some of the cases with eEF1A2 mutations (Table.1). The GO analysis on the 
pathways enriched for in significantly upregulated genes found that particular ones that 
may contribute to the development of the aforementioned diseases that can share 
pathology with MND, however the oxidative stress response is also upregulated may be a 
response to the neuronal damage occurring in the wasted mice. 
 
GO enrichment analysis of significantly differentially expressed genes of those both 
downregulated and upregulated are involved in predominantly catalytic and binding 
activity. Examining the molecular function of these genes revealed many associated with 
actin binding and calcium ion binding in both downregulated and upregulated genes.This 
is of note as a non-canonical role of eEF1A isoforms has been demonstrated to remodel 
cytoskeleton. Upon dimerization the isoforms can bind to F-actin resulting in actin 
bundling. Yet the F-actin is loosened when eEF1A isoforms bind to Ca2+/calmodulin 
(Bunei et al., 2006). The pathways that these gene lists may be involved in the 
development of neuronal damage when dysregulated. The genes that are differentially 
expressed between wasted and wildtype mice have shown connections to neuronal 




The microarray results have identified many differentially expressed genes through 
significance analysis and few more by observing genes with fold changes. Given that the 
dataset analysis demonstrates good quality and that there are clear differences in overall 
gene expression between the spinal cords wildtypes and wasted mice at p21. Both the 
hierarchal cluster analysis and heat map clearly discern each group. For class comparison 
studies as such, the number of biological replicates is deemed appropriate for explorative 
purposes. Six samples per group is sufficient enough to distinguish true differences 
between the conditions. It also facilitates meaningful permutation tests such as SAM. The 
technical replicates of particular genes on the array itself demonstrated little variance 
between them. However the addition of more samples would increase the statistical power 
of the analysis. 
The thresholds chosen were the same as those applied in the analysis of the LFQ-MS data 
in Chapter 4.4.1. Just as in proteomic studies the thresholds are set as deemed appropriate 
for the dataset. In this case as it is exploring for possible biomarkers, a lower threshold 




less stringent criteria was beneficial and found more GO terms associated with the 
diseased group (Dalman et al., 2012), but this being said validation of these results will 
also be key in identifying significantly differentially expressed genes. As mentioned 
previously probing for differential expression by using fold changes is limited when 
assessing significance in datasets with high variability (Murie et al., 2009), which is the 
case in the microarray dataset. Hence why SAM was utilized. It overcomes the multiple 
testing problem and copes well with the large datasets output from microarray experiments 
and controls for false discoveries. However, there have been critiques as to the 
performance of SAM due to its FDR estimations (Zhang, 2009, Jeanmougin et al., 2010). 
The FDR is estimated by analysing the permutations of the genes, which has a tendency 
to overestimate the level of FDRs (Hirakawa et al. 2007). Its bias lies in the lack of strict 
assumptions made upon the data, it has also been critiqued for overestimating the number 
of false positives in by estimating the distribution of non-differentially expressed genes as 
more dispersed based on the permutations than the data truly is (Hirakawa et al. 2007). So 
although SAM can cope with analysis of larger datasets it still struggles to impose 
appropriate corrections. Other studies have proposed alternatives to SAM (Jeanmougin et 
al., 2010), but the majority of microarray analysis to identify differentially expressed 
genes is conducted using SAM. 
The GO analysis demonstrated that some of the differentially expressed genes in the 
wasted mice were associated with neuronal degeneration. There is a possibility that the 
reason for these genes upregulation is activation of pathways that protect against the 
damages developing. The Wnt signalling that was enriched for in the pathways has been 
linked to a neuroprotective role in Alzheimer’s disease (Inestrosa and Toledo, 2008). In 
addition, genes for the cell stress response were upregulated, this is more suggestive of a 
response to the neuronal damage and not dysregulation of it necessarily. 
The microarray data revealed many significantly differentially expressed genes between 
the wasted and wildtype mice, which led to strongly discriminate genetic profiles (Fig.27 
and Fig.28). However differentially expressed genes would still be required to be validated 
by western blot or ELISA, especially considering SAMs critiques on FDR correction. 
Some of these genes revealed themselves to be associated with neuronal damage, yet 









Chapter 6: Proteins and genes in the context of MND. 
 
This data-driven search for differentially expressed proteins has identified a few proteins 
of interest. The proteomic study identified differences in abundance between the eEF1A2 
nulls and wildtypes, which have been implicated in the development of motor neuron 
degeneration. Fgf12, Dync1i2, Kif5c and Dnajc5 have presented themselves as of 
biological significance. They all were detected as downregulated in the eEF1A2 nulls 
except for Fgf12 which was upregulated. Although these changes were significant at a 
protein level they were not all seen to change as significantly at a genomic level from the 
microarray data, it was only Kif5c that showed significance in both datasets. However the 
functions and pathways of these select proteins were heavily represented in GO analysis 
in the microarray data. The proteins were chosen based on their differential expression, 
their functional role being connected to that of eEF1A2s non-canonical roles and their 
emergence as also being connected with MND pathology. 
 
6.1 Fibroblast growth factor 12 (Fgf12). 
 
Abundance of Fgf12 was detected as downregulated in the eEF1A2 null mice. It 
demonstrated the greatest fold change at -2.4 and returned as significantly differentially 
expressed by statistical tests. It is also known as FHF1 and encodes a small cytosolic 
protein that interacts with the cytoplasmic tails of voltage gated sodium channels 
(Siekierska et al., 2016). It promotes neuronal excitability by elevating the voltage 
dependence of the neuronal sodium channel SCN8A fast and long-term inactivation. 
Fibroblast-growth-factor homologous factors (FHFs) compose a family of 4 proteins in 
many vertebrate species. Developing and mature neurons show the highest expression as 
seen in Fig.35. Expression starts during embryogenesis after post-mitotic neurons emerge 
at different neuronal sites (Goldfarb 2005). FHF1 knockout mouse have shown moderate 
muscle weakness, however when knocked along with anther FHF the phenotype becomes 
more pronounced and mice show ataxia and gait impairments, seemingly similar to 
eEF1A2 null homozygotes. However, there was no reports on abnormality in the nervous 




Fig.35. mRNA expression of Fgf12 in human brain. The mRNA expression in 
postmortum human brains at different ages. There is a sharp increase initial weeks after 
birth, then levels remain high until old age. 
Mutations in Fgf12 have been recorded in humans with early-onset epilepsy. De novo 
mutations and patients with inherited mutations have been identified and is rarely verified 
to be the cause of epilepsy (Guella et al., 2016, Al-Mehmedi et al., 2016). The cases have 
also presented epileptic encephalopathy, which has also been a phenotype presented in 
humans with eEF1A2 mutations (Lam et al., 2016). The mutation responsible for these 5 
cases was shown to be a toxic gain of function mutation (Siekierska et al., 2016) which is 
of interest as Fgf12 was observed to be upregulated. The remarkable similar phenotype in 
human cases and mice, as well as the fact that it is upregulated at both the protein and 
genomic levels shows potential for being a biomarker. However the lack of pathology 
manifesting in the nervous system along with the pattern of expression, which is markedly 
similar to eEF1A2 expression (as detected from the same database, see supplementary 
information) does cast doubt on whether Fgf12 would act as a biomarker for MND.  
 
6.1 Cytoplasmic dynein 1 intermediate chain 2 (Dync1i2). 
 
Dync1i2 expression was observed to be significantly reduced in the Del.22.Ex.3 
homozygotes. However it was not seen to reduce as drastically at a genomic level in the 
wasted mice reporting a fold change of -1. Nonetheless the functional role of this protein 
implicates it in the motor neuron degeneration phenotype observed in the mice. 
Dync1i2 is one of the several non-catalytic accessory components located in the tail 




by homodimerization is the most abundant from the two cytoplasmic dynein complexes, 
it is responsible for the retrograde transport in neurons. It acts as an adenosine triphosphate 
(ATP) driven motor, moving along microtubules to transporting essential signals in 
vesicles and organelles from distal site to the cell body. It is also involved in spindle-pole 
organisation, nuclear migration during mitosis and the positioning and functioning of the 
endoplasmic reticulum, Golgi apparatus and nucleus (Pfister et al., 2006). The 
cytoplasmic dynein 1 complex links dynein to cargos and adapter proteins to regulate 
dynein function. 
 
Fig.36. The cytoplasmic dynein complex. (Left). A model of the motor domain built 
from yeast cytoplasmic dynein and the mouse microtubule-binding domain (MTBD), 
overlapped with the schematic of the dynein HC in its apo or post-power stroke form.  
Conformational changes driven by ATP hydrolysis in the motor domain, alter the relative 
position of the stem and the tail/linker, are hypothesised to lead to the power stroke and 
progression on microtubules. The Heavy chains (purple) contain the six AAA ATPase 
domains (in red), the stalk region (light yellow), the buttress (orange), and the linker 
region. Heavy chains are associated with light intermediate chains (Dync1li1 and 
Dync1li2) (green), intermediate chains (in cyan), and light chains (dark yellow). (Right) 
The electron micrograph of an isolated molecule of monomeric dynein 
from Chlamydomonas reinhardtii flagella in its pre-power stroke form. Diagram taken 
from (Schiavo et al. 2013). 
 
The intermediate chains (Dync1i1 and Dync1i2) are distinctly clustered separately in 
phylogenetic trees based on sequence analysis. Dync1i2 is present in vertebrate species 
only (Schiavo et al., 2013). Inferred from its primary sequence, Dync1i2 is thought to be 
post-translationally modified by phosphorylation (Hughes et al. 1995). Its phosphorylated 
form is found only in the slow component of axonal transport whereas its 




Axonal transport has been implicated as a possible contributor to motor neuron 
degeneration. Impaired axonal retrograde transport is identified as one of the earliest 
pathological events in the SOD1 mouse a popular model for MND. Mutations in the 
components of cytoplasmic dynein complex have recapitulated several characteristics of 
MND in mice (Hafezparast et al., 2003, Munch et al., 2004). Intriguingly, aberrations in 
facial motor neuron migration, many diverged prematurely and assembled at a more 
anterior position as they do not dislocate in the direction of axon extension to their correct 
destination (Hafezparast et al., 2003). Facial abnormalities have also been seen in some 
of the human cases with EEF1A2 mutations, therefore there may be a link between the 
impairment of axonal transport as a result of eEF1A2 function being disrupted. The 
connection between axonal transport and MND development has also been made in 
humans. In a family with autosomal dominant form of lower motor neuron degeneration 
was identified with a mutation in the largest subunit (p150) of dynactin (Puls et al. 2003), 
a complex which links dynein to the cargo for transport (Vaughan and Vallee, 1993). The 
disruption of axonal transport would result in signals and other vital molecules to not be 
delivered to their appropriate locations. This can cause an accumulation of proteins which 
is regarded as having a central role in MND development, however the mechanisms are 
still not fully understood (Reynaud 2010), but the pathology is clear that it is characteristic 
in motor neuron degeneration. The expression of Dync1i2 is upregulated during cell 
differentiation and neurite extension upon stimulation of the nerve growth factor (NGF) 
(Angelastro et al.,2000). NGF is a neurotrophic factor that is transport retrogradely and 
expressed throughout adult life (Conner et al., 2009). It has been demonstrated as an 
essential factor for maintaining synaptic plasticity (Vivar et al., 2013). The delivery of 
NGF is facilitated by the actin network, therefore regulation of this network is crucial in 
sustaining synaptic plasticity.  
In some mice from the aforementioned study (Hafezparast et al., 2003), the age-related 
neurodegeneration may have been caused by a constantly reduced supply of NGF. 
The downregulation of Dync1i2 in the proteome of eEF1A2 nulls may be indicative of 
the mechanism of moto neuron degeneration observed in the mice. As eEF1A has been 
implicated in microtubule reorganisation, or lack of, in the case of eEF1A2 mutations, 
hence it may disrupt the networks dynamics or as eEF1A2 is non-functional, Dync1i2 is 
downregulated, impairing retrograde transport causing neuronal degeneration due to toxic 
protein accumulation. Thus, reducing synaptic plasticity and being responsible for the 
retraction of synapse observed in eEF1A2 null mice. However if this is the case, Dync1i2 
may be a potential biomarker, its biochemistry and already established connections with 
motor neuron degeneration, in which it is seen as one of the earliest pathologies can 





6.2 DnaJ homolog subfamily C member 5 (Dnajc5). 
 
In the proteomic study Dnajc5 was downregulated in eEF1A2 null mice. Dnajc5, 
otherwise known as cysteine string protein (CSP) is part of a group of proteins belonging 
to the conserved J protein family, also known as Heat shock protein 40kD (Hsp40) or 
(DnaJ) that are co-chaperones for maintaining proteostatis in cells by assisting in protein 
folding, assembly and stability and prevent the toxic aggregation of proteins. Dnajc5 
domains follow the organisation of DnaJ C-class Hsp40 co-chaperones; it consists of a J 
domain and a C-terminal cysteine motif of a stretch of 25 cysteine residues (Patel et al., 
2016). Dnajc5 is expressed at higher levels in neuronal tissues (NCBI BioProject, 2017) 
and restricted to the presynaptic termini (Zinsmaier et al., 1990, Kohan et al., 1995).  
As a synaptic vesicle protein and molecular chaperone they function in membrane 
trafficking and protein folding by interacting with Hsp70 (heat shock protein 70kD), a 
chaperone involved in protein folding through its J domain. As well as Heat shock cognate 
70 (Hsc70), which is the main responder as in neuronal cells Hsp70 induction is reduced. 
In response to cell stress, Dnajc5 stimulates the ATPase activity of Hsc70 (Fernandez-
Chacon et al., 2004). Dnajc5 and Hsc70 then forms a trimeric complex with small 
glutamine-rich tetratricopeptide repeat-containing protein (SGT), recruiting them the 




activity to catalyse the refolding of denatured proteins into its native state, with nucleotide 
exchange factor (NEF) stimulating the exchange of ATP-ADP (Gorenberg et al., 2017). 
 
Fig.37 Model Showing the Association-Dissociation Cycle of the CSP/Hsc70/SGT 
Complex on the Synaptic Vesicle. Dnajc5 (here denoted as CSP) recruits Hsc70 and 
SGT at the synaptic vesicle surface. This complex in the presence of ATP and available 
substrate this protein complex dissociates. As a consequence of ATP hydrolysis and 
chaperone catalysis, unfolded protein substrates in the vicinity of the synaptic vesicle 
surface are refolded and reactivated. Taken from (Tobaben et al., 2001). 
 
Mutations in the Dnajc5 gene in humans has been identified in adult onset neuronal ceroid 
lipofuscinosis (ANCL), by whole exome sequencing, linkage analysis and candidate gene 
resequencing (Burgoyne and Morgan, 2015). ANCL is a rare hereditary 
neurodegenerative disease that is often misdiagnosed due to its broad clinical variability, 
common symptoms include generalised epilepsy, ataxia and progressive dementia 




Knock out of Dnajc5 has been shown to result in a neurodegenerative phenotype in mice, 
flies and C.elegans (Gorenberg and Chandra, 2017, Rozas et al., 2012, Zinsmaier et al., 
1994, Burgoyne and Morgan, 2015). Dnajc5 nulls in flies were embryonic lethal for 95%, 
survivors went on to develop progressive sluggishness, uncoordinated movements, high 
temperature paralysis and premature death The phenotype was attributed to 
neurotransmitter deficits, defects in Ca2+ dynamics and the progressive deterioration of 
Dnajc5 null synapses. This could have been resultant from the accumulation of misfolded 
proteins at presynaptic termini that led to the debilitated neurotransmitter release. 
(Gorenberg and Chandra, 2017). When Dnajc5 was knocked out in mice however they 
appeared normal at birth. It was only at ~20 days that they displayed progressive 
neurodegeneration and eventual death, which are the similar timelines for the eEF1A2 
nulls. It was recorded that there was age-dependent synapse degeneration, selective 
vulnerability of synaptotagmin-2+ GABAergic cells to deterioration and deficits in 
neurotransmission and activity-dependent loss of synapses (Rozas et al., 2012, García-
Junco-Clemente et al., 2010). Further analysis upon the mice revealed impaired synaptic 
vesicle recycling at the neuromuscular junctions of motor neurons, decreasing the 
abundance of releasable vesicles thus reducing exocytosis and the neurons excitory 
capacity (Rozas et al., 2012). Notably α-synuclein, a presynaptic neuronal protein 
associated with Parkinson’s disease, when overexpressed in the mice can rescue the 
phenotype fully, whilst knocking it out worsens the phenotype (Chandra et al., 2005). 
Studies done with the mutant α-synucleinha30p in the Dnajc5 knock out mice found it 
improved synaptic organisation, synaptic vesicle content and protected against 
neurodegeneration in the mice (Ruiz et al., 2014). The α-synuclein is thought to contribute 
to neuronal disease such as Parkinson’s by aggregating to toxic levels, and is already being 
probed in itself as a biomarker or give way to the identification of novel therapeutic targets 
(Stefanis, 2012).  
A decrease in Dnajc5 was found by quantitative mass spectrometry, in the frontal cortex 
of ~40% in post-mortem brains of Alzheimer patients when compared with age-matched 
controls (Zhang et al., 2012). A decrease of ~30% in Dnajc5 was found in the eEF1A2 
nulls. Although this difference is not as radical as other potential biomarkers for MND, it 
has informed upon a key mechanism of neuronal deterioration occurring in the 
Del.22.Ex.3 mice and has shown Dnajc5 to be involved in neurodegeneration in another 
line of mice. 
There is already evidence for the vulnerability of motor neurons to cellular stress damage 
(Shamovsky et al., 2006), in addition to the impaired heat shock response as eEF1A2 
replaces eEF1A1 (Vera et al., 2014). Dnajc5’s role in recruiting key heat shock response 
proteins in neurons suggests it contributes to neuronal degeneration. Furthermore the 
reduced expression of Dnajc5 in differing model organisms has been demonstrated to 
induce a neurodegenerative phenotype that is improved by already established MND 




it unequivocally is involved in the deterioration of neuronal cells and impaired excitory 
capacity of motor neurons. Given the aforementioned reasons, it would be a promising 
biomarker. 
 
6.3 Kinesin heavy chain isoform 5C (Kif5C). 
 
Kinesin heavy chain isoform 5C (Kif5c) is a subunit of kinesin, it belongs to the class of 
N-1 kinesins (Miki et al., 2001). Kinesins are the motors that mediate anterograde axonal 
transport along microtubules. The kinesin-1 family (Kif5) within this includes three 
isoforms; Kif5a, Kif5b and Kif5c. Kif5c is expressed selectively in neurons, enriched at 
motor neurons, among cranial nerves and the spinal cord (Kanai et al., 2000, Aizawa et 
al.,1998). It is upregulated in the differentiated motor neurons of 2 week old mice and 
older. Kif5C null mice were viable and demonstrated little phenotype apart from smaller 
brain size and relative loss of motor neurons to sensory neurons. This would suggest 
Kif5C plays a role in the maintenance of motor neurons (Kanai et al., 2000). Kif5C is the 
primary motor for mitochondrial transport in neurons (Pilling et al., 2006). It has also been 
crucial in reducing mitochondria from clustering near cell centres (Tanaka et al., 1998). 
Kif5 acts a tetramer, assembling with another heavy chain and two light chain kinesins. It 
contains an ATPase at its N-terminal and C-terminal for binding the cargo for transport or 
the cargo adaptor. It is through adaptor proteins that Kif5C attaches to mitochondria, this 





Fig.38. Mitochondrial trafficking and anchoring in neurons. The transporting of 
mitochondria to A) the presynaptic bouton and B) the axon terminal along microtubules. 
The polarity of the microtubules directs the movement of mitochondria whilst dynein or 
kinesins conduct the activity. In axons the (+) ends is oriented towards the axonal terminal 
whilst the (-) ends lead to the soma. Kif5 mediate anterograde transport whereas dynein 
retrograde, both proteins can facilitate the transportation of mitochondria with the motor 
adaptor Trak proteins. Myosin motors are thought to drive short-range mitochondrial 
movement at the presynaptic terminals. The mitochondria can then be recruited into 
station pools by dynamic anchoring interactions between syntaphillin and microtubules 
or other unknown actin-based anchoring receptors. Diagram taken from (Sheng 2014).  
The efficient and appropriate transport of mitochondria in synapses is crucial in 
maintaining cell survival, especially in neurons that have high metabolic demands. 
Synaptic mitochondria regulate neurotransmission by maintaining Ca2+ buffering capacity 
in neurons, it is also incites short-term synaptic plasticity by uptake of presynaptic 
Ca2+transients educed by a sequence of action potential and releasing after stimulation 
(Levy et al., 2003). This study also found that in mice developed impaired learning and 
hippocampal synaptic plasticity when deficient in mitochondrial voltage-dependent anion 
channels, a pore on the outer membrane of mitochondria that facilitate the diffusion of 
small molecules including Ca2+. The neurodegenerative phenotype observed in the 
Del.22.Ex.3 mice may have been caused in part by impaired kinesin activity as it was 
significantly reduced in the null mice. Impaired transport of mitochondria in neurons can 
cause a range of damage if not delivered to the appropriate location or if damaged 
mitochondria are not removed efficiently. The region deficient in mitochondria may not 
receive enough ATP, which in synapses can be fatal as their high-energy demands are not 
met (Le Masson et al., 2014). It also means that the Ca2+ buffering capacity in the neuron 




release of reactive oxygen species (ROS). Mitochondria are the largest producer in the 
cell of ROS and mitochondrial-derived ROS (mROS) production is regulated by 
intracellular Ca2+ level. Higher concentrations of Ca2+ results in an increase of mROS 
(Beckhauser et al., 2016). Toxic levels of ROS can cause oxidative stress in cells that can 
lead to neurodegeneration.  
It is evident that Kif5C has a role in maintaining neuronal survival by ensuring efficient 
transport of mitochondria to synapses. The issues that arise from dysfunction of this 
mechanism causes oxidative stress and reduced synaptic plasticity in the affected neurons, 
which appears to be predominantly terminally-differentiated motor neurons based upon 
the expression pattern of Kif5C. Dysfunctional mitochondria has long been associated 
with neurodegenerative pathology (Court and Coleman, 2012). Mutations in kinesins, 
including Kif5C have been identified in patients suffering from severe ID, microcephaly, 
epilepsy and cortical malformation. The mutation was recapitulated in rat hippocampal 
neurons and found the mutated protein to accumulate in the cell body and show abridged 
movement as it was detected at reduced levels in distal dendrites. The mutation also led 
to a decreased miniature excitatory postsynaptic currents (mEPSC), which implied that 
the excitatory capacity of the neuron is altered (Willemsem et al., 2014). Aberrant Kif5C 
expression can lead to a disruption of the neurons homeostatic plasticity, which often 
precedes neuronal death. So although Kif5C has not been probed as a potential biomarker 
previously it has been heavily implicated in the development of neurodevelopmental 
disorders and neurodegenerative disease and is significantly differentially expressed at 
both a genomic and proteomic level. 
6.4 Discussion. 
 
The differences between the wildtype and eEF1A2 null protein expression has led to the 
discovery of proteins shown to be implicated in neuronal degeneration and disease. This 
has alluded to the pathology of the neurodegeneration in the Del.22.Ex.3 mice, they are 
collectively indicative of impaired axonal transport and oxidative damage in motor 
neurons. Additionally, they have be observed to be differentially expressed in human cases 
and/or considered the underlying mutation of neurodevelopmental disorders. Although the 
differences in expression between wildtypes and eEF1A2 nulls are not as radical for these 
proteins as other researched biomarkers are momentarily, this was a small scale 
preliminary study and more is required to validate these differences. However, their 
biochemical functions and causative role in the development of neurodegenerative 
phenotypes in model organisms and human cases are supportive of their potential as 





Chapter 7: Discussion. 
 
eEF1A2 is unique in its nature as being the sole translation factor whose expression is 
tissue-dependant. It is highly conserved across the animal kingdom and one of the most 
abundant proteins in cells. All this alludes to its essentiality, that becomes ever clearer as 
more is learnt about the isoforms non-canonical roles that are critical in cell functioning 
and survival.  
eEF1A2 has also repeatedly been implicated in neurological disorders in humans and 
demonstrated sufficient to cause motor neuron degenerative phenotypes in mice either 
through its loss of expression or non-functioning protein forms. The phenotypes observed 
can vary drastically on a case by case basis that is regarded to be due to the various 
different mutations reported in sufferers. One of these mutations, D252H, was recreated 
in mice so as to discern the effects the mutation has on protein expression and manifesting 
pathology. The CRISPR/Cas9 experiment generated mice with a range of different 
mutations, insertions, deletions and mosaicism that showed a variation of protein 
expression profiles. 
The proteomic study was conducted upon the Del.22.Ex.3 mice which had no eEF1A2 
expression. This line was compared with wildtypes and the study found several proteins 
that were differentially expressed that have been associated with neuronal damage and 
therefore potential biomarkers for MND. The microarray data analysed had confirmed 
some of these changes and involvement in neuronal damage as present at a transcriptomic 
level too, supporting their validity as markers of the motor neuron degeneration phenotype 
and not necessarily the impaired translation. 
 
7.1 eEF1A2 and protein expression: 
 
The CRISPR/Cas9 experiment to develop the D252H line resulted in a range of mutations 
in the founder mice. Initial genotyping revealed multiple alleles that could not be 
unpicked, which when separated by TOPO cloning revealed mosaicism in particular mice 
and varied insertions and deletions, with most mice retaining a wildtype allele. The most 
severely affected mouse (#10) had no wildtype allele, the insertion and deletion generated 
in its genotype had probably caused ablated or non-functional eEF1A2 protein, although 
this was unable to be measured as the mouse had had to be euthanized. The other mice 
had no visible phenotype and this was most likely due to the retention of a wildtype allele. 
However upon protein expression analysis it was revealed that the expression of eEF1A2 
was depleted in mice with mutations in at least one allele, yet there were some 
discrepancies between the genotype and phenotype when compared with the expected 
protein expression that may have been resultant of the TOPO cloning experiment and 




suggest that low levels of eEF1A2 are sufficient to resist the development of neuronal 
degeneration. This suggests that the missense mutation does not entirely result in loss of 
function. It is also a promising prospect for gene therapy to compensate for either the loss 
of or dysfunctional eEF1A2 protein, as the success rate of integration of corrected protein 
can vary with often only low levels being seen in apparently unaffected mice. What is 
notable however is that although mice homozygous for mutations in eEF1A2 present a 
diseased phenotype, the cases found in humans are all heterozygous apart from two 
siblings (see Table 1). This may mean that mice have more tolerance for the dysfunctional 
eEF1A2.  
 
7.2 MND in mice and eEF1A2: 
 
The use of mouse models has advanced many differing fields in biology, its heavy usage 
has also resulted in it undergoing great scrutiny in the efficiency of research, ethical 
aspects and ability for results to be extrapolated to humans. Much research conducted in 
MND for the development of therapeutics fails upon trials conducted on humans and there 
is a deficit of translational research for neuronal diseases. This has led to a great waste of 
resources and time. Therefore identifying biomarkers in mice may aid in the prognosis of 
therapies to be made more accurately before they progress onto humans. If the biomarkers 
identified in mice were to ever be translated into humans, it would have to be identified 
in tissues that can be tested non-invasively. This presents a challenge as currently most of 
the indicators of damage have been found in the areas of damage themselves, such as brain 
and spinal cord. Although the brain tissue is unsuitable for collection until post-mortem, 
the extraction of spinal fluid is practised but exceedingly dangerous and disquieting for 
the patients. What is also notable in the context of this research project is that the mice 
seem to have a degree of tolerance in comparison with humans for eEF1A2 mutations as 
humans heterozygous for eEF1A2 mutations are severely affected but only homozygous 
mice develop a phenotype. Although the Del.22.Ex.3 and D252H lines are not suitable as 
a model organisms for MND as their phenotype cannot be determined, in the Del.22.Ex.3 
because of their seizures it would be unethical or even impossible to keep them alive. 
However, the MND phenotype in the lines make them still appropriate organisms for 
searching for potential biomarkers that can act as tools for prognosis in the development 
of therapies and perhaps in future diagnostics.  
 
In the established D252H and Del.22.Ex.3 lines sections of the spinal cords were analysed 
to observe the extent of neuronal damage that is resultant from the missense mutation and 
complete loss of eEF1A2. Another eEF1A2 null line, wasted, demonstrated neuronal 
degeneration occurred rostrocaudally in homozygous mice, which would suggest that 
eEF1A1 is switched off progressively (Newbury et al. 2005). The analysis of different 
regions of the spinal cords in Del.22.Ex.3 and D252H mice revealed that cervical regions 
showed greater neuronal damage than the more caudal area in mice homozygous for 
mutated Eef1a2 in agreement with the findings in wasted mice. The H+E stains analysed 
by Colin Smith also unequivocally demonstrated this. The GFAP staining also showed 




which had overall a lesser degree of GFAP staining. GFAP in the heterozygotes however 
were not consistent with a rostrocaudal gradient of GFAP manifesting in the D252H and 
showed no discernible pattern in the Del.22.Ex.3 heterozygotes. This degree of neuronal 
damage as detected by GFAP was unprecedented as it contradicts the phenotype observed 
in all heterozygote mice from these lines. In addition, the wasted heterozygotes also show 
no neuronal damage. A possible reason for the GFAP appearing as a gradient may be 
down to variations in staining, it may be that there is no pattern of gliosis in the 
heterozygotes but that in one D252H mouse it was the case. However, a larger cohort of 
mice is required to support the identification of a rostrocaudal gradient in homozygotes 
and clarify the ambiguity surrounding the heterozygotes. In addition to this, the analysis 
was made by observations alone and is subject to interpretation, to ensure confidence in 
the analysis using a statistical approach to comparing sections would be more effective. 
This could be done by foci counts in stains or employ additional tests for 
neurodegeneration such as the use of the styryl dye FMI-43 which would visualize the 
neuromuscular junctions and the rate of exocytosis and endocytosis (Amaral et al. 2011). 
Observations of this would also be interesting as some of the differentially expressed 
proteins that were downregulated in eEF1A2 nulls were associated with reduced 
exocytosis. 
 
The spinal cords were used for a biomarker search by monitoring protein expression 
changes across glial and motor neuron cells. By analyzing the whole spinal cord, 
observations of differential expression in glial cells would not be affected directly by the 
mutation and downregulation of protein synthesis given that glial cells only express the 
eEF1A1 isoform (Newbury et al 2007). Motor neurons however express only eEF1A2 
and would be expected to display numerous changes in expression, predominantly 
resulting from downregulation of protein synthesis. Spinal cords were extracted from 21 
day old mice, a time-point in which the switch between eEF1A isoforms is more or less 
completed, with only trace amounts of eEF1A1 being expressed (Chambers et al., 1996). 
As mentioned before, concurrent with the onset of symptoms of motor neuron 
degeneration associated with eEF1A2 null genotypes (Newbury et al. 2005). Therefore 
the studied spinal cords should display changes affected by the loss of eEF1A2 but before 
differences in protein expression can be heavily influenced by impaired translation; if 
analysis was conducted upon later timepoints any resulting differences may be 
confounded by the loss of translation.  
 
 
7.3 The search for biomarkers: 
 
The demand for biomarkers for MND is increasing as there is an absence of diagnostic 
tools in early stages of the disorder that are efficient in diagnosis. The failures of novel 
therapies to be translated into humans after successful trials in model organisms also 
highlights the need for biomarkers for prognostic purposes. It is speculated that the failures 




organisms (Perrin, 2014). Therefore to ensure the treatment is effective, the model 
organisms must also be tested on a biochemical level which can be facilitated by the use 
of biomarkers. However biomarker discovery remains challenging because of the absence 
of standardization of approaches in proteomics and genomic studies, it is also greatly 
hindered at the data analysis stage, especially in regards to proteomics as the technology 
and analysis is still being developed. 
 
To search for potential biomarkers for MND, a comparative quantitative analysis into the 
proteome of the spinal cords of eEF1A2 nulls and wildtypes was conducted using LFQ-
MS to identify the proteins present and their abundances. Statistical analysis of the spinal 
cord proteomes of Del.22.Ex.3 mice did not reveal much difference between that of the 
wildtypes. The overall protein expression profiles of each sample did not vary greatly 
from one another, to the extent that the diseased group were not discernible from the 
wildtypes.  The cluster analysis (Fig.18) and heatmap (Fig.20) demonstrated this visually. 
The samples were from age matched littermates and prepared for mass spectrometry with 
the same reagent and protocol for homogenisation, inspection of their clustering was not 
dependent on sex either therefore the clustering cannot have resulted from these factors. 
From this it must be accepted that there are no proteome differences between the spinal 
cords at p21 of Del.22.Ex.3 mice and wildtypes. However this conclusion is weakened 
somewhat by the issue that arose in the LFQ-MS experiment. The deficiency of Lys-C in 
the peptide digestion stage resulted in incomplete digestion as digestion by trypsin alone 
is not efficient enough for tightly folded proteins and lysine residues (Giansanti et al., 
2016). As mentioned before this can lead to reduced sequence coverage that can 
discriminate closely related protein isoforms, as well as aid precise protein identification 
and quantification. This may impede analysis as the MaxQuant software that processed 
the experimental data works on the assumption of high digestion efficiency. The failure 
of tandem digestion may have caused missed proteins in the biological system or led to 
the misidentification of certain proteins, although initially, proteomic studies used only 
trypsin for digestion. Nonetheless the data was analysed with the acknowledgement that 
only trypsin was used for digestion. It must be made clear that the proteome of the spinal 
cord may include proteins that are potentially differentially expressed, but not identified 
due to lack of efficient digestion; missing out sites of post-translational modifications, 
protein segments or even subsets of proteins. The reliability of LFQ-MS is also impeded 
by its inefficiency to detect proteins with low abundances. The proteome of a sample may 
not be identified in its entirety, limiting the range of proteins that can be possible 
biomarkers. The pre-processing of the data for analysis had also removed many of these 
low abundance proteins as proteins that returned a 0 in 2/3 biological replicates were 
removed. Whether these proteins were expressed below the level of detection, or false 
identifications is unknown, but to rely upon a single value to represent the abundance 
would be dubious. The missing values remaining were imputated by assuming that they 
were below the level of detection of the mass spectrometer instrumentation. This can often 
result in a skew of data points towards the zero, however it did not disturb the overall 
distribution of the dataset. Although there are different methods of imputation, a superior 
one has not been revealed (Webb-Roberston et al.,2015, Miecznikowski et al., 2010, 




approaches and algorithms lend themselves to particular attributes of a dataset; the 
variance, distribution and size. Therefore how much influence utilizing a different 
imputation method on the output in downstream analysis is questionable. It would be of 
interest to see how variations in imputation of missing values affects the amount of 
potential biomarkers discovered. A repeat of the experiment with tandem digestion and 
the inclusion of more biological replicates could increase the amount of proteins detected 
and improve correct identification as well as reduce the degree of proteins eliminated 
entirely because of a median of 0 among their respective groups. However, given that for 
a biomarker to be practical it must be reproducible, proteins with low levels in both groups 
may not necessarily be promising. Especially if the biomarker is for prognosis use in 
model organisms, as it may not always be possible to collect enough tissue for low 
abundance proteins to be repeatedly measured.  
Two approaches were used to search for proteins with differential expression; fold 
changes and the student’s t test. Examining proteins that have fold change is the most 
simplistic approach to determining differential expression, but is somewhat limited in this 
simplicity. It uses the sample means alone and measures changes of expression between 
the two groups superficially. It did however identify proteins that may be involved in the 
development of MND in the mice. The functional roles of these implicate them in the 
developing neuronal degeneration phenotype, Gstk1 being involved in the oxidative stress 
response and Fgf12 a member of the fibroblast growth factor family which dysregulation 
of has been found in neurological disease (Hensel et al., 2016). Additionally mutations in 
Fgf12 were found in humans that demonstrated early-onset epilepsy (Guella et al., 2016, 
Al-Mehmadi et al., 2016), a symptom that is also present in some of the cases with 
eEF1A2 mutations (Table.1). The t tests also identified certain proteins of interest, 
although these were not the most significantly differentiated proteins, they have been 
heavily implicated in the development of neurodegeneration and connected with eEF1A 
isoforms non-canonical roles. However, differences between the two groups have failed 
to manifest with great certainty the proteins that have been identified as of interest and 
potential markers must be taken with caution. The absence of standard procedure for 
analysing quantitative mass spectrometry has also meant that different methods of analysis 
can lead to differing interpretations of the results.  The analysis of the data revealed the 
proteins Kif5c, Dnajc5 and Dync1i2 to all be significantly downregulated and Fgf12 
upregulated in the eEF1A2 null mice. Although the student’s t test is a common approach 
when assessing differences between two groups results in small sample size error 
estimation methods (Murie e al., 2009), it can also overestimate statistical significance 
(Ting et al., 2009). If this was the case in these findings, it reduces further confidence in 
the proteins identified as differentially expressed. A major caveat of the data analysis is 
the lack of corrections made for false discoveries. Without this, some of the differentially 
expressed proteins have a chance of being false statistically significant changes. The large 
amount of data requires multiple testing corrections to be made to adjust p-values to 
account for the occurrence of false positives as t test analysis conducted assesses the 




large datasets, but in proteomics the use of FDR is usually the approach chosen. This 
would have reduced the amount of discoveries of differentially expressed proteins by 5% 
and reporting proteins that more are likely to be truly significantly differentially 
expressed. Given the size of the dataset and low number of biological differences the rate 
of false discoveries may be a substantial issue resulting in the detection of differentially 
expressed proteins that cannot be reproduced as they that are not truly significant, thus 
encumbering the search for biomarkers as these proteins are pursued for further analysis 
instead of actually differentially expressed proteins that would be indicative of MND. This 
filtration is an important step in determining biomarkers but this was just an explorative 
project. Additionally, the distribution of p-values was uniform, suggesting there were little 
to no significantly differentially expressed proteins. Hence if FDR correction was to be 
applied it would most likely remove all significant hits. For this reason, the proteins 
identified as possible novel markers of MND cannot be assumed as truly indicative of the 
disease until validation.  
The small sample size is also a limitation in assessing differential expression. There is low 
statistical power with just 3 biological replicates for each group.  A repeat of the 
experiment with the addition of more replicates may better identify false positives as well 
as have great protein coverage revealing more potential biomarkers that are more likely 
to be indicative of MND. Also, using other statistical tests may be more sensitive to truly 
differentially expressed changes and better biomarkers. Yet the most important stage is 
validation of potential findings. The lack of standardization in data analysis causes each 
proteomic study to generate results based on individual interpretation. Although studies 
are attempting to modulate the approach to analysing significantly differential expression, 
validation of results is a crucial step in determining true discoveries. 
 
Previous microarray data analysed by Andy Sims on p21 spinal cords of wasted mice was 
analysed to investigate genes that were differentially expressed between eEF1A2 nulls 
and wildtype mice. This was done as a complement to the proteomics research, having 
outlined the translational activity of eEF1A2 nulls from the Del.22.Ex.3 line and identified 
differentially expressed proteins that demonstrated potential as biomarkers, it would be 
intriguing to see if these changes were reflected at the transcriptomic level, which would 
add power to the findings from the proteomics discoveries.  
The microarray data demonstrated the gene expression profiles of wasted and wildtype 
mice are strongly distinguished from each other. It revealed many significantly 
differentially expressed genes between the wasted and wildtype mice by SAM and fold 
change analysis. These genes however cannot be accepted as truly differentially expressed 
until validated by western blot. The GO analysis showed that many of the genes were 
associated with neuronal damage. Some of the findings in the microarray data supported 
the proteomics results and the proteins of interest as being significantly differentially 
regulated, whilst not being confounded by varying protein turnover rates or stability. 
Many more genes were identified as being statistically significant than in the proteomics 
study, however this may be due to the fact that the microarray observed far more genes 




data. The comparisons made between the microarray and proteomics data is limited in part 
due to the differing backgrounds of the mice. However they were age matched and had 
ablated expression of eEF1A2.  
 
The GO analysis revealed that the molecular functions enriched for across all significantly 
differentially expressed genes and proteins were predominantly those involved in binding, 
catalytic and structural activity. However the structural activity as less represented in the 
microarray data. The pathways enriched for differed slightly between the proteins and 
genes; there were far more pathways presented by the mRNA analysis, yet this may be in 
part because there were far more transcripts included than proteins and not necessarily 
that there were more diverse set of genes differentially expressed in eEF1A2 nulls. Both 
the proteins and trancripts of eEF1A2 nulls were represented in pathways of neuronal 
disorders (Alzheimer’s, Huntington’s and Parkinson’s) along with Wnt signalling which 
has shown to be linked to a neuroprotective role in Alzheimer’s disease (Inestrosa and 
Toledo, 2008). Although Fgf12 was not identified as significantly differentially expressed 
in the microarray data, the FGF signalling pathway was enriched for. In addition to these 
connections with neuronal damage, the proteins and genes demonstrated enrichment for 
structural and stress response. These were predominantly actin and oxidative stress 
associated proteins and genes which is notable as the eEF1A isoforms have been shown 
to have roles in the regulation of these in cells. The dysregulation of actin associated genes 
and resultant proteins in cells may have led to abnormal actin bundling, which in neurons 
may also be linked with synaptic function (Cingolani and Goda, 2008). The proteins of 
interest Dync1i2 and Kif5c are reliant upon the cytoskeleton for efficient axonal transport 
that it maintains. Dnajc5 is involved in the stress response and directly interacts with 





















Chapter 8: Conclusion. 
 
Mutations in eEF1A2 have disastrous effects on mice homozygous for the mutation. They 
suffered from a severe neurodegenerative phenotype whilst mice heterozygous for 
eEF1A2 mutations remained unaffected. The founder mice from the CRISPR/Cas9 
experiment mice incorporated the desired D252H mutation, but also presented a varied 
amount of large insertions and deletions that were strongly suggested to be damaging to 
the resultant protein’s functioning. The CRISPR/Cas9 experiment also induced mosaicism 
in some of the mice. The expression of eEF1A2 across the founder mice was 
predominantly reduced, which correlated with the genotyping results that were predictive 
of the mutations being damaging. This would suggest haplosufficiency in the founders, 
even in those that had incorporated the D252H mutation, #15 and #16. Despite having 
significantly reduced eEF1A2, mice that retained wildtype alleles did not manifest the 
neurodegenerative phenotype. The neuronal damage in the D252H mice as well as in an 
eEF1A2 null line (Del.22.Ex.3) that was visualized by GFAP in the spinal cords showed 
the extent of the phenotype on a pathological level. The homozygotes, as speculated, 
demonstrated the greatest degree of neuronal damage both by IHC with GFAP and H+E 
stains when compared with heterozygotes and wildtypes. The neuronal degeneration also 
presented itself as a rostrocaudal gradient in homozygotes from both lines. However the 
strength of these findings is weakened when the heterozygous mice are examined, despite 
showing no phenotype, there is consistent GFAP staining which means that the findings 
are not altogether concrete and would need further investigation into whether this is the 
case. Nonetheless it is clear that ablated expression of eEF1A2 causes motor neuron 
degeneration from the phenotype homozygous mice present. The mass spectrometry 
experiment, although hindered by the absence of tandem digestion, identified a range of 
proteins in the spinal cords some of which were determined to be differentially expressed 
between the eEF1A2 nulls and wildtypes. However the overall proteome profiles 
remained unchanged with the two groups being undiscernible from one another.  The 
significantly differentially expressed proteins were revealed to be associated with 
functions and pathways upon GO analysis, that when dysregulated have been implicated 
in MND as well as the non-canonical roles of eEF1A2. From these Fgf12, Dync1i2, Kif5c 
and Dnajc5 demonstrated significant differential expression, functional roles that were 
associated to eEF1A2s non-canonical roles and also emerged as being involved in the 
pathology or neurodegeneration and MND. The data analysis conducted on the microarray 
data demonstrated far greater differences in the gene expression profiles between wasted 
and wildtype than was observed in the proteomics experiment. They were however, 
enriched for similar functions and pathways that were represented by the significantly 
differentially expressed proteins as well. Although the majority proteins of promise as 
biomarkers were not shown to be as significantly different between the wasted and 
wildtype. The functions and pathways that they are part of include stress response in cells. 




differentially expressed at both a protein and transcriptomic level as well as being heavily 
implicated in the pathogenesis of MND.  
Although there are promising biomarkers being developed, they as of yet still fail to be 
translated into practise. It is always of benefit to search further and investigate other 
possibilities and this investigation has identified potential markers that, upon further 
examination of their validity, may be useful as prognostic tools in the development of 
therapies. The exploration of biomarkers has also hinted at the disease’s enigmatic 
mechanisms and pathogenesis which in turn may lend itself towards further possible 
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Supplementary Information:  
 
CLUSTAL O(1.2.4) multiple sequence alignment of EEF1A2. 
 
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Mus              ------------------------------------------------------------ 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           CCACCCCTCCATTTCTCTCATCCCTCCATCTTCCTCCCATCTCCTTACCTCCATCTCTTG 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Mus              ------------------------------------------------------------ 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           TTTCTCTTTCCTCTTTTCCTCTTATTGTTCAATTTCTCCCTCCCTCCATCTTCCTCCCTT 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Mus              ------------------------------------------------------------ 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           CTCTTTACCTCCCATCCTTCTGTCTGCATCCTCCTCTCTCCATCTCTCTTCCATTTCTCC 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Mus              ------------------------------------------------------------ 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           TAACCTTCCACTCTTCCTAACCCTCTATTTATCTCTCCCTCCATTTCTCCCATCCCTTTA 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Mus              ------------------------------------------------------------ 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           TCCCCCATCTCTTCCCATCCATCCATCTCCCACCCTTCCACCTCTCCCACCCATCTGTCT 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Mus              ------------------------------------------------------------ 
Bos              ------------------------------------------------------------ 




Gallus           ACTGCTCCTCCATCTCTCCTCCCTTCCTCCCATCCTTCTATTCCCCCTATCCCCCTATTC 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             --------------GCCCC-------------------------GC-------------- 
Mus              --------------------------------------------GT-------------- 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           CTCCCATCCCTTTACCCCTGGTCTCTACATCTCCCACTACTCCAGCTTTCATCCATTTCT 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             ------------CCCCGCCCGCGGCGCGTTTCTCCCCCGCCTCCCGCGTCCGTCTTTGCA 
Mus              ------------TCTCGCTCA----CTGGTTCTCTCCCTC-GCTCCGGTGCATCATTGCA 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           CCCATCCCTCCATCTTCCTCCCAT-CCCTTTATCCCCC--ATCTCCTCCCCATCTCCCAC 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             GCCCGCGCCTCCCGCATCGC-----------CTCGCGTCCCCGTG------GCGCCCGCC 
Mus              GCTGCGTCCTCTCGGATCCTCATTACGCCGGCCCGCGTCCGTGGGTGCGCGGCCCCTGCG 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           TCTTCCACCTCTTCCATCTACCTTCCATCCCCAGTTCTCCCC--CTCC---GCCTCTCCC 
                                                                              
 
Danio            ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
Homo             -----CGCG----------------------------------CGCGTCCGCGCCCCGCC 
Mus              -----TCCACGCATCTTTCGCATCCCA--------TCTGCCAGCCGCTCGGCGCC-CG-C 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           TGCTCTCTCCTCCTCTTTCTCTTCCTCCTCCTCCTCCTCCCCCCGGCT---CGCCTCCTC 
                                                                              
 
Danio            ----------------------------------------GAGTTCATCACACACACAC- 
Oryctolagus      ------------------------------------------------------------ 
Homo             CCCTCCCGCGCGGTTCCGCATTGGCGTGCTGCAGG-GCG-CGGTGCACTGCGCCGCCACC 
Mus              CTCCCCCCTCCGGTACCGCATTGCCGTACTGCAGGGGCG-CAGTGCATTGCGCCGGCACC 
Bos              ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           CTCCCCCGCCCGGTACCGCATTGCCGTAGTGCGGGGGGGCCGCTGCATTGCGCTGCCGCC 
                                                                              
 
Danio            ----AGACCTGGACT-CTTCCGCCAGCTTTGAA------------GGATTTCATAGTGTC 
Oryctolagus      ------------------------------------------------------------ 
Homo             GTCAATAGGTGGACCCCCTCCCGGA--GATAAAACCGCCGGCGCCGGCGCCGCCAGTCCC 
Mus              GTCAATAGGTGGACCCCCTCCTGGAGAGATAAAACCGCCGGCGCCGGCGCCACCAGTCCT 
Bos              ---------------------------------------------------------CCC 
Xenopus          ------------------------------------------------------------ 
Gallus           GTCAATAGGTGGGCC-CCTCCCGGGGAGATAAAGCCGCCGGAGCCCAAGCTGGCAGCCTC 
                                                                              
 
Danio            TGTTTGCTGAGCGGAAAGCAGGGTCTGC--------------CTGTCTGCTGCAGAC-AG 
Oryctolagus      ------------------------------------------------------------ 




Mus              TCT-GACTGAG----TCCTCGGCTCTGGAGTTCCTGCCCAGCATATACCCTCAACCCCAA 
Bos              TCT-GGCTGAG----ACCTCGGCTCTGGACTCACTGCTCAGCTTC--CCCT-CACCCTGA 
Xenopus          --------------------------------------------------------C-TT 
Gallus           TGC-CGCCCCG----ACCGCCGCTCCGCCTCT--------CCATAAACGCAGCTGCG-TC 
                                                                              
 
Danio            AAGAAAGCACCT--CTTACTGTTCTCTCTTGCC--GCCCCGAGTCAACATGGGGAAAGAG 
Oryctolagus      -----------------------CTCGGCTCCGG-AGCCCCCGGCAGAATGGGCAAGGAG 
Homo             GCCAGAGCACCCCGGGTCCCGCCAGCCCCTCAC---ACTCCCAGCAAAATGGGCAAGGAG 
Mus              ACCAGAGCCCCCA---CAGTGCCAGCCCCTCCCT--CACCCAGGCAGAATGGGCAAGGAG 
Bos              GCCAGAGCACCCCAGGTCGTGCCAGCCCCTCCCCACGCCCCAGGCAGAATGGGCAAGGAG 
Xenopus          CCT----------------TGCACTCTCGCTAGTGTCACCCCAGGAGGATGGGGAAAGAG 
Gallus           CCCAGCGCTCCC--CCCACTGCCCGCCCTCCACGCGTAGCCCACCAGCATGGGGAAGGAG 
                                          *             *     *  ***** ** *** 
 
Danio            AAGATCCACATCAACATTGTGGTGATCGGCCATGTTGATTCTGGGAAATCAACCACCACT 
Oryctolagus      AAGACGCACATCAACATCGTGGTCATCGGCCATGTGGACTCGGGCAAGTCCACCACCACC 
Homo             AAGACCCACATCAACATCGTGGTCATCGGCCACGTGGACTCCGGAAAGTCCACCACCACG 
Mus              AAGACACACATCAACATTGTGGTCATTGGCCACGTGGACTCAGGCAAGTCCACCACGACA 
Bos              AAGACCCACATCAACATAGTGGTCATCGGCCACGTGGACTCAGGCAAGTCCACCACGACT 
Xenopus          AAGACACACATCAACATCGTGGTCATTGGCCACGTGGACTCTGGCAAGTCCACAACCACC 
Gallus           AAGACGCACATCAACATTGTCGTCATCGGGCATGTGGACTCTGGGAAATCCACCACCACC 
                 ****  *********** ** ** ** ** ** ** ** ** ** ** ** ** ** **  
 
Danio            GGGCATCTCATCTACAAATGTGGAGGAATTGATAAAAGAACCATTGAGAAGTTTGAGAAA 
Oryctolagus      GGCCACCTCATCTACAAGTGCGGGGGCATCGACAAGAGGACCATCGAGAAGTTTGAAAAG 
Homo             GGCCACCTCATCTACAAATGCGGAGGTATTGACAAAAGGACCATTGAGAAGTTCGAGAAG 
Mus              GGCCACCTCATCTACAAGTGTGGTGGCATCGACAAGCGGACCATCGAGAAGTTTGAGAAG 
Bos              GGCCACCTCATCTACAAATGCGGGGGCATCGACAAGAGGACCATCGAGAAGTTTGAGAAG 
Xenopus          GGCCACCTGATCTACAAGTGCGGGGGCATCGACAAAAGGACGATAGAGAAGTTTGAGAAG 
Gallus           GGGCACCTCATCTACAAATGCGGGGGCATTGACAAAAGGACCATTGAGAAATTCGAGAAG 
                 ** ** ** ******** ** ** ** ** ** **  * ** ** ***** ** ** **  
 
Danio            GAGGCAGCTGAGATGGGAAAAGGTTCTTTTAAGTATGCCTGGGTCCTGGATAAGTTGAAG 
Oryctolagus      GAGGCGGCCGAGATGGGGAAAGGCTCCTTCAAGTACGCCTGGGTGCTGGACAAGCTGAAG 
Homo             GAGGCGGCTGAGATGGGGAAGGGATCCTTCAAGTATGCCTGGGTGCTGGACAAGCTGAAG 
Mus              GAGGCAGCAGAGATGGGGAAGGGCTCTTTTAAATATGCCTGGGTGCTGGACAAGCTGAAG 
Bos              GAGGCGGCCGAGATGGGAAAGGGCTCCTTCAAGTATGCCTGGGTACTGGACAAGCTGAAG 
Xenopus          GAGGCGGCCGAGATGGGGAAAGGTTCCTTCAAGTACGCTTGGGTTTTGGACAAGCTGAAG 
Gallus           GAGGCTGCCGAGATGGGGAAGGGGTCCTTCAAATACGCCTGGGTGCTGGACAAGCTGAAG 
                 ***** ** ******** ** ** ** ** ** ** ** *****  **** *** ***** 
 
Danio            GCTGAGAGGGAGAGAGGCATCACCATAGACATCTCACTCTGGAAGTTTGAGACCACTAAA 
Oryctolagus      GCCGAGCGGGAGCGCGGCATCACCATCGACATCTCCCTCTGGAAGTTCGAGACCACCAAG 
Homo             GCGGAGCGTGAGCGCGGCATCACCATCGACATCTCCCTCTGGAAGTTCGAGACCACCAAG 
Mus              GCCGAGCGGGAACGAGGCATCACCATCGACATCTCCCTCTGGAAGTTTGAGACCACCAAG 
Bos              GCAGAGCGGGAACGCGGCATCACCATCGACATCTCCCTCTGGAAATTTGAGACCACCAAA 
Xenopus          GCTGAGAGGGAGCGAGGAATCACCATTGATATCTCCCTTTGGAAGTTTGAGACAAACAAA 
Gallus           GCCGAGCGTGAGCGTGGCATCACCATTGACATCTCACTGTGGAAATTTGAAACAAGCAAG 
                 ** *** * **  * ** ******** ** ***** ** ***** ** ** ** *  **  
 
Danio            TACTACATAACCATAATAGATGCTCCAGGACATAGAGACTTTATCAAAAACATGATCACT 
Oryctolagus      TACTACATCACCATCATCGACGCGCCCGGCCACCGCGACTTCATCAAGAACATGATCACG 
Homo             TACTACATCACCATCATCGATGCCCCCGGCCACCGCGACTTCATCAAGAACATGATCACG 
Mus              TACTACATCACCATCATCGATGCTCCAGGACACCGAGACTTCATCAAGAATATGATTACA 
Bos              TACTACATCACCATCATCGACGCCCCAGGCCACCGCGACTTCATTAAGAACATGATCACA 
Xenopus          TATTACATCACCATCATTGATGCCCCCGGACATCGAGACTTCATCAAGAATATGATCACT 
Gallus           TACTACGTCACCATCATCGATGCGCCCGGCCACAGGGACTTCATCAAGAACATGATCACT 





Danio            GGGACATCTCAGGCGGATTGTGCTGTCTTAATTGTAGCGGCTGGAGTGGGTGAATTTGAG 
Oryctolagus      GGCACGTCCCAGGCGGACTGCGCGGTGCTCATCGTGGCCGCGGGCGTGGGCGAGTTTGAG 
Homo             GGTACATCCCAGGCGGACTGCGCAGTGCTGATCGTGGCGGCGGGCGTGGGCGAGTTCGAG 
Mus              GGCACATCCCAGGCGGACTGCGCAGTGCTGATCGTGGCAGCCGGTGTGGGCGAGTTTGAG 
Bos              GGCACATCCCAGGCGGACTGCGCCGTGCTGATTGTGGCCGCAGGAGTGGGTGAGTTCGAG 
Xenopus          GGAACCTCTCAGGCAGACTGTGCAGTGCTGATAGTGGCAGCCGGAGTGGGTGAGTTTGAA 
Gallus           GGCACATCCCAGGCTGACTGCGCCGTACTGATTGTTGCTGCCGGTGTCGGTGAGTTTGAA 
                 ** ** ** ***** ** ** ** **  * ** ** ** ** ** ** ** ** ** **  
 
Danio            GCAGGCATTTCCAAAAATGGCCAAACAAGGGAACACGCCCTGCTGGCCTACACACTTGGT 
Oryctolagus      GCCGGCATCTCCAAGAACGGGCAGACGCGGGAGCACGCGCTGCTGGCCTACACGCTGGGC 
Homo             GCGGGCATCTCCAAGAATGGGCAGACGCGGGAGCATGCCCTGCTGGCCTACACGCTGGGT 
Mus              GCGGGCATCTCCAAGAACGGGCAAACCCGGGAACACGCACTCCTGGCCTACACTCTGGGT 
Bos              GCAGGCATCTCCAAGAATGGGCAGACCCGGGAGCACGCGCTGCTGGCCTACACGCTGGGC 
Xenopus          GCTGGCATCTCCAAGAATGGACAGACCCGTGAACATGCCCTCCTGGCTTACACCCTCGGA 
Gallus           GCCGGCATCTCCAAGAACGGGCAGACCCGTGAGCACGCCCTGCTGGCTTACACCCTGGGG 
                 ** ***** ***** ** ** ** **  * ** ** ** ** ***** ***** ** **  
 
Danio            GTCAAGCAACTGATCGTAGCCGTCAACAAGATGGACTCCACCGAGCCTTCCTACAGTGAG 
Oryctolagus      GTGAAGCAGCTCATCGTGGGCGTCAACAAGATGGACTCCACAGAGCCGGCCTACAGCGAG 
Homo             GTGAAGCAGCTCATCGTGGGCGTGAACAAAATGGACTCCACAGAGCCGGCCTACAGCGAG 
Mus              GTGAAGCAGCTCATTGTGGGTGTCAACAAGATGGACTCCACGGAACCAGCCTACAGCGAG 
Bos              GTGAAGCAGCTCATCGTGGGGGTGAACAAGATGGACTCCACGGAGCCCGCCTACAGCGAG 
Xenopus          GTCAAACAGCTCATCGTGGGAATCAATAAAATGGACTCCACCGAGCCTCCCTACAGCGAG 
Gallus           GTGAAGCAGCTCATTGTGGGCATCAACAAGATGGATTCCACGGAGCCTGCATACAGCGAG 
                 ** ** ** ** ** ** *   * ** ** ***** ***** ** **  * ***** *** 
 
Danio            AAACGCTATGATGAGATCGTCAAAGAAGTGAGCGCCTACATCAAAAAGATTGGTTATAGT 
Oryctolagus      AAGCGCTACGACGAGATCGTCAAGGAGGTCAGCGCCTACATCAAGAAGATCGGCTACAAC 
Homo             AAGCGCTACGACGAGATCGTCAAGGAAGTCAGCGCCTACATCAAGAAGATCGGCTACAAC 
Mus              AAGCGCTATGATGAGATTGTTAAGGAGGTCAGCGCCTACATCAAGAAGATCGGCTACAAC 
Bos              AAGCGCTATGATGAAATTGTCAAGGAGGTCAGCGCCTACATCAAGAAGATCGGCTACAAC 
Xenopus          AAACGTTATGATGAGATCGTCAAGGAGGTCAGCGCCTACATCAAGAAGATTGGCTACAAC 
Gallus           AAACGCTATGATGAGATCGTCAAGGAGGTCAGCGCCTACATCAAGAAGATCGGCTACAAC 
                 ** ** ** ** ** ** ** ** ** ** ************** ***** ** ** *   
 
Danio            CCAGCTTCCGTACCCTTTGTCCCTATTTCAGGCTGGCATGGCGACAACATGCTGGAACCG 
Oryctolagus      CCGGCCACCGTGCCCTTCGTGCCCATCTCGGGCTGGCACGGGGACAACATGCTGGAGCCC 
Homo             CCGGCCACCGTGCCCTTTGTGCCCATCTCCGGCTGGCACGGTGACAACATGCTGGAGCCC 
Mus              CCAGCCACGGTGCCCTTCGTGCCCATCTCGGGCTGGCATGGTGACAACATGCTGGAGCCT 
Bos              CCCGCCACTGTACCCTTCGTGCCCATCTCAGGCTGGCACGGCGACAACATGCTGGAGCCC 
Xenopus          CCAGCTACAGTTCCCTTCGTACCCATTTCTGGCTGGCATGGAGATAACATGTTGGAGCCC 
Gallus           CCAGCCACGGTTCCCTTCGTGCCCATCTCGGGCTGGCACGGGGACAACATGCTGGAGCCA 
                 ** **  * ** ***** ** ** ** ** ******** ** ** ****** **** **  
 
Danio            TCTTCCAATATGCCATGGTTTAAAGGCTGGAAGCTGGACAGGAAGGAGCACCATGCCGGT 
Oryctolagus      TCCCCCAACATGCCGTGGTTCAAGGGCTGGAAAGTGGAGCGGAAGGAAGGCAATGCCAGC 
Homo             TCCCCCAACATGCCGTGGTTCAAGGGCTGGAAGGTGGAGCGTAAGGAGGGCAACGCAAGC 
Mus              TCACCTAATATGCCATGGTTCAAGGGCTGGAAAGTAGAGCGTAAGGAAGGAAATGCAAGC 
Bos              TCACCCAACATGCCCTGGTTCAAGGGCTGGAAAGTGGAGAGGAAGGAAGGGAACGCCAGT 
Xenopus          TCTCCCAATATGCCATGGTTCAAGGGATGGAAAGTGGAGAGGAAGGAAGGCAATGCCAAT 
Gallus           TCCCCCAATATGCCTTGGTTCAAGGGCTGGAAGGTGGAGCGCAAGGAAGGCAACGCAAGC 
                 **  * ** ***** ***** ** ** *****  * **  * *****     * **     
 
Danio            GGTGTTACTCTATTGGAAGCTCTTGATACCATCATGCCTCCAACACGGCCCACTGATAAA 
Oryctolagus      GGCGTGTCCCTGCTCGAGGCGCTGGACACCATCCTGCCCCCCACGCGCCCCACAGACAAG 
Homo             GGCGTGTCCCTGCTGGAGGCCCTGGACACCATCCTGCCCCCCACGCGCCCCACGGACAAG 
Mus              GGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAG 
Bos              GGCGTGTCCCTCCTGGAGGCCCTGGACACCATCCTGCCCCCCACACGCCCCACAGACAAG 




Gallus           GGGGTGTCCCTCCTGGAGGCCCTGGACACCATCCTGCCCCCCACCCGCCCCACAGACAAA 
                 ** **  * **  * ** **  * ** ** *** * ** ** ** ** ** ** ** **  
 
Danio            CCCTTACGTCTTCCACTACAAGATGTCTACAAGATTGGAGGAATCGGGACTGTGCCAGTG 
Oryctolagus      CCGCTGCGCCTGCCCCTGCAGGACGTGTACAAGATTGGCGGCATCGGCACGGTGCCCGTG 
Homo             CCCCTGCGCCTGCCGCTGCAGGACGTGTACAAGATTGGCGGCATTGGCACGGTGCCCGTG 
Mus              CCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGCATTGGGACCGTGCCTGTG 
Bos              CCCCTGCGTCTGCCACTGCAGGATGTGTACAAGATTGGTGGCATTGGCACTGTGCCCGTG 
Xenopus          CCTCTGCGTCTTCCCCTGCAAGATGTCTATAAAATTGGAGGAATCGGCACAGTTCCAGTG 
Gallus           CCCCTGCGCCTGCCCCTGCAGGATGTCTACAAAATTGGAGGAATTGGCACAGTTCCCGTG 
                 **  * ** ** ** ** ** ** ** ** ** ***** ** ** ** ** ** ** *** 
 
Danio            GGCAGGGTAGAGACGGGTGTTCTCCGGCCCAGTATGGTGGTGACCTTTGCCCCAGTCAAC 
Oryctolagus      GGCCGCGTGGAGACCGGCATCCTGCGGCCCGGCATGGTGGTGACCTTTGCCCCCGTGAAC 
Homo             GGCCGGGTGGAGACCGGCATCCTGCGGCCGGGCATGGTGGTGACCTTTGCGCCAGTGAAC 
Mus              GGCCGAGTGGAGACCGGTATCCTCCGGCCTGGTATGGTGGTGACCTTTGCGCCAGTCAAC 
Bos              GGCCGAGTGGAGACAGGGATCCTGCGGCCTGGCATGGTGGTGACCTTCGCGCCCGTGAAC 
Xenopus          GGTCGTGTAGAGACTGGCATTCTAAAGCCGGGCATGGTGGTGACCTTTGCTCCAGTCAAT 
Gallus           GGCCGAGTGGAGACTGGCATCCTGCGACCCGGCATGGTGGTCACCTTTGCGCCTGTGAAT 
                 **  * ** ***** **  * **    **  * ******** ***** ** ** ** **  
 
Danio            ATCACTACAGAAGTGAAGTCCGTGGAGATGCATCACGAGTCTCTAAGTGAAGCTCTTCCA 
Oryctolagus      ATCACCACGGAGGTGAAGTCGGTGGAGATGCACCATGAGGCGCTGAGCGAGGCGCTGCCC 
Homo             ATCACCACTGAGGTGAAGTCAGTGGAGATGCACCACGAGGCTCTGAGCGAAGCTCTGCCC 
Mus              ATCACCACAGAGGTGAAGTCTGTGGAAATGCACCATGAGGCACTTAGCGAGGCCCTGCCT 
Bos              ATCACCACGGAGGTGAAGTCGGTGGAGATGCACCACGAGGCTCTGAGTGAGGCCCTTCCT 
Xenopus          ATCACAACTGAGGTCAAGTCCGTTGAGATGCACCATGAGGCTCTGAGCGAGGCTCTGCCT 
Gallus           ATCACCACTGAGGTGAAGTCAGTGGAGATGCACCACGAGGCGCTGAGCGAGGCCCTGCCT 
                 ***** ** ** ** ***** ** ** ***** ** *** * ** ** ** ** ** **  
 
Danio            GGAGACAATGTGGGCTTTAATGTGAAGAACGTGTCCGTAAAAGACATTCGAAGAGGTAAC 
Oryctolagus      GGGGACAACGTGGGCTTCAACGTCAAGAACGTGTCCGTGAAGGACATCCGGCGGGGCAAC 
Homo             GGCGACAACGTCGGCTTCAATGTGAAGAACGTGTCGGTGAAGGACATCCGGCGGGGCAAC 
Mus              GGTGACAATGTCGGGTTCAATGTGAAGAATGTGTCCGTTAAGGATATTCGCCGGGGCAAT 
Bos              GGGGACAATGTTGGCTTCAACGTGAAGAACGTGTCAGTCAAGGACATCCGCCGGGGCAAC 
Xenopus          GGGGACAATGTTGGCTTCAATGTCAAGAACGTGTCAGTAAAGGACATTCGCCGAGGCAAC 
Gallus           GGAGACAATGTTGGCTTCAACGTGAAGAATGTCTCCGTCAAGGACATCCGCCGTGGGAAT 
                 ** ***** ** ** ** ** ** ***** ** ** ** ** ** ** **  * ** **  
 
Danio            GTTTGTGGAGACAGTAAGTCCGACCCGCCTCAGGAAGCATCAGGGTTTACAGCACAGGTC 
Oryctolagus      GTGTGTGGGGACAGCAAGTCCGACCCGCCGCAGGAGGCCGCGCAGTTCACCTCCCAGGTC 
Homo             GTGTGTGGGGACAGCAAGTCTGACCCGCCGCAGGAGGCTGCTCAGTTCACCTCCCAGGTC 
Mus              GTCTGCGGGGACAGCAAAGCTGACCCGCCTCAGGAGGCTGCCCAGTTCACCTCTCAGGTT 
Bos              GTGTGTGGGGACAGCAAGTCCGACCCACCCCAGGAAGCCGCCCAGTTCACGTCCCAGGTC 
Xenopus          GTTTGTGGGGACAGCAAGAGTGACCCACCCCAGGAAGCTGCTGGTTTCACTTCTCAGGTG 
Gallus           GTCTGTGGGGACAGCAAGTCAGACCCGCCGCAGGAGGCAGCACAGTTCACGTCTCAGGTG 
                 ** ** ** ***** **    ***** ** ***** **  *    ** **  * *****  
 
Danio            ATCATTTTGAATCACCCAGGACAGATCAGTTCAGGTTACTCTCCTGTCATAGACTGTCAC 
Oryctolagus      ATCATCCTGAACCACCCCGGCCAGATCAGCGCCGGCTACTCGCCGGTCATCGACTGCCAC 
Homo             ATCATCCTGAACCACCCGGGGCAGATTAGCGCCGGCTACTCCCCGGTCATCGACTGCCAC 
Mus              ATCATCCTGAACCACCCTGGGCAAATCAGCGCTGGCTACTCGCCAGTCATCGACTGTCAC 
Bos              ATCATTCTGAACCACCCTGGGCAGATCAGCGCTGGCTACTCACCAGTCATTGACTGCCAC 
Xenopus          ATCATCTTAAACCACCCTGGTCAGATCAGTGCTGGATATTCCCCAGTCATTGACTGCCAC 
Gallus           ATCATCCTGAACCACCCTGGGCAGATCAGCGCCGGATACTCACCTGTCATCGACTGCCAC 
                 *****  * ** ***** ** ** ** **  * ** ** ** ** ***** ***** *** 
 
Danio            ACTGCTCATATCGCCTGCAAGTTTGCTGAACTCAAGGAGAAGATTGATCGCCGCTCAGGC 
Oryctolagus      ACGGCCCACATCGCCTGCAAGTTCGCCGAGCTCAAGGAGAAGATCGACCGGCGCTCGGGC 




Mus              ACGGCCCACATTGCCTGCAAGTTTGCCGAGCTAAAGGAGAAGATTGACCGTCGTTCTGGC 
Bos              ACAGCCCACATCGCCTGCAAGTTTGCTGAGCTGAAGGAGAAGATTGACCGGCGCTCTGGC 
Xenopus          ACTGCCCACATCGCCTGTAAGTTTGCAGAGCTGAAAGAGAAGATCGATCGCCGGTCCGGC 
Gallus           ACTGCTCACATCGCCTGCAAGTTTGCTGAGCTGAAGGAGAAGATCGACCGACGCTCTGGC 
                 ** ** ** ** ***** ***** ** ** ** ** ******** ** ** ** ** *** 
 
Danio            AAGAAGCTAGAAGACAATCCCAAAAGCCTGAAGTCTGGAGATGCCGCCATAGTGGACATG 
Oryctolagus      AAGAAGCTGGAGGACAACCCCAAGTCCCTCAAGTCCGGGGACGCGGCCATCGTGGAGATG 
Homo             AAGAAGCTGGAGGACAACCCCAAGTCCCTGAAGTCTGGAGACGCGGCCATCGTGGAGATG 
Mus              AAGAAGCTGGAGGATAACCCCAAGTCCCTGAAGTCTGGTGATGCAGCCATTGTTGAGATG 
Bos              AAGAAGTTGGAGGACAACCCCAAGTCCCTGAAGTCCGGTGATGCAGCCATTGTGGAGATG 
Xenopus          AAGAAGCTTGAGGACAACCCCAAGTCCCTGAAATCTGGAGACGCGGCTATTGTGGAGATG 
Gallus           AAGAAGCTGGAGGACAACCCCAAATCCCTGAAATCGGGTGATGCGGCCATCGTGGAGATG 
                 ****** * ** ** ** *****   *** ** ** ** ** ** ** ** ** ** *** 
 
Danio            ATCCCAGGAAAACCAATGTGTGTGGAGAGCTTCTCTCAGTATCCTCCACTGGGACGCTTT 
Oryctolagus      GTGCCCGGGAAGCCCATGTGTGTGGAGAGCTTCTCCCAGTACCCGCCCCTCGGCCGCTTC 
Homo             GTGCCGGGAAAGCCCATGTGTGTGGAGAGCTTCTCCCAGTACCCGCCTCTCGGCCGCTTC 
Mus              GTCCCTGGAAAACCCATGTGTGTGGAGAGCTTCTCACAGTACCCACCTCTCGGCCGCTTC 
Bos              GTCCCGGGGAAGCCTATGTGTGTGGAGAGCTTCTCCCAGTACCCACCTCTCGGCCGCTTC 
Xenopus          ATCCCTGGGAAGCCTATGTGTGTAGAGAGCTTCTCCCAGTACCCACCTCTTGGGCGCTTT 
Gallus           ATTCCTGGCAAGCCGATGTGTGTGGAGAGCTTCTCCCAGTACCCACCCCTTGGCCGCTTT 
                  * ** ** ** ** ******** *********** ***** ** ** ** ** *****  
 
Danio            GCTGTCCGAGATATGAGACAGACCGTTGCAGTCGGTGTGATCAAAAATGTGGAGAAGAAG 
Oryctolagus      GCCGTGCGCGACATGCGGCAGACGGTGGCCGTGGGCGTCATCAAGAACGTGGAGAAGAAG 
Homo             GCCGTGCGCGACATGAGGCAGACGGTGGCCGTAGGCGTCATCAAGAACGTGGAGAAGAAG 
Mus              GCCGTGCGCGACATGCGGCAGACTGTGGCCGTGGGCGTCATCAAGAACGTGGAGAAGAAG 
Bos              GCCGTGCGCGACATGCGGCAGACAGTGGCCGTGGGCGTCATCAAGAACGTGGAGAAGAAG 
Xenopus          GCAGTGAGAGACATGAGGCAGACTGTGGCCGTGGGAGTCATTAAGAACGTGGAGAAGAAA 
Gallus           GCTGTCCGTGACATGCGGCAGACCGTGGCCGTGGGCGTCATCAAGAACGTGGAGAAGAAG 
                 ** **  * ** *** * ***** ** ** ** ** ** ** ** ** ***********  
 
Danio            ATTGGCGGCAGCGGGAGAGTGACCAAATCAGCTCAGAAAGCTCAAAAATCTAGCAAATGA 
Oryctolagus      AGCGGCGGCGCCGGCAAGGTCACCAAGTCGGCGCAGAAGGCGCAGAAGGCCGGCAAGTGA 
Homo             AGCGGCGGCGCCGGCAAGGTCACCAAGTCGGCGCAGAAGGCGCAGAAGGCGGGCAAGTGA 
Mus              AGCGGCGGCGCAGGCAAGGTCACCAAGTCCGCACAGAAGGCTCAGAAAGCGGGCAAGTGA 
Bos              AGCGGCGGCGCCGGCAAGGTCACCAAGTCGGCGCAGAAGGCACAGAAGGCGGGCAAGTGA 
Xenopus          AGCGGAGGAGCCGGCAAGGTGACCAAGTCCGCACAGAAAGCCCAGAAGGCTGGCAAATGA 
Gallus           AGCGGCGGGGCCGGCAAAGTCACCAAGTCTGCCCAGAAGGCCCAGAAGGCTGGCAAATGA 
                 *  ** **    ** *  ** ***** ** ** ***** ** ** **  *  **** *** 
 
Danio            ATCTGAATCTCCAAGACAGTCACCTTA------GGCCCTGTCCCA-GCTTACATGCCTCT 
Oryctolagus      AGCGCGGGCGCCCGCGGCGCGGCCCCCGCCGGCGGCGCCGCGCCCCCGCCCCCGCCCCCG 
Homo             AGCGCGGGCGCCCGCGGCGCGACCCTCCCCGGCGGCGCCGCGCTCCGAACCCCGGCCCG- 
Mus              AGCGCGGGCGCCCGCGGCGTGGCCCTCCCCAACGGCGCCGCGCCGCGCCCCCAGCCCCG- 
Bos              AGCGCGGGCGCCCGCGGCGCGACCCTCCCCGGCGGCGCCGCGCCCCGCCCCCGCCCCCA- 
Xenopus          ATTGCCGGTTCCCTCCGTCTGGCACAC--------------------AAGCCCTGCCCC- 
Gallus           ATCGTGGGCTCCCAGTGCGTAGCGCAG--------------------AAACCATCCCTG- 
                 *         **          *                            *   **    
 
Danio            CTCATTTAGGCATGCTCAGTCAGTTCCTTCCCTGTGTGCTTGAAATATATACTCGAACCA 
Oryctolagus      C----CGCGGC-CGCGCGCCGCGCCCCGCCCCCCG--------------GCCCCGCCCCG 
Homo             ----------------------------------G--------------CCCCC------ 
Mus              ----------------------------CCCCCGG--------------CACTG------ 
Bos              ----------------------------CC------------------------------ 
Xenopus          ----------------------------T--CTGG--------------GAA-------- 
Gallus           ----------------------------ACACCAG--------------GAC-------- 





Danio            ACTGGA-GTT-TGATAGACTGAAGGAAAATATTGAAAAACTAGCATTATCACATTTTGAC 
Oryctolagus      GCCGCGCGCCCCGCC---CCGCCC--------CCAGACCCCGGCCCT-GCCCC------G 
Homo             -------GCCCCGCC----------------------------CCCG-CCCCG------C 
Mus              -------GCCCCGCC----------------------------CCCG-CCCCA------G 
Bos              ---------CCCGGC----------------------------CCCG-TCCCA------G 
Xenopus          -------GGTCCGTC--------------------------------------------- 
Gallus           -------GCT--GCC--------------------------------------------- 
                             *                                                
 
Danio            TGGTTGCACTGTATATTCACTTTTAATAGCAGACCGGTACACACGTTGCATGGATGTTTG 
Oryctolagus      GCGCGGCCCCG------------------GCGCCGCGCGCCCCCGCCAGGCGCACGTCTG 
Homo             GCGCCGCTCCG------------------GCGCCCCGCACCCCCGCCAGGCGCATGTCTG 
Mus              GCGCGGCCCCT------------------CTGCCCCGACCCCCTGCCAGGCGCATGTCTG 
Bos              GCGCGGCCCCG------------------GCGCCCCGCCCCCCCGCCAGGCGCATGTCTG 
Xenopus          -----------------------------------CCCTTCTCTTTGAGGTGCACGCCAG 
Gallus           -----------------------------------ACCGTCTCCCCCCGGCGCATGTGTG 
                                                                    * * *   * 
 
Danio            CACGACATCTGTTAAATGAATGTAGCTGGTATTGCTGTGTGTGTGCGTGCGTGCGTGCGT 
Oryctolagus      CACCTCCGCTTGTCGGCGGCTGTC-----------------GGTCAGCGACTGG------ 
Homo             CACCTCCGCTTGCCAGAGGCCCTC-----------------GGTCAGCGACTGG------ 
Mus              CACCTCCGCTTGTAAGAGGCTCTA-----------------CGTCAGCGACTGG------ 
Bos              CACCTCCGCTTGTAAGAGGCTCTC-----------------CGTCAGCGACTGG------ 
Xenopus          CCCATCTGCTTGTAAAAGCCTGTA-----------------TGTCAACGACTGG------ 
Gallus           CACATCAGCTTGTAAGAGTTTATA-----------------TGTCAACGACTGG------ 
                 * *  *  **       *    *                   **    *  **        
 
Danio            GCGTGCGTGTGTGCGCGCATGTTGAAAGAAGAAACTGCACTTTGACCAAACTGGAAAGCA 
Oryctolagus      ----------ATGCTCGC--CATCAAGGT--CCAGTGGAAGTTCTTCAAGCGGAAAG-CG 
Homo             ----------ATGCTCGC--CATCAAGGT--CCAGTGGAAGTTCTTCAAGAGGAAAGGCG 
Mus              ----------ATGCTCGC--CATCAAAGT--CCAGTGGAAATTCTTCAAGAGGAAAAGCG 
Bos              ----------ATGCTCGC--CATCAAGGT--CCAGTGGAAGTTCTTTAAGAGGAAAAGCG 
Xenopus          ----------ATGCTCAC--CATTAAAGT--CCAGTGGAAGTTCTTTAAGAGGAAAAGCA 
Gallus           ----------ATGCTCAC--CATTAAGGT--CCAGTGGAAATTCTTTAAAAGGAAAAGCA 
                            *** * *    * ** *     * ** *  **    **   * **  *  
 
Danio            AAC-TGCTGATGATAATTTTGTATGATTTATAAATGAGCACTGATGATGAAAGGCTATTC 
Oryctolagus      ---CCGCCGCC---------------------------------------CCGGCTTCGC 
Homo             CCCCCGCC--C---------------------------------------CAGGCTTCCG 
Mus              CCCCCGCC--C---------------------------------------CAGGCTTCCG 
Bos              TCCCCGCCGCC---------------------------------------CCGGCTTCCG 
Xenopus          TGC--------------------------------------------------------- 
Gallus           TGT--------------------------------------------------------- 
                                                                              
 
Danio            GATCCAAAGCACCATTTGTCTCCTTTCGGACCCTTGCTGC---TCAAA--------CCTG 
Oryctolagus      GCCC-----GCG-----CCCCCGCCCCGTGCCCGTGTTTCCAATAAACCGAGC-CCCCG- 
Homo             CGCC-----CAGCGCTCGCCACGCTCAGTGCCCGTTTTACCAATAAACTGAGC-GACCCC 
Mus              CG-C-----CAGCGCTCACCACGCTCAGTGCCCGTTTTCCCAATAAACTGAGC-GACCCC 
Bos              CGTC-----CAGCCTTTGTCACGCTCAGTGCCCGTTTTACCAATAAACTGAGC-GACCCC 
Xenopus          --TC-----CTGC-TCTGTAATCTTTAGTGTCCATTTTACCAATTAAACTGGTTCAACAT 
Gallus           --TC-----CAGCGTTTGTGAGGCTTCATGTTAATTTTACCAATAAAACTGGTACAACAT 
                    *                              *  * *   * **          *   
 
Danio            TGACAAATAAAG---------A-----AACT-GTTGT---CCA-----AAAAA-AAA-AA 
Oryctolagus      ------------------------------------------------------------ 
Homo             AGAAAAAAAAAAAAAAAAAA---------------------------------------- 
Mus              AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA-----A-AAA-AAA-AA 
Bos              CAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 




Gallus           CCACA------------------------------------------------------- 
                                                                              
 
Danio            A-AA-AAA-A-AA-AAAAA 
Oryctolagus      ------------------- 
Homo             ------------------- 
Mus              A-AA-AAA-A-AA-AAAAA 
Bos              AAAAAAAAAAAAAAAAAAA 
Xenopus          ------------------- 
Gallus           ------------------- 
 
CLUSTAL O(1.2.4) multiple sequence alignment of EEF1A1. 
 
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              CTGGTGCCTGGTGGAGGCGGCGCGGGGTAATCTGGGAAAGTGGTGTCGTGTGCTGGCTCC 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           -----------------------------------------------ACGCCGTGCGGGT 
Bos              GCCCTTTTCCCCGAGGGTGGGGGGAGAACCGTATATAAGTGCCGTAGTCTCCGTGAACGT 
Mus              -------TTCCCGAGGGTGG-GGGAGAACGGTATATAAGTGCGGCAGTCGCCTTGGACGT 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ---------------------------GAGTGATCTCTC--------AATCTTGAAA--- 
Xenopus          --------GCGGCGAGTT------------TTAAGTGTC--------CACCGCCAAACAT 
Gallus           GTCGTTTCTC-----TTTG---GCCGGAAGAAAG---------------AAGCTAAAG-- 
Bos              TCTTTTTCGCAACGGGTTTGCCGCCGGGACACAGGTGTCGTGAAAACCACCGTTAAAC-- 
Mus              TCTTTTTCGCAACGGGTTTGCCGTCAGAACGCAGGTGTTGTGAAAACCACCGCTAATT-- 
Homo             -CTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTGTCGTGAAAACTACCCCTAA---- 
Oryctolagus      -------------------------GGCACGAGCTCGTGCTGAAAACCACCGCTAAAT-- 
                                                                       **     
 
Danio            ---CTTATCAATCATGGGAAAGGAAAAGACCCACATTAACATCGTGGTTATTGGCCACGT 
Xenopus          CTAACAATCCACAATGGGAAAGGAAAAGACTCACATCAACATCGTCGTCATTGGACACGT 
Gallus           ---ACCATCCGAAATGGGAAAGGAGAAGACCCACATCAACATCGTCGTCATCGGCCACGT 
Bos              ---CTAAGCCAAAATGGGAAAGGAGAAGACCCACATCAACATCGTTGTCATTGGGCACGT 
Mus              ---CAAAGCAAAAATGGGAAAGGAAAAGACTCACATCAACATCGTCGTAATCGGACACGT 
Homo             -----AAGCCAAAATGGGAAAGGAAAAGACTCATATCAACATTGTCGTCATTGGACACGT 
Oryctolagus      ---CAAAGCCAAAATGGGAAAGGAAAAGACTCACATCAACATCGTCGTCATTGGCCACGT 
                       * *    *********** ***** ** ** ***** ** ** ** ** ***** 
 
Danio            CGACTCCGGAAAGTCCACCACCACCGGCCATCTGATCTACAAATGCGGTGGAATCGACAA 
Xenopus          AGATTCTGGAAAGTCCACAACAACTGGACATCTTATCTACAAATGTGGTGGTATCGACAA 
Gallus           CGATTCCGGCAAGTCCACCACCACCGGGCACCTCATCTACAAATGTGGTGGCATCGACAA 
Bos              AGATTCAGGGAAGTCTACCACGACTGGCCATCTGATCTATAAATGTGGCGGGATCGACAA 
Mus              AGATTCCGGCAAGTCCACCACAACCGGCCACCTGATCTACAAATGTGGTGGAATCGACAA 
Homo             AGATTCGGGCAAGTCCACCACTACTGGCCATCTGATCTATAAATGCGGTGGCATCGACAA 
Oryctolagus      AGATTCGGGCAAGTCCACCACCACTGGCCATCTGATCTACAAATGTGGTGGCATCGACAA 





Danio            GAGAACCATCGAGAAGTTCGAGAAGGAAGCCGCTGAGATGGGCAAGGGCTCCTTCAAGTA 
Xenopus          GAGAACCATCGAAAAGTTCGAGAAGGAAGCTGCTGAGATGGGCAAGGGCTCCTTCAAGTA 
Gallus           GAGGACCATCGAGAAGTTCGAGAAGGAGGCGGCCGAGATGGGCAAAGGTTCCTTCAAATA 
Bos              GAGAACAATTGAAAAGTTCGAGAAGGAGGCTGCCGAGATGGGAAAGGGCTCCTTCAAATA 
Mus              GCGAACCATCGAAAAGTTTGAGAAGGAGGCTGCTGAGATGGGAAAGGGCTCCTTCAAGTA 
Homo             AAGAACCATTGAAAAATTTGAGAAGGAGGCTGCTGAGATGGGAAAGGGCTCCTTCAAGTA 
Oryctolagus      AAGAACCATTGAAAAATTTGAGAAGGAGGCTGCCGAGATGGGAAAGGGCTCCTTCAAGTA 
                   * ** ** ** ** ** ******** ** ** ******** ** ** ******** ** 
 
Danio            CGCCTGGGTGTTGGACAAACTGAAGGCCGAGCGTGAGCGTGGTATCACCATTGACATTGC 
Xenopus          CGCCTGGGTCTTGGACAAACTGAAGGCCGAGCGTGAACGTGGTATCACCATTGACATCTC 
Gallus           TGCCTGGGTCTTGGACAAGCTCAAGGCTGAGCGTGAGCGTGGTATCACTATCGATATTTC 
Bos              TGCCTGGGTCTTGGACAAACTTAAAGCTGAACGTGAGCGTGGTATCACCATTGATATCTC 
Mus              CGCCTGGGTCTTAGACAAACTGAAAGCTGAGCGTGAGCGTGGTATCACTATTGACATCTC 
Homo             TGCCTGGGTCTTGGATAAACTGAAAGCTGAGCGTGAACGTGGTATCACCATTGATATCTC 
Oryctolagus      TGCCTGGGTCTTGGATAAACTGAAAGCCGAGCGTGAGCGTGGTATCACCATCGACATCTC 
                  ******** ** ** ** ** ** ** ** ***** *********** ** ** **  * 
 
Danio            TCTCTGGAAATTCGAGACCAGCAAATACTACGTCACCATCATTGATGCCCCTGGACACAG 
Xenopus          CCTGTGGAAATTTGAGACCAGCAAATATTATGTTACTATCATTGATGCTCCAGGACACAG 
Gallus           CCTGTGGAAATTTGAAACAAGCAAGTACTACGTCACCATCATCGATGCTCCTGGGCACAG 
Bos              CCTGTGGAAATTTGAGACCAGCAAGTACTATGTTACCATCATTGATGCCCCAGGACACAG 
Mus              CCTGTGGAAATTCGAGACCAGCAAATACTATGTGACCATCATTGATGCCCCAGGACACAG 
Homo             CTTGTGGAAATTTGAGACCAGCAAGTACTATGTGACTATCATTGATGCCCCAGGACACAG 
Oryctolagus      CCTGTGGAAATTTGAGACCAGCAAGTATTACGTGACTATCATTGATGCCCCAGGACACAG 
                   * ******** ** ** ***** ** ** ** ** ***** ***** ** ** ***** 
 
Danio            AGACTTCATCAAGAACATGATCACTGGTACTTCTCAGGCTGACTGTGCTGTGCTGATTGT 
Xenopus          AGACTTCATCAAGAACATGATCACTGGTACCTCTCAGGCTGACTGTGCTGTCCTGATTGT 
Gallus           AGACTTCATTAAGAACATGATTACTGGAACTTCTCAGGCTGATTGTGCTGTCCTGATTGT 
Bos              AGACTTCATCAAAAACATGATTACAGGCACATCCCAGGCTGACTGTGCTGTCCTGATCGT 
Mus              AGACTTCATCAAAAACATGATTACAGGCACATCCCAGGCTGACTGTGCTGTCCTGATTGT 
Homo             AGACTTTATCAAAAACATGATTACAGGGACATCTCAGGCTGACTGTGCTGTCCTGATTGT 
Oryctolagus      AGACTTCATCAAAAACATGATTACAGGCACATCTCAGGCTGACTGTGCCGTCCTGATTGT 
                 ****** ** ** ******** ** ** ** ** ******** ***** ** ***** ** 
 
Danio            TGCTGGTGGTGTCGGTGAGTTTGAGGCTGGTATCTCCAAGAACGGACAGACCCGTGAGCA 
Xenopus          TGCTGCTGGTGTTGGTGAATTTGAAGCTGGTATCTCAAAGAACGGACAAACTCGTGAGCA 
Gallus           TGCTGCTGGTGTTGGTGAGTTCGAGGCCGGTATTTCTAAGAACGGGCAGACCCGTGAGCA 
Bos              TGCTGCTGGTGTTGGTGAATTTGAAGCCGGTATCTCCAAGAACGGGCAGACCCGTGAGCA 
Mus              TGCTGCTGGTGTTGGTGAATTTGAAGCTGGTATCTCCAAGAACGGGCAGACCCGCGAGCA 
Homo             TGCTGCTGGTGTTGGTGAATTTGAAGCTGGTATCTCCAAGAATGGGCAGACCCGAGAGCA 
Oryctolagus      TGCTGCTGGTGTCGGGGAATTTGAAGCTGGTATCTCCAAGAACGGGCAGACCCGTGAGCA 
                 ***** ****** ** ** ** ** ** ***** ** ***** ** ** ** ** ***** 
 
Danio            CGCCCTCCTGGCTTTCACCCTGGGAGTGAAACAGCTGATCGTTGGAGTCAACAAGATGGA 
Xenopus          TGCCCTCCTTGCCTACACTCTGGGAGTAAAGCAACTGATCGTTGGTGTTAACAAAATGGA 
Gallus           CGCTCTTCTGGCCTACACCCTGGGTGTGAAACAGCTGATCGTTGGTGTTAACAAGATGGA 
Bos              TGCCCTTTTGGCTTACACCCTGGGTGTGAAACAACTAATTGTTGGCGTTAACAAAATGGA 
Mus              TGCTCTTCTGGCTTACACCCTGGGTGTGAAACAGCTGATTGTTGGTGTCAACAAAATGGA 
Homo             TGCCCTTCTGGCTTACACACTGGGTGTGAAACAACTAATTGTCGGTGTTAACAAAATGGA 
Oryctolagus      TGCCCTTCTGGCTTACACGCTGGGTGTGAAACAGCTAATTGTTGGTGTTAACAAGATGGA 
                  ** **  * ** * *** ***** ** ** ** ** ** ** ** ** ***** ***** 
 
Danio            CTCCACTGAGCCCCCTTACAGCCAGGCTCGTTTTGAGGAAATCACCAAGGAAGTCAGCGC 
Xenopus          TTCAACTGAACCCCCATACAGCCAGAAAAGATATGAGGAAATCGTTAAGGAAGTCAGCAC 
Gallus           TTCCACTGAGCCACCTTACAGCCAGAAGAGATACGAAGAGATCGTCAAGGAAGTCAGCAC 
Bos              TTCCACTGAGCCACCCTATAGCCAGAAGAGATACGAAGAAATTGTTAAGGAAGTCAGCAC 
Mus              TTCCACCGAGCCACCATACAGTCAGAAGAGATACGAGGAAATCGTTAAGGAAGTCAGCAC 




Oryctolagus      TTCCACTGAGCCACCCTACAGCCAGAAGAGATACGAGGAAATCGTTAAGGAAGTCAGCAC 
                  ** ** ** ** ** ** ** ***    * *  ** ** **    ************ * 
 
Danio            ATACATCAAGAAGATCGGCTACAACCCTGCCAGTGTTGCCTTCGTCCCAATTTCAGGATG 
Xenopus          ATACATCAAGAAGATTGGTTACAACCCTGATACTGTTGCCTTTGTACCTATTTCTGGATG 
Gallus           TTACATCAAGAAAATTGGCTACAACCCAGACACTGTAGCTTTTGTGCCAATCTCTGGTTG 
Bos              CTATATTAAGAAAATTGGCTACAACCCCGACACAGTAGCATTTGTGCCAATTTCTGGCTG 
Mus              CTACATTAAGAAAATTGGCTACAACCCTGACACAGTAGCATTTGTGCCAATTTCTGGTTG 
Homo             TTACATTAAGAAAATTGGCTACAACCCCGACACAGTAGCATTTGTGCCAATTTCTGGTTG 
Oryctolagus      CTACATTAAGAAAATTGGCTACAACCCTGACACAGTAGCATTTGTGCCAATTTCTGGTTG 
                  ** ** ***** ** ** ******** *  *  ** ** ** ** ** ** ** ** ** 
 
Danio            GCACGGTGACAACATGCTGGAGGCCAGCTCAAACATGGGCTGGTTCAAGGGATGGAAGAT 
Xenopus          GAACGGTGACAACATGCTTGAGCCCAGCGCCAATATGCCTTGGTTTAAGGGGTGGAAAAT 
Gallus           GAACGGGGACAACATGCTGGAGCCTAGCTCTAACATGCCCTGGTTCAAGGGATGGAAGGT 
Bos              GAATGGTGACAACATGCTAGAACCAAGTGCTAATATGCCATGGTTCAAGGGATGGAAAGT 
Mus              GAATGGTGACAACATGCTGGAGCCAAGTGCTAATATGCCTTGGTTCAAGGGATGGAAAGT 
Homo             GAATGGTGACAACATGCTGGAGCCAAGTGCTAACATGCCTTGGTTCAAGGGATGGAAAGT 
Oryctolagus      GAACGGTGACAACATGCTGGAGCCAAGTGCTAATATGCCGTGGTTCAAGGGATGGAAAGT 
                 * * ** *********** **  * **  * ** ***   ***** ***** *****  * 
 
Danio            TGAGCGCAAGGAGGGTAATGCTAGCGGTACTACTCTTCTTGATGCCCTTGATGCCATTCT 
Xenopus          CTCACGTAAAGAGGGATCTGGCAGCGGAACTACCCTGCTGGAAGCTCTTGACTGCATTTT 
Gallus           TACCCGGAAAGATGGCAATGCCAGTGGAACCACCCTCCTGGAAGCCTTGGACTGCATCCT 
Bos              CACCCGTAAGGACGGCAATGCCAGTGGAACCACCCTGCTTGAAGCTCTGGATTGCATTCT 
Mus              CACCCGCAAAGATGGCAGTGCCAGTGGCACCACGCTGCTGGAAGCTTTGGATTGTATCCT 
Homo             CACCCGTAAGGATGGCAATGCCAGTGGAACCACGCTGCTTGAGGCTCTGGACTGCATCCT 
Oryctolagus      CACCCGCAAAGATGGCAATGCCAGTGGAACCACACTGCTTGAAGCCCTGGACTGCATCCT 
                     ** ** ** **   **  ** ** ** ** ** ** ** **  * **    **  * 
 
Danio            GCCCCCTAGCCGTCCCACCGACAAGCCCCTCCGTCTGCCACTTCAGGATGTGTACAAAAT 
Xenopus          GCCACCAAGTCGCCCAACTGATAAGCCTCTGCGTCTGCCTCTGCAGGATGTCTACAAAAT 
Gallus           GCCTCCAACTCGTCCAACTGACAAACCTCTGCGTCTGCCTCTTCAAGATGTCTACAAAAT 
Bos              GCCACCAACTCGCCCAACTGACAAACCCTTGCGTTTGCCTCTCCAGGATGTCTATAAAAT 
Mus              ACCACCAACTCGTCCAACTGACAAGCCCCTGCGACTGCCCCTCCAGGATGTCTATAAAAT 
Homo             ACCACCAACTCGTCCAACTGACAAGCCCTTGCGCCTGCCTCTCCAGGATGTCTACAAAAT 
Oryctolagus      TCCACCAACTAGACCAACTGACAAGCCTCTGCGTCTGCCCCTACAGGATGTCTACAAAAT 
                  ** ** *   * ** ** ** ** **  * **  **** ** ** ***** ** ***** 
 
Danio            TGGAGGTATTGGAACTGTACCTGTGGGTCGTGTGGAGACTGGTGTCCTCAAGCCTGGTAT 
Xenopus          TGGCGGTATTGGTACTGTACCAGTTGGTCGTGTGGAGACTGGTGTCCTTAAGCCAGGCAT 
Gallus           TGGTGGCATTGGTACTGTACCAGTTGGCCGTGTGGAAACTGGTGTCCTGAAGCCAGGTAT 
Bos              TGGTGGTATTGGTACTGTCCCTGTGGGTCGTGTGGAGACTGGTGTTCTCAAACCTGGCAT 
Mus              TGGAGGCATTGGCACTGTCCCTGTGGGCCGAGTGGAGACTGGTGTTCTCAAGCCTGGCAT 
Homo             TGGTGGTATTGGTACTGTTCCTGTTGGCCGAGTGGAGACTGGTGTTCTCAAACCCGGTAT 
Oryctolagus      TGGTGGTATTGGCACTGTCCCTGTGGGCCGAGTGGAGACTGGTGTTCTCAAACCTGGCAT 
                 *** ** ***** ***** ** ** ** ** ***** ******** ** ** ** ** ** 
 
Danio            GGTTGTGACCTTCGCCCCTGCCAATGTAACCACTGAGGTCAAGTCTGTTGAGATGCACCA 
Xenopus          GGTGGTTACTTTTGCCCCTGTTAATGTAACAACTGAAGTTAAATCTGTTGAAATGCACCA 
Gallus           GGTGGTCACATTTGCCCCCGTCAACGTTACAACTGAAGTAAAGTCTGTTGAGATGCACCA 
Bos              GGTGGTCACCTTTGCTCCAGTCAATGTAACAACTGAAGTGAAGTCTGTAGAAATGCACCA 
Mus              GGTGGTTACCTTTGCTCCAGTCAATGTAACAACTGAAGTCAAGTCTGTTGAAATGCACCA 
Homo             GGTGGTCACCTTTGCTCCAGTCAACGTTACAACGGAAGTAAAATCTGTCGAAATGCACCA 
Oryctolagus      GGTGGTAACTTTTGCTCCAGTCAATGTCACAACTGAAGTCAAGTCCGTCGAAATGCACCA 
                 *** ** ** ** ** ** *  ** ** ** ** ** ** ** ** ** ** ******** 
 
Danio            CGAGTCTCTGACTGAGGCCACTCCTGGTGACAACGTTGGCTTCAACGTTAAGAACGTGTC 
Xenopus          TGAAGCCCTTAGCGAGGCCATGCCCGGTGACAATGTTGGCTTTAACGTGAAAAACGTTTC 




Bos              TGAAGCATTGAGTGAAGCCCTTCCTGGGGACAATGTGGGCTTTAATGTCAAAAACGTGTC 
Mus              TGAAGCTTTGAGTGAAGCTCTTCCTGGGGACAATGTGGGCTTCAATGTAAAGAACGTGTC 
Homo             TGAAGCTTTGAGTGAAGCTCTTCCTGGGGACAATGTGGGCTTCAATGTCAAGAATGTGTC 
Oryctolagus      TGAAGCTTTGAGTGAAGCTCTTCCTGGGGACAATGTGGGCTTCAATGTCAAGAACGTGTC 
                  **  *  * *  ** **    ** ** ** ** ** ***** ** ** ** ** ** ** 
 
Danio            AGTCAAGGACATCCGTCGTGGTAATGTGGCTGGAGACAGCAAGAACGACCCACCCATGGA 
Xenopus          TGTGAAGGACGTCCGTCGTGGCAACGTTGCTGGTGACAGCAAGAATGACCCACCAATGGA 
Gallus           TGTGAAAGATGTCCGCCGTGGTAACGTTGCTGGTGACAGCAAGAATGATCCTCCAATGGA 
Bos              TGTCAAAGATGTCCGTCGTGGCAATGTGGCTGGTGACAGCAAAAATGATCCACCCATGGA 
Mus              GGTCAAAGATGTTAGACGAGGCAATGTTGCTGGTGACAGCAAAAACGACCCACCAATGGA 
Homo             TGTCAAGGATGTTCGTCGTGGCAACGTTGCTGGTGACAGCAAAAATGACCCACCAATGGA 
Oryctolagus      TGTCAAAGATGTTCGTCGTGGCAACGTTGCTGGTGACAGCAAAAATGACCCACCAATGGA 
                  ** ** **  *  * ** ** ** ** ***** ******** ** ** ** ** ***** 
 
Danio            GGCTGCCAACTTCAACGCTCAGGTCATCATCCTGAACCACCCTGGTCAGATCTCTCAGGG 
Xenopus          AGCTGGTACCTTTACAGCACAGGTTATCATCCTGAACCACCCAGGCCAGATTGGTGCTGG 
Gallus           AGCTGCTGGCTTTACTGCGCAGGTTATTATCCTGAACCACCCTGGCCAAATCAGTGCTGG 
Bos              AGCTGCTGGCTTCACAGCTCAGGTGATTATTTTGAACCATCCAGGCCAAATCAGTGCTGG 
Mus              AGCAGCTGGCTTCACTGCTCAGGTGATTATCCTGAACCATCCAGGCCAAATCAGTGCTGG 
Homo             AGCAGCTGGCTTCACTGCTCAGGTGATTATCCTGAACCATCCAGGCCAAATAAGCGCCGG 
Oryctolagus      AGCAGCTGGCTTCACTGCTCAGGTGATCATCCTGAACCATCCAGGTCAGATCAGTGCTGG 
                  ** *    *** *  ** ***** ** **  ******* ** ** ** **       ** 
 
Danio            TTACGCCCCAGTGCTGGATTGCCACACTGCTCACATCGCCTGCAAGTTTGCTGAGCTCAA 
Xenopus          ATATGCCCCTGTGTTGGATTGCCACACAGCTCACATTGCTTGCAAGTTTGCTGAGCTGAA 
Gallus           TTATGCCCCTGTGCTGGATTGCCACACTGCTCACATTGCCTGCAAGTTTGCTGAGCTCAA 
Bos              ATATGCACCTGTGCTGGATTGTCACACAGCTCACATTGCTTGCAAGTTTGCTGAGCTGAA 
Mus              CTACGCTCCTGTTCTGGATTGTCACACAGCCCACATAGCATGCAAGTTTGCTGAGCTTAA 
Homo             CTATGCCCCTGTATTGGATTGCCACACGGCTCACATTGCATGCAAGTTTGCTGAGCTGAA 
Oryctolagus      GTATGCCCCTGTACTGGATTGTCACACAGCTCACATTGCTTGCAAGTTTGCTGAGCTGAA 
                  ** ** ** **  ******* ***** ** ***** ** ***************** ** 
 
Danio            GGAGAAGATCGACCGTCGTTCTGGCAAGAAGCTTGAAGACAACCCCAAGGCTCTCAAATC 
Xenopus          GGAAAAGATTGATCGCCGTTCTGGTAAGAAACTGGAAGACAATCCCAAGTTCCTGAAGTC 
Gallus           GGAGAAGATTGATCGTCGTTCCGGCAAGAAGCTGGAGGATGGCCCGAAGTTCCTGAAATC 
Bos              GGAGAAGATTGATCGTCGTTCTGGGAAAAAGCTGGAAGATGGCCCTAAATTCTTGAAATC 
Mus              AGAAAAGATCGATCGTCGTTCTGGTAAGAAGCTGGAAGATGGCCCCAAGTTCCTGAAGTC 
Homo             GGAAAAGATTGATCGCCGTTCTGGTAAAAAGCTGGAAGATGGCCCTAAATTCTTGAAGTC 
Oryctolagus      GGAAAAGATTGATCGTCGTTCTGGAAAGAAGTTGGAAGATGGCCCTAAATTCTTGAAATC 
                  ** ***** ** ** ***** ** ** **  * ** **    ** **     * ** ** 
 
Danio            CGGAGATGCCGCCATTGTTGAGATGGTCCCTGGCAAGCCCATGTGTGTGGAGAGCTTCTC 
Xenopus          TGGTGATGCTGCCATTGTTGACATGATCCCAGGAAAGCCTATGTGCGTGGAGAGCTTCTC 
Gallus           TGGAGACGCTGCCATTGTTGATATGATCCCTGGCAAACCCATGTGTGTTGAGAGCTTCTC 
Bos              TGGTGACGCTGCCATCGTTGATATGGTTCCTGGCAAGCCCATGTGTGTCGAGAGCTTCTC 
Mus              TGGCGATGCTGCCATTGTTGATATGGTCCCTGGCAAGCCCATGTGTGTTGAGAGCTTCTC 
Homo             TGGTGATGCTGCCATTGTTGATATGGTTCCTGGCAAGCCCATGTGTGTTGAGAGCTTCTC 
Oryctolagus      TGGTGATGCTGCCATTGTTGATATGGTTCCCGGCAAGCCCATGTGTGTTGAGAGCTTCTC 
                  ** ** ** ***** ***** *** * ** ** ** ** ***** ** *********** 
 
Danio            TACCTACCCTCCTCTTGGTCGCTTTGCTGTGCGTGACATGAGGCAGACCGTTGCTGTCGG 
Xenopus          TGACTACCCCCCTCTTGGTCGTTTTGCTGTCCGTGACATGAGGCAGACTGTTGCTGTAGG 
Gallus           TGATTATCCTCCTCTGGGTCGTTTCGCTGTGCGTGACATGAGACAGACGGTTGCTGTTGG 
Bos              TGATTATCCTCCCCTGGGCCGTTTTGCTGTGCGTGACATGAGACAGACAGTCGCTGTGGG 
Mus              TGACTACCCTCCACTTGGTCGCTTTGCTGTTCGTGACATGAGGCAGACAGTTGCTGTGGG 
Homo             AGACTATCCACCTTTGGGTCGCTTTGCTGTTCGTGATATGAGACAGACAGTTGCGGTGGG 
Oryctolagus      TGACTATCCTCCTCTGGGTCGTTTCGCTGTCCGTGATATGAGACAGACGGTTGCTGTGGG 





Danio            CGTCATCAAGAGCGTTGAGAAGAAAATCGGTGGTGCTGGCAAGGTCACAAAGTCTGCACA 
Xenopus          AGTCATCAAGGCGGTCGATAAGAAGGCTGCTGGAGCTGGCAAAGTCACAAAGTCTGCTCA 
Gallus           TGTCATCAAGGCCGTCGACAAGAAGGCTGGTGGAGCCGGCAAGGTCACAAAGTCTGCTCA 
Bos              TGTCATCAAAGCAGTGGACAAGAAGGCAGCTGGAGCTGGCAAGGTCACCAAGTCTGCCCA 
Mus              TGTCATCAAAGCTGTGGACAAGAAGGCTGCTGGAGCTGGCAAAGTCACCAAGTCTGCCCA 
Homo             TGTCATCAAAGCAGTGGACAAGAAGGCTGCTGGAGCTGGCAAGGTCACCAAGTCTGCCCA 
Oryctolagus      TGTGATCAAAGCAGTGGACAAGAAGGCTGCTGGAGCTGGCAAGGTCACCAAGTCTGCCCA 
                  ** *****    ** ** *****    * *** ** ***** ***** ******** ** 
 
Danio            GAAGGCTGCCAAGACCAAGTGAATTTCC-CTCAATC-------ACACCGTTC-----CAA 
Xenopus          GAAAGCACAGAAAGGCAAATGAATATT---TCCAGCATCTCTCACCTCAGTCATAACCAG 
Gallus           GAAGGCCCAGAAGGCTAAATGAAAATTCTGTACATCAGCTGCCACCTCAGTCGTAATCAG 
Bos              GAAAGCTCAGAAGGCTAAATGAATATTATCCCCAATACCTGCCACCCCAGTCTTAATCAG 
Mus              GAAAGCTCAGAAGGCTAAATGAATATTACCCCTAACACCTGCCACCCCAGTCTTAATCAG 
Homo             GAAAGCTCAGAAGGCTAAATGAATATTATCCCTAATACCTGCCACCCCACTCTTAATCAG 
Oryctolagus      GAAAGCTCAGAAGGCTAAATGAATATTACCCCTAATACCTGCCACCCCAGTCTTAATCAG 
                 *** **    **    ** ****  *       *         **  *  **     **  
 
Danio            AGGTTGCGGCGTGTTCTTCCCAACCTCTTGGAATTTCTCTAAACCTGGGCAC-------- 
Xenopus          TGGTGGAGGATTGGTCTC-A-GAACTCT------TTCTATCAA-TTGGCCATCAGAGTTT 
Gallus           TGGTGGAAGAACGGTCTC-A-GAACTGT------TTGTCTCAA-TTGGCCATTTAAGTTT 
Bos              TGGTGGAAGAACGGTCTC-A-GAACTGT------TTGTCTCAA-TTGGCCATTTAAGTTT 
Mus              TGGTGGAAGAACGGTCTC-A-GAACTGT------TTGTCTCAA-TTGGCCATTTAAGTTT 
Homo             TGGTGGAAGAACGGTCTC-A-GAACTGT------TTGTTTCAA-TTGGCCATTTAAGTTT 
Oryctolagus      TGGTGGAAGAACGGTCTC-A-GAACTGT------TTGTCTCAA-TTGGCCATTTAAGTTT 
                  *** *  *   * ***     * ** *      ** * * **  *** **          
 
Danio            TCTACTTAAGGACTGGATAATGCTGATTAAAACCCATCGGAAAAATTTTCGCAGGAAAGG 
Xenopus          AATAGTCAAAGACTGGTTAAT---GATTACAATGCATCGCAAAAGCTTCAGAAGGAAAAA 
Gallus           AATAGTAAAAGACTGGTTAAT---GATTACAATGCATCGTAAAAGCTTCAGAAGGAAAGG 
Bos              AATAGTAAAAGACTGGTTAAT---GATAACAATGCATCGTAAAACCTTCAGAAGGAAAGG 
Mus              AATAGTAAAAGACTGGTTAAT---GATAACAATGCATCGTAAAACCTTCAGAAGGAAAGA 
Homo             AGTAGTAAAAGACTGGTTAAT---GATAACAATGCATCGTAAAACCTTCAGAAGGAAAGG 
Oryctolagus      AATAGTAAAAGACTGGTTAAT---GATAACAATGCATCGTAAAACCTTCAGAAGGAAAGG 
                   ** * ** ****** ****   *** * **  ***** ****  **  * ******   
 
Danio            AAAACAACT-TGGATTTAAGTGTGGCTCCATTTATTGACTGATAGTGCCT--CTTTCAGT 
Xenopus          A--ATG--CTCGTGGACACAT-------------TT----GTTTGTGGCAGTTTTTAAGT 
Gallus           A--ATG--TTTGTGGACCATTT---------GTTT--------CGTGGCAGTT--TAAGT 
Bos              AGAATGTTTTTGTGGACCATAT---------GTTTT----GTGTGTGGCAGTT--TAAGT 
Mus              A---T--G-TTGTGGACCATTT---------TTTTT----GTGTGTGGCAGTT-TTAAGT 
Homo             AGAATGTT-TTGTGGACCACTTTGGTTTTCTTTTTT----GCGTGTGGCAGTT-TTAAGT 
Oryctolagus      AGAATGTT-TTGTGGACCATTT--------TTTTTT----GTGCGTGGCAGTT-TTAAGT 
                 *          *                      *         *** *      * *** 
 
Danio            TATTAAATTTGTG------------TTTTGATGGTTTAGAACTGCACCT----GTTGCCA 
Xenopus          TATTAGTGTTTTAAATCCAGTAATTTCTAAATGGA-AGCAACTTGACCAA-AATCTGTCA 
Gallus           TATTAGTCTTTAAAATCGATTAATTT-TTTAAAAT-GGAAACTTGACCAAAAATCTGTCA 
Bos              TATTAGTTTTTAAAATCAGT-ACTTT-TTAATGAA-AACAACTTGACCAAAAATCTGTCA 
Mus              TATTAGTTTTCAAAATCAGT-ACTTT-TTAATGGA-AACAACTTGACCAAAAATCTGTCA 
Homo             TATTAGTTTTTAAAATCAGT-ACTTT-TTAATGGA-AACAACTTGACCAAAAATTTGTCA 
Oryctolagus      TATTAGTTTTTAAAATCAGT-ACTTT-TTAATGGA-AACAACTTGACCAAAAATCTGTCA 
                 *****   **               * *  *        ****  ***       ** ** 
 
Danio            CAGTACAATTTGGAAACGC-TGATGAATAAACTAAT----AAAG----GTAT-------- 
Xenopus          CC---AAA--TTGAGAC-CATTAAAAAAAAGTTAAAAGAAAAAAAAAAA----------- 
Gallus           ------------------------------------------------------------ 
Bos              CA---GAAT-TTGAGACCCATTAAAA-AAAGTTTAATGAGAAACCTGTGTCTTCCTTTTG 
Mus              CA---GAATTTTGAGACCA-TTAAAA-CAAGTTTAATGAGAAA----------------- 




Oryctolagus      CA---GAATTTTGAGACCCATTAAAACAAAGTTTAATGAG-------------------- 
                                                                              
 
Danio            -TAAAAATTGAAAAAA--------AAA-----------A--------------------- 
Xenopus          ---AAAAAAAAAAAAA---AAA--AAA--AAAAAAAAAA---------AA---------- 
Gallus           ------------------------------------------------------------ 
Bos              GTCAACACTGTAACTCCCTACAGTACTACTTTGGTAAGAGTTGCTCATAAGCTATTTCTG 
Mus              ------------------------------------------------------------ 
Homo             GTCAACACCGAGACAT-------------TTAGGTGAAAGA-------CATCTAATTCTG 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GTAAAACAATTT-----------TC-------AAATTATGGGTTTGTATTTCTAGGGTGG 
Mus              ------------------------------------------------------------ 
Homo             GTTTTACGAATCTGGAAACTTCTTGAAAATGTAATTCTTGAGTTAACACTTCT-GGGTGG 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AGCTTCAGGTTTGTTAACCTTG---TGTTGAGAACTCATCTGTTTTAATAACATCTTAAG 
Mus              ------------------------------------------------------------ 
Homo             AGAATAGGGTTGTTTTCCCCCCACATAATTGGAA----GGGGAAGGAATATCATTTAAAG 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              CATTGGTGCAACACTTTTCTAGATTAGGACAGATGAACA-AAGTAACTATGTTTTATATG 
Mus              ------------------------------------------------------------ 
Homo             CTATGGG---AGGGTTGCTTTGATTACAACACTGGAGAGAAATGCAGCATGTTGCTGAT- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TAAGCTAGTTTGTA----AGGTCAGATTCTAGAGTATAGAAGCTCCTGTTGCATATAAAA 
Mus              ------------------------------------------------------------ 
Homo             --TGCCTGTCACTAAAACAGGCCAAAA-------ACTGAGTCCTTGTGTTGCATAGAAAG 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTTTGTATGGTTACATAAATG---AATAAATCTATGTCAT---TTAGTTTGCCAGGTATG 
Mus              ------------------------------------------------------------ 
Homo             CTTCATGTTGCTAAACCAATGTTAAGTGAATCTTTGGAAACAAAATGTTTCCAAATTACT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 




Bos              AGGATGTGCATTCACATTTATAATAAGTAGTTAATCTAAAATGTGAGACTTAATAGTATT 
Mus              ------------------------------------------------------------ 
Homo             GGGATGTGCATGTTG-----------------------AAACGTGG--GTTAAAATGACT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GAGTACTGCCTTGCTAGAGTTAATTGTATAC-AGGTTCTAGGAAAAATAAAAGATGCTGG 
Mus              ------------------------------------------------------------ 
Homo             GGGCA-------GTGAAAGTTGACTATTTGCCATGACATAAG--AAATAA----GTGTAG 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AGGCTAATTGTGTTTCCTGTCACTTAAATAGAAATGAACTTTATAGGAATTCTCATCAAA 
Mus              ------------------------------------------------------------ 
Homo             TGGCTAG-TGTACACCCTATGA-------------------------------------- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TGGGCAAGGTTGGGTGAATGAGAACATTGCTACATTGGTGAGGAGGTAAGGCCCATTTGG 
Mus              ------------------------------------------------------------ 
Homo             -------------GT-----------------------------GGAAGGGTCCATTTTG 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GTCTGAGTGTAGG----TTCAT-CT-AGTTAATGTTTTCAAA-G-----TTAACTGCCAT 
Mus              ------------------------------------------------------------ 
Homo             AAGTCAGTGGAGTAAGCTTTATGCCAGTTTGATGGTTTCACAAGTTCTATTGAGTGCTAT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTTAAAAACTAGAAAGGA-----AACTGGAACTTGTCATTTGCAGGTTGCTATAACTTGA 
Mus              ------------------------------------------------------------ 
Homo             TCAGAATAGGAACAAGGTTCTAATAGAAAAAGATGGCAATTTGAAGTAGCTATAAAATTA 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              CAGTTGAATGAAAATAACCCTTAACTCTAGAG-----GAATTACTTTCATAACCTGTCAA 
Mus              ------------------------------------------------------------ 
Homo             GACT--AATCTACATTG--CTTTTCTCCTGCAGAGTCTAATACCTTTTATGCTTTGATAA 
Oryctolagus      ------------------------------------------------------------ 





Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTGTAGGGCTTGTTCACAAATGGGAAAAACTAGGTGGTCAGTTGATAATTGATCTCTGGT 
Mus              ------------------------------------------------------------ 
Homo             TTA--------------------------GCAGTTTGT------CTACTTGGTCACT--- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              ATAAGCAATGTAATTCTAAGTTAACCTTGGTTTTGATAGTCTTACACATTTGCAGAAAC- 
Mus              ------------------------------------------------------------ 
Homo             ---AGGAATGAAACTACATG------------GTAATAGGCTTAA-CAGGTGTAATAGCC 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              ------------------TGAGTAATTCTGTATCTGATAACTAGGCTTTTATAATAGGAA 
Mus              ------------------------------------------------------------ 
Homo             CACTTACTCCTGAATCTTTAAGCATTTGTGCATTTGAAAAAT--GCTTTT---------- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AATTAATCCAGCTGAAACTGGTGAAATCACACC----AGATACCATTCTAGAAGCCTTTT 
Mus              ------------------------------------------------------------ 
Homo             -------CGCGATCTTCCTGCTGGGATTACAGGCATGAGCCACTGTGCCTGAC--CT--- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTATGAATAGAAAGCATCCTGTGAGCTGTAGACAGATGGATTAATTGCAGTTTTTCCTAG 
Mus              ------------------------------------------------------------ 
Homo             --------------------CCCATATGTAAAA--GTG-TCTAAAGGTTTTTTTTTGGTT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              ATAAAA--ATAATTTATATGGCCATTGGTAGGGACTCTAAAATGACAAAGGATTTGGTCC 
Mus              ------------------------------------------------------------ 
Homo             ATAAAAGGAAAATTTTTGCTTAAGTTTGAAGGATAGGTAAAATT--AAAGGACATGCTTT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              CTAGCTTGTTCCTTAATGTTTTGATAGATATGGTGTTAACTGATGAAAGGAGATATGAAT 
Mus              ------------------------------------------------------------ 




Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AAAGATTGCTAGCTAGTAAATAGCTGGTGAAGACTTGTCTTCACAAGGAAGGTTTCATTG 
Mus              ------------------------------------------------------------ 
Homo             -----------------------------------------------GATGGTT-----T 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              CAGAAAATAGCTTTTAAGTGGAAGTTTAAGGAGAGCAGGACAGTTGGCATGCTTGGAGCC 
Mus              ------------------------------------------------------------ 
Homo             TTAAAAATTTTTTTTAAGATGGAGTTCTTGTTGCCCAGGCTAGAATGCAAT---GG---C 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              ATAGATTTGTCTGTACAGAAGTGCTGTGAGCGCCACCTACTGG----------------- 
Mus              ------------------------------------------------------------ 
Homo             A-AAATCT-------------CACTGCAATCTCCTCCTCCTGGGTTCAAGCAATTCTCCT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              -------------------TGGTCACTACAGACTAGTTTAAAACATGAATTTCTAGATTC 
Mus              ------------------------------------------------------------ 
Homo             ACTTCAGCCTCCCAAGTAGCTGGGATTACAGGCATGTGCTA------------------- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AGGATGAATGTTTTGCTCAGTTTTATACAGTTGC--TTTCTGAATA-TGAACTGACTGAA 
Mus              ------------------------------------------------------------ 
Homo             ----------ATTTGGTGTTTTTAATAGAGATGAGGTTTTTCCATGTTGGTCAGGCTGG- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AAGATTTATAAAACAAACTGGTGCTTGACCTTAAACCCCATTTTTAAAATTGCCTAGC-- 
Mus              ------------------------------------------------------------ 
Homo             ------TC----TCAAACT----CCTGACCTTAGG-----------TGATCGCCTCGGCC 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 




Bos              --------TGTTGAAA-TGGAATCTTGTTGAAA----CTTGGCCCCAGGAATTCTTCTGT 
Mus              ------------------------------------------------------------ 
Homo             TCCTAAAGTGCTGGAATTACAGGCATGAGCCACCATGCCTGG--CCAGGACATG---TGT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GGTTTCAGAATATGAGAGGCAGTATG-A---TTTCT---GAAAAAATGATTCTTAACCCT 
Mus              ------------------------------------------------------------ 
Homo             T-CTTAAGGACATGCTAAGCAGGAGTTAAAGCAGCCCAAGAGATAAGGCCTCTTAAAGT- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              ATTCCCAGGATAGGCAGTATAGTTGAGTTTTGGCCAGATTAACTATGCTTCAGGGGTTTT 
Mus              ------------------------------------------------------------ 
Homo             --------GACTGGCAAT------GTGTATTGCTC---------AAGATTCAAAGGTACT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTCAAGA-GCATGAGCAATTCA-TGTGGTTGGGTTCTGGTCTGCCCAAAAG------CAA 
Mus              ------------------------------------------------------------ 
Homo             TGAATTGGCCATAGACAAGTCTGTAATGAAGTGTTATCGTTTTCCCTCATCTGAGTCTGA 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              ATTGCATATACTGAAGAGCTTGATTATTAGTAATTTGCAGAATGGGGTATATAAATACCA 
Mus              ------------------------------------------------------------ 
Homo             ATTAGATAAA-----ATGCCTTCCCATCAGCCAGTG---CTCTGAGGTATC--AAGTC-T 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GGACAGGACTATAGATATTTTTATTAAAATGTATTTACCTTGGTTACCTTTTGTTAGGTT 
Mus              ------------------------------------------------------------ 
Homo             AAATTGAACTAGAGATTTTTGTCCTTA------GTTT-CTTTGCTATCTAATGTTTAC-- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GAGCACTGAGCTCATGCCAAAAACAGGCTGTTTCTGGCTCTGTATACAATTCTTGAAATG 
Mus              ------------------------------------------------------------ 
Homo             -----------ACAAG---TAAATAGTCTAAGATTTGCT--GGA--------------TG 
Oryctolagus      ------------------------------------------------------------ 





Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GGCAGCTCTAGAAAAGGGATGAAAACTTGTGTGTCAAGATGTCCTTTTATGTTTTCTGTT 
Mus              ------------------------------------------------------------ 
Homo             -------ACAGAAAA--------AACAGGT--------AAGGCCTTTA---------ATA 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GATAGGTGTTAGATGTCCTTGTGAAATGCTGCAAGATGATGTATAGTCACTTGGGAATTA 
Mus              ------------------------------------------------------------ 
Homo             GATGGCCAATAGATGCCCTGATA-----ATGAAAGTTGA--------CACCTGTAAG-AT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTAAAGGTATATTAGTTATTCCCTTGTATCTTAAAAGGAATGAGCAGCATGAGTTCTCAA 
Mus              ------------------------------------------------------------ 
Homo             TTACCAGTAGAGA-ATTCTTGA-------CATGCAAGGA------AGCAAGATTTAA--- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TCTTGTGATGAGAAGAGCAAGCTCTTCCATATGAGAAAGAAGGTGGAATGAAATGCATCT 
Mus              ------------------------------------------------------------ 
Homo             -------CTGAA------AAATTGTTCCCACTG-----GAAGCAGGAATGAG-------T 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TCCTTTATTTGCAACGTTCCTGAAACTTTTCCTGATCTGGTTTTGGTTTTCATGACTTCT 
Mus              ------------------------------------------------------------ 
Homo             CAGTTTACTTGCATA--TACTGAGA-----------------TTGAGATT---AACT--- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              GTCCTTTTTTCTTCCAAACTTAGAGGTTCTCTCACCCAGGTGGCATCAGAGTCCTCTGTT 
Mus              ------------------------------------------------------------ 
Homo             --------TCCTGTGAAACCCAGTG--TCTTAGACAACTGTGGCTTGAGCACCACCTGCT 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TGCAGGCCTCCGGGAACTTCCTAGACTAGTTAAAATCACAATTGAAGTTGCATTGCTTGC 
Mus              ------------------------------------------------------------ 




Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TCAGGTGATAGTGATTTAGAAAAAACTTTGGAAACTGCCACATGGCTTCTGAGAGGTCAT 
Mus              ------------------------------------------------------------ 
Homo             ------------GCTTTAAAAAAAAAAAAAAAAAA------------------------- 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TGACCTCTGATCCAATGGAAAACTTGGAAAGGATCATATGGGTTTCTTTTCTAAATAGGT 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TATGCTACATAGTTCTGCTGTTAATAGAAATGAGTGAGATTAGTGAGTTTGTCATATACC 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTGGACAACCTTCAGCAGGTCCATGGATCACCAAGCCTTGAGTGCTCAGTGACAACAAAG 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AGCATGTTAATATTTCAAGTAAGCAATAATAGAAAAGTTAGCAGAATATAAAGTTCTTAC 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              AACTTTTTTCATTAAAATTTACCCTGTAAAAAGCATTTTGCAAGTTTTGATAAAGTTTAC 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 




Bos              CAAAAAACAGTTTATTTACCACAATCATGGTATAGAATATTTCCGTCACTTTTCCCCTTC 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              CCAAATTTCCCACGTCCCTGTATGGTCAATCACTCTTCTCTACCTCTTATTCTTGGTAAC 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TACTGACCTATATTCTTTCCCCGTTTCGATTTTTAGCAGTGTCACATACCTGAGTTGATA 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              CCATATGTAGCCTTTGAATCTGGTTTCTTTACTTAGCATGATGCCTTTGAGATGATCTGT 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              TTTGCATGTATCAGTAATCTGTTCCTTTTTAATAACTATAAGCTTGTTTACAGCTGAGGG 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            ------------------------------------------------------------ 
Xenopus          ------------------------------------------------------------ 
Gallus           ------------------------------------------------------------ 
Bos              ACATTGGTTGTTTTGGATAATTACAAATAAACCACTAAACATTCACATATAAAAAAAAAA 
Mus              ------------------------------------------------------------ 
Homo             ------------------------------------------------------------ 
Oryctolagus      ------------------------------------------------------------ 
                                                                              
 
Danio            -------- 
Xenopus          -------- 
Gallus           -------- 
Bos              AAAAAAAA 
Mus              -------- 
Homo             -------- 





Comparison table of currently commercially available mouse models for 
ALS as offered by the Jackson Laboratory. Outlining mutation and 













Human SOD1 with 
glycine to alanine 
transition at 
position 93 
Decreased grip strength, 
impaired coordination, motor 
neuron degeneration, severe 
muscle weakness beyond 3 
months old, hind limb tremors at 
14 weeks old, become 








Human SOD1 with 
glycine to alanine 
transition at 
position 93 
Decreased grip strength, 
impaired coordination, motor 
neuron degeneration, decreased 
muscle size, hind limb tremors 
at 14 weeks of age, become 









promoter driving a 
modified human 
TAR DNA binding 
protein with an 
A315T amino acid 
substitution 
Progressive and fatal 
neurodegenerative disease, 
frontotemporal lobar 
















Sequences highlighting various alleles and annotated from D252H mice. 
EXON 5 





#1     10.13R      ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
     10.1R       ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
       10.4        ACCCGCCCCACTGGCAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
       10.2R       ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
     10.6R       ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
       10.11       ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
     10.9        ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
     10.8        ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
     10.7        ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 
     10.10       ACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTT 








 #1 11.4R       CCCACCCGCCCCACTGACAAGCCCCTTCGTC-GCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.6R       CCCACCCGCCCCACTGACAAGCCCCTTCGTC-GCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.3        CCCACCCGCCCCACTGACAAGCCCCTTCGTC-GCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.13       CCCACCCGCCCCACTGACAAGCCCCTTCGTC-GCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.11       CCCACCCGCCCCACTGACAAGCCCCTTCGTC-GCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.7        CCCACCCGCCCCACTGACAAGCCCCTTCGTC-GCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.1R       CCCACCCGCCCCACTGACAAGCCCCTTCGTC-GCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 
 
#2 11.2        CCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.12R      CCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.8        CCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.9        CCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.10       CCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 11.5        CCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCT 
 
# 12 Alleles 
 
#1 12.13       CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 
 
#2 12.4        CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 12.8        CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 12.7        CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 12.5        CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 




 12.3        CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 12.10R      CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 12.6R       CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 12.12R      CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 12.2R       CCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTG-----------------------ACAGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTC 
 
 
# 14 Alleles 
 
#1 14.11R      CCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTC 
 14.6R       CCCCCCACCCGCCCCGCTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTC 
 14.7        CCCCCCACCAGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTC 
 14.9        CCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTC 
 14.8        CCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTC 
 14.1R       CCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTC 
 
 
#2 14.10       GACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTCA-----------AGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTG 
 14.13R      GACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTCA-----------AGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTG 
 
 
#3 14.5R       CTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTG 





#1 15.2        CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGSATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 15.4        CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAAGCGCTTGCCTACTCTGCTCCAAA 
 15.8        CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 15.13       CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 15.7        CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCGGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 15.6        CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 15.11R      CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 15.1        CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 
#2 15.3R       CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 
 15.10R      CCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCTGCTCCAAA 




#1 16.13       CTGCCCCCCATCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.11R      CTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.4        CTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.8R       CTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.9        CTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 





#3 16.7        CTGCCCCCCACCCGCCCTACTGACAAGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.12R      CTGCCCCCCACCCGCCCTACTGACAAGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.2R       CTGCCCCCCACCCGCCCTACTGACAGGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.5R       CTGCCCCCCACCCGCCCTACTGACAGGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.10R      CTGCCCCCCACCCGCCCTACTGACAAGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.1        CTGCCCCCCACCCGCCCTACTGACAAGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 16.3R       CTGCCCCCCACCCGCCCTACTGACAAGCCCCTTCGTCTGCCTCTGCAGCATGTGTACAAGATTGGCGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCAGGCGCTTGCCTACTCT 
 
 
#17 Alleles  
#1 17.12       GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTG 
#2 17.4        GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.5        GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.6        GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.8        GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.13R      GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.10R      GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.1R       GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.11R      GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 
17.2R       GCGGCGTGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACT-------------------------------------GTATTGGGGGTGAGTGAGGGTTCAGTG 





#1 18.4          GGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGG 
 18.8          GGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGG 
 18.14         GGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGG 
 
#2 18.3          GGACACAATCCTGCCCCCCACCCGCCCTACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGG 
 
 18.3-Continued        AAACCCTGACTAGGATATCCTGAGTGGATATCTGCAGGATGTGCACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACT 
 18.3-Continued        GCGGCAGGCGCTTGCCTACTCTGCTCCAAACCCTGACTAGGANATCAACAAGGAATCTTG 
 
 
#3 18.6          GGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGT------CTGCAGGACGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGG 
    





#1 21.2R       CCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCGTCTGCCTCTGCAGGATTCTGCCTCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCGGTGCTGGGGCTCACTGCGGCA 













#1      24.6        AAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAG-------------------TGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCA 
         24.4        AAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAG-------------------TGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCA 
       24.3        AAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAG-------------------TGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCA 
       24.11       AAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAG-------------------TGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCA 
       24.13R      AAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAG-------------------TGGATGTGTACAAGACTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCCCACTGCGGCA 
       24.8R       AAGACCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAG-------------------TGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGGCTCACTGCGGCA 
      





#1 25.6        TGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCG------TCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGG 
 25.10       TGTCCCTGCTGGAAGCCCTGGACACAATCCTGCCCCCCACCCGCCCCACTGACAAGCCCCTTCG------TCTGCAGGATGTGTACAAGATTGGGGGTGAGTGAGGGTTCAGTGCTGGGG 
 





Proteins with p-value <0.05. 
 
 
 Down regulated in eEF1A2 null 







































































































































































SAM 500 genes. 
 
 
 Down regulated in wasted 
 Up regulated in wasted 
 
Gene.name q.value log2.fc 
Eef1a2 0.0327 -7.02808 
Eef1a2 0.0327 -6.8819 
Eef1a2 0.0549 -4.99321 
Chrna4 0.0414 -1.83851 
Ahnak2 0.0483 -1.1011 
Kcng4 0.0404 -1.03422 
Fbxo9 0.0327 -0.89958 
Igfbp2 0.0494 -0.85266 
Igfbp2 0.0523 -0.80323 
Kcng4 0.0532 -0.76408 
Pla2g3 0.0553 -0.76024 
Mrvi1 0.0416 -0.62258 
Card10 0.0788 -0.60361 
Eml1 0.0799 -0.56785 
Dhcr24 0.0756 -0.54255 
Prph 0.053 -0.53 
LOC100041194 0.0813 -0.52565 
Tmprss5 0.0416 -0.52511 
Etv4 0.0637 -0.52338 
Dhcr24 0.0549 -0.51004 
E130012A19Rik 0.0637 -0.50453 
6330503H08Rik 0.0743 -0.49859 
Unc13c 0.0549 -0.49703 
Dync1i1 0.0523 -0.49652 
Dysf 0.0532 -0.48723 
Gpd1 0.0494 -0.48561 
Gene.name q.value log2.fc 
Itih3 0.0862 -0.48045 
Unc13c 0.0523 -0.46791 
Plekho2 0.0523 -0.46727 
Mvd 0.045 -0.46285 
Itih3 0.0615 -0.45993 
Acy3 0.081 -0.45057 
Aacs 0.0826 -0.444 
Txnl4a 0.0587 -0.44098 
Prph 0.0646 -0.43986 
Gprasp1 0.0577 -0.43313 
Whrn 0.0735 -0.42905 
Whrn 0.059 -0.42407 
Fgfrl1 0.0579 -0.41937 
Calr3 0.0539 -0.4189 
Gprasp1 0.045 -0.41612 
Elmo2 0.0735 -0.40706 
Stk32a 0.0584 -0.39763 
Pcyt1b 0.075 -0.39723 
2310047M10Rik 0.0742 -0.39577 
Acly 0.059 -0.38436 
Gls2 0.0607 -0.384 
Parva 0.0606 -0.3826 
Rgs11 0.075 -0.3826 
E2f1 0.0742 -0.37747 
2310047M10Rik 0.0556 -0.37466 




Gene.name q.value log2.fc 
Gjc2 0.0749 -0.36106 
1500031L02Rik 0.0681 -0.35785 
Tubb2c 0.076 -0.35664 
Arhgef4 0.045 -0.35326 
BC067047 0.0735 -0.3493 
2310058D17Rik 0.0494 -0.34712 
Fmr1 0.0679 -0.3443 
Tlcd1 0.0646 -0.34146 
Amhr2 0.0532 -0.3358 
Rgs7bp 0.0569 -0.33376 
Blvrb 0.0682 -0.33183 
Sqle 0.0523 -0.3318 
Ankmy2 0.0509 -0.33027 
6330442E10Rik 0.0561 -0.32585 
Pstpip1 0.0605 -0.3236 
LOC100045304 0.0494 -0.3231 
2610019E17Rik 0.075 -0.32266 
Cryba2 0.0603 -0.32084 
Lgr6 0.0416 -0.31931 
Serpine2 0.0743 -0.31509 
Nat8l 0.0735 -0.31474 
Bcan 0.0759 -0.31458 
Frmd8 0.0855 -0.31235 
Dos 0.081 -0.3084 
Gls2 0.0584 -0.30809 
Copg 0.0615 -0.30499 
Gpld1 0.0742 -0.30454 
Hrh3 0.0404 -0.30293 
Spata13 0.076 -0.30195 
Hebp2 0.0742 -0.30174 
Esrrb 0.0549 -0.3003 
6330442E10Rik 0.059 -0.29985 
Kcnip3 0.0561 -0.29798 
9330175B01Rik 0.0749 -0.29745 
Necab3 0.0587 -0.2973 
Gpld1 0.076 -0.29634 
Asb1 0.0657 -0.29577 
Elovl5 0.0764 -0.29493 
Sh3bp5l 0.0436 -0.29049 
Gene.name q.value log2.fc 
Pgrmc2 0.0742 -0.29039 
Sc5d 0.0494 -0.28738 
Acaa1b 0.045 -0.28408 
Ctnnbip1 0.0523 -0.28406 
Rdh11 0.075 -0.28245 
Stk16 0.075 -0.27354 
C130057N11Rik 0.0735 -0.27067 
Ppp1r3f 0.0549 -0.27062 
Mid1ip1 0.045 -0.26963 
Eif2ak1 0.0742 -0.26529 
Tmem2 0.0799 -0.2636 
Eif5 0.0532 -0.26169 
1500012F01Rik 0.0549 -0.25865 
2810017I02Rik 0.0735 -0.25843 
Mtap 0.0549 -0.25834 
LOC100047651 0.0786 -0.25692 
Spna2 0.0735 -0.25452 
Rasl10b 0.0608 -0.25296 
Snn 0.0416 -0.25208 
Mtap 0.075 -0.25022 
Tnfrsf22 0.0862 -0.24991 
Slc29a4 0.0735 -0.24909 
Rassf4 0.0808 -0.24864 
Cyp27a1 0.0555 -0.24735 
Tubb2b 0.0564 -0.24665 
Rassf4 0.0603 -0.24579 
Nat8l 0.0826 -0.24226 
Plxnb3 0.0697 -0.24064 
Smox 0.0799 -0.23802 
Mar-02 0.0657 -0.238 
LOC100046996 0.0826 -0.23761 
Nefm 0.0756 -0.23577 
Eif4a2 0.0756 -0.23267 
BC014795 0.0782 -0.23135 
Zswim6 0.0615 -0.22877 
Muted 0.0523 -0.22871 
Tpm1 0.0549 -0.22794 
9030024J15Rik 0.0561 -0.22663 




Gene.name q.value log2.fc 
Ttf2 0.0657 -0.22542 
Oaz2 0.0816 -0.22541 
Snhg10 0.0786 -0.22439 
Snx27 0.0561 -0.22367 
Mag 0.073 -0.22294 
Phf21b 0.0742 -0.22275 
LOC100043671 0.0742 -0.22274 
Spg7 0.0839 -0.22262 
Rasgef1a 0.0787 -0.22078 
Cand1 0.0799 -0.21619 
Tmem38b 0.0602 -0.21516 
Slc39a13 0.0726 -0.21324 
Usp7 0.075 -0.20747 
Efcab2 0.0618 -0.2067 
Tmem98 0.0844 -0.2064 
Sord 0.059 -0.20612 
Lrig1 0.0757 -0.20567 
Mtap7d1 0.0799 -0.20455 
Ufsp2 0.075 -0.20394 
Tnip1 0.0584 -0.20301 
Rap2a 0.0739 -0.20286 
Mfsd2 0.0681 -0.20244 
Thsd7a 0.0754 -0.20243 
Stk3 0.0523 -0.20233 
Pcdh12 0.0681 -0.20231 
Nsf 0.076 -0.20185 
Atmin 0.0504 -0.20156 
Fsd2 0.0539 -0.20015 
Dennd2a 0.0561 -0.19848 
Vegfb 0.0523 -0.19824 
Igbp1 0.076 -0.19379 
2310028O11Rik 0.0615 -0.19257 
Eif5 0.0549 -0.18955 
Sap30l 0.075 -0.18827 
Tmem141 0.0816 -0.18808 
Sfrp1 0.0638 -0.18806 
Farp2 0.0756 -0.1879 
Serpine2 0.075 -0.18747 
Shisa2 0.0556 -0.18725 
Gene.name q.value log2.fc 
Zfp251 0.0726 -0.18678 
Paip2b 0.0638 -0.18634 
4932415G12Rik 0.0735 -0.18525 
LOC100044190 0.0735 -0.18499 
Rab39 0.0556 -0.18475 
Adora1 0.075 -0.18341 
Nutf2 0.0787 -0.18272 
LOC100045697 0.0816 -0.18146 
Sorl1 0.0681 -0.18118 
Nsmaf 0.0696 -0.18031 
1110029I05Rik 0.075 -0.17979 
Lrsam1 0.0816 -0.17874 
1110038D17Rik 0.0638 -0.17848 
Pmvk 0.0657 -0.17802 
Lcmt1 0.0555 -0.17703 
Rpl22 0.045 -0.17488 
Col22a1 0.045 -0.17425 
H2afj 0.0813 -0.17391 
4930572J05Rik 0.0801 -0.1732 
Impa2 0.0816 -0.17045 
Ppa1 0.0483 -0.16995 
Slc27a1 0.0754 -0.1695 
Syn2 0.0799 -0.16919 
Dscr1 0.0754 -0.16909 
Ank3 0.0608 -0.16719 
Gnptab 0.0799 -0.16565 
4930563E22Rik 0.045 -0.16038 
Gng11 0.081 -0.15902 
LOC100046953 0.075 -0.15887 
Pgs1 0.0651 -0.1585 
Haghl 0.075 -0.15844 
Pcyt2 0.0845 -0.15743 
A830080H07Rik 0.0658 -0.15728 
Etl4 0.0754 -0.15691 
Zdhhc3 0.053 -0.15675 
L3mbtl3 0.0549 -0.15599 
Dlgap3 0.0688 -0.15551 
Zyx 0.0556 -0.15325 




Gene.name q.value log2.fc 
Depdc5 0.0726 -0.15068 
9530064J02 0.0799 -0.14855 
Pipox 0.0816 -0.148 
Rnpepl1 0.0862 -0.14799 
LOC385156 0.0556 -0.14757 
Phf20 0.075 -0.14639 
Rhox12 0.0549 -0.14481 
Pfkm 0.076 -0.14244 
Rapgef6 0.0826 -0.14112 
Zkscan6 0.0556 -0.13749 
Ankrd6 0.0695 -0.1351 
LOC100041343 0.0735 -0.13405 
Slc6a9 0.0826 -0.13165 
Slc4a2 0.0626 -0.13148 
EG626549 0.0813 -0.12942 
Tceb1 0.0681 -0.1269 
Lrrfip2 0.0872 -0.12215 
2010317E24Rik 0.0556 -0.12126 
C130090G16Rik 0.075 -0.11593 
Aak1 0.0839 -0.11567 
LOC672339 0.0839 -0.11469 
Harbi1 0.0754 -0.11464 
C230098K08Rik 0.0799 -0.11421 
Rit1 0.0532 -0.1139 
2610110G12Rik 0.0801 -0.11352 
Tmem121 0.0756 -0.11339 
H2-T18 0.0523 -0.11302 
Ctage5 0.0561 -0.1116 
Slc28a1 0.0556 -0.11119 
Akap11 0.0754 -0.11067 
4833411B01Rik 0.0523 -0.11043 
A130076G11Rik 0.045 -0.11027 
Rhoc 0.0848 -0.10735 
Calu 0.0743 -0.10719 
Rabep1 0.0756 -0.10641 
Pcdha7 0.075 -0.10206 
Pi4ka 0.0657 -0.10081 
Col5a2 0.081 -0.09981 
Xpc 0.0532 -0.09446 
Gene.name q.value log2.fc 
E330036I19Rik 0.0681 -0.09095 
Plekhm3 0.0681 -0.09026 
Zbtb8os 0.075 -0.08416 
Add1 0.0811 -0.08323 
Tlr12 0.0608 -0.08113 
AA536749 0.053 -0.07966 
Ugcgl2 0.045 -0.07729 
Tbcel 0.0638 -0.063 
3830408C21Rik 0.075 -0.06219 
Arhgef1 0.0754 -0.06187 
Synj1 0.0799 -0.05242 
1700010M22Rik 0.0845 0.043094 
4933415I03Rik 0.076 0.066763 
Krt2-1 0.0742 0.071064 
Chst7 0.0615 0.076695 
2610024G14Rik 0.0579 0.082937 
LOC385985 0.076 0.086921 
Tptf-pending 0.0556 0.087338 
Ptgfrn 0.075 0.092881 
D430036M17Rik 0.0416 0.100094 
Klhl23 0.075 0.109857 
LOC272714 0.0742 0.111978 
Stxbp4 0.0646 0.113948 
9430022P05Rik 0.0404 0.114923 
1810026J23Rik 0.0743 0.115461 
Sap30bp 0.0799 0.119045 
2310003F16Rik 0.0555 0.121071 
Ube2h 0.0839 0.121233 
Tardbp 0.075 0.122426 
9530048O09Rik 0.0845 0.1289 
LOC385111 0.0735 0.128979 
LOC100044812 0.0579 0.130231 
Pomp 0.0756 0.132681 
Syngr3 0.085 0.133064 
Slc25a19 0.0579 0.135193 
Eif3i 0.0598 0.135825 
Pelo 0.0523 0.136615 
Erlin1 0.045 0.136714 




Gene.name q.value log2.fc 
Mapbpip-
pending 0.0764 0.139446 
Skiv2l2 0.0807 0.140494 
Chchd1 0.078 0.142138 
Sorcs3 0.0657 0.143041 
Hsf1 0.0754 0.146896 
Htf9c 0.0766 0.147031 
Ubl5 0.0764 0.14722 
Ppp2r5c 0.0839 0.147956 
Lhx9 0.0798 0.14814 
Idh3a 0.0523 0.151136 
Tomm7 0.045 0.154455 
Blcap 0.0615 0.155789 
2310061F22Rik 0.0587 0.156537 
Trim26 0.0681 0.156835 
Gnptg 0.0799 0.157897 
Ergic1 0.0603 0.157975 
2210015D19Rik 0.0549 0.158015 
Rab40c 0.0742 0.158067 
Ndufs8 0.0556 0.158472 
Erp29 0.0825 0.160188 
Lsm4 0.0584 0.162286 
Vti1a 0.0494 0.163822 
Cbln2 0.0598 0.168021 
Gabbr2 0.0765 0.16866 
Gpr19 0.0523 0.169462 
Wdr74 0.0638 0.169641 
Ndufa9 0.0555 0.170207 
Rars 0.076 0.170789 
Pdcd2 0.0726 0.174155 
Maged1 0.075 0.17445 
Slc25a38 0.076 0.174801 
Sar1b 0.0726 0.178197 
Ttc19 0.0826 0.178894 
D10Ertd641e 0.0672 0.179399 
Uck2 0.075 0.180541 
Ppapdc1 0.0743 0.180922 
Ndufa13 0.0532 0.18222 
C330023M02Rik 0.0756 0.183026 
Gene.name q.value log2.fc 
Nudt19 0.0804 0.184195 
Eif1ad 0.0799 0.184327 
B230210A04Rik 0.0584 0.185029 
2700062C07Rik 0.0826 0.18609 
Shmt2 0.0735 0.186753 
Sf3b5 0.0556 0.187823 
2700062C07Rik 0.0799 0.188424 
A830006F12Rik 0.0681 0.189706 
Pcdhac2 0.0632 0.189731 
Chic2 0.0598 0.189993 
Mkln1 0.0549 0.191883 
Gria3 0.0681 0.191964 
Kctd1 0.0404 0.197811 
Ypel3 0.0743 0.197938 
EG666387 0.0799 0.198215 
Mettl1 0.081 0.198442 
Rag1ap1 0.0799 0.198749 
Ndufa2 0.0735 0.198927 
Nxph1 0.0553 0.198976 
Rnf185 0.0606 0.203597 
Tmem120a 0.0807 0.20386 
Ndufb6 0.0681 0.204013 
2310066E14Rik 0.0631 0.20409 
Hint1 0.0743 0.204559 
6720458F09Rik 0.069 0.204846 
2310014G06Rik 0.0523 0.205697 
LOC100041835 0.0775 0.206471 
9030025P20Rik 0.0638 0.20743 
Srpk1 0.0756 0.207591 
Klhl26 0.0606 0.210569 
4933411K20Rik 0.076 0.212715 
Map3k12 0.0821 0.212811 
Cnpy2 0.0826 0.214376 
1110002E23Rik 0.0735 0.215243 
Dhodh 0.0735 0.217043 
Ndufa7 0.0695 0.217345 
EG574403 0.0799 0.21788 
Btbd11 0.0416 0.22226 




Gene.name q.value log2.fc 
Angptl6 0.0804 0.226248 
Tmsb10 0.0759 0.226995 
Ogfr 0.045 0.229161 
2010003O18Rik 0.0579 0.229409 
Ndufs6 0.0549 0.233281 
Ppp2r5e 0.0549 0.233817 
Dusp4 0.0698 0.234588 
Acp2 0.0404 0.237202 
Mrpl49 0.0681 0.239236 
Lypd1 0.0756 0.240299 
BC029169 0.0799 0.24238 
Tro 0.0587 0.243054 
Gcap26 0.0764 0.244058 
Nme1 0.053 0.244166 
Nt5c 0.0549 0.244727 
Golga3 0.0556 0.246693 
Brp16 0.076 0.247201 
Ppih 0.0799 0.247883 
Pqlc3 0.0549 0.249532 
Pfdn4 0.0532 0.249651 
Ssr4 0.0555 0.251496 
Slc19a1 0.0679 0.251817 
Eme2 0.0754 0.25349 
Cebpg 0.0656 0.263251 
Rpl24 0.0638 0.26468 
Rbm42 0.0799 0.265469 
Vamp2 0.0681 0.267441 
2310004N11Rik 0.0726 0.268146 
Nol1 0.0735 0.269544 
AI593442 0.0816 0.272164 
Hspa9 0.0742 0.272165 
Mrps33 0.0416 0.273369 
Cited2 0.083 0.273823 
Sco1 0.0742 0.275207 
2310045N01Rik 0.0626 0.275701 
Resp18 0.059 0.279951 
Kcnq2 0.0532 0.28061 
B930075F07 0.0555 0.280965 
0610009O20Rik 0.0799 0.283195 
Gene.name q.value log2.fc 
Atg12 0.0494 0.28384 
Cited2 0.0532 0.288039 
Aars 0.053 0.288954 
Prodh 0.0799 0.290377 
Itfg2 0.0749 0.291127 
Dph2 0.0556 0.292175 
B930076A02 0.0813 0.292318 
Txndc13 0.0549 0.292341 
Spry3 0.0566 0.293702 
Lrrc24 0.0811 0.293813 
Gars 0.073 0.294331 
Mrpl34 0.075 0.297914 
Lars 0.0737 0.299517 
Creb3 0.0735 0.299579 
Psenen 0.0799 0.300067 
Ppp1r11 0.0404 0.300205 
Ttc9c 0.0534 0.300392 
Prkrip1 0.0726 0.30044 
Scg2 0.0615 0.30054 
4932417H02Rik 0.0556 0.302188 
A630084D02Rik 0.0799 0.304275 
Herpud1 0.0572 0.307249 
2310001H12Rik 0.059 0.312295 
Crcp 0.0799 0.312586 
Phf5a 0.076 0.31422 
Lor 0.0603 0.315525 
Sobp 0.0783 0.316202 
Slc1a4 0.0327 0.316264 
2700007P21Rik 0.0483 0.319815 
Lars 0.0742 0.31988 
Sobp 0.0816 0.321579 
Dph2 0.0637 0.322526 
Ppfia1 0.0523 0.32476 
LOC219106 0.0756 0.328118 
Armc6 0.045 0.332464 
Ccl3 0.0735 0.338499 
Samd14 0.0523 0.342155 
LOC100042179 0.0756 0.34237 




Gene.name q.value log2.fc 
Cebpb 0.0749 0.34316 
Fbxw7 0.0799 0.344797 
Silg111 0.0549 0.3499 
Polrmt 0.0807 0.355044 
Hn1 0.0816 0.357982 
Tmsb10 0.0799 0.359909 
Hspa9 0.0549 0.361298 
Traf3 0.0555 0.36274 
Cda 0.078 0.362949 
Ppp2r5d 0.0799 0.366861 
Krtcap2 0.0523 0.369508 
Rpp21 0.0773 0.371909 
Kif5c 0.0523 0.372773 
Otub2 0.0822 0.373273 
Asns 0.0523 0.377895 
Adprh 0.0756 0.379301 
Traf3 0.0822 0.38194 
2210418O10Rik 0.0726 0.388602 
Atf4 0.0756 0.388824 
Lonp1 0.045 0.388884 
Aldh18a1 0.0613 0.39186 
Cox10 0.0523 0.391958 
Cox6a2 0.0598 0.397847 
Inpp5e 0.0788 0.406217 
Herpud1 0.0742 0.41637 
Trib3 0.0556 0.424718 
Spin2 0.045 0.431905 
Asns 0.0832 0.433114 
LOC100044736 0.0549 0.437268 
Gm129 0.0579 0.440883 
Fbxw7 0.045 0.442991 
Otub2 0.0735 0.446521 
Spin2 0.0589 0.447936 
Plekhm2 0.0416 0.450606 
Nol5a 0.0799 0.457729 
1810005K13Rik 0.078 0.462703 
Otub2 0.0436 0.471952 
Ppfia1 0.0556 0.47242 
B230206N24Rik 0.0735 0.491784 
Gene.name q.value log2.fc 
Alkbh7 0.0607 0.493248 
Bdnf 0.045 0.52505 
Kif5a 0.0539 0.542309 
Ppfia3 0.0603 0.544676 
1110008P14Rik 0.075 0.550547 
Crhbp 0.0549 0.55113 
Serpinf1 0.0404 0.556089 
Osbpl6 0.0532 0.566368 
Stbd1 0.075 0.649952 
Kif5a 0.0416 0.660935 
Fos 0.0688 0.667382 
Kif5a 0.0532 0.718964 
Tnfrsf12a 0.0523 0.742107 
Mthfd2 0.0726 0.767083 
D330014H01Rik 0.0756 0.840207 
Ccl4 0.0579 0.857928 
Vgf 0.0416 0.928688 
Ddit3 0.0549 1.211976 
Ddit3 0.0735 1.364746 




mRNA expression of eEF1A2 from Brain Cloud database. 
 
 
